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 Riassunto 
Il diabete mellito è una delle più comuni e gravi patologie croniche al mondo. Anche se il numero di 
farmaci/ composti disponibili per gestire il diabete continua ad espandersi rapidamente, il trattamento 
delle complicazioni diabetiche, come la neuropatia, rimane una sfida sostanziale. La neuropatia 
diabetica periferica è infatti una delle complicanze più frequenti del diabete mellito [Aring et al., 2005]. 
La patofisiologia della neuropatia diabetica è molto complessa e non è ancora completamente chiarita; 
è caratterizzata da meccanismi multipatogenici che causano una diversità di sintomi fisici, tra cui: 
allodinia, iperalgesia, intorpidimento e ulcerazione cutanea [Vinik et al., 1995]. Il dolore neuropatico 
persistente interferisce in modo significativo con la qualità della vita dei pazienti, compromettendone il 
sonno e il benessere emotivo. Recenti progressi nei meccanismi coinvolti nel dolore neuropatico hanno 
dimostrato che le citochine pro- ed anti-infiammatorie prodotte da cellule immunitarie, nonché da glia e 
microglia a livello dei nervi, dei gangli della radice dorsale (DRG) e del midollo spinale sono denominatori 
comuni nel dolore neuropatico [Sacerdote et al. 2013; Old et al., 2015]. Le citochine iniziano infatti una 
cascata di eventi correlati alla neuro-infiammazione che possono mantenere e peggiorare la lesione 
originale, partecipando alla generazione del dolore e alla sua cronicizzazione [Valsecchi et al., 2011; 
Sommer and Kress, 2004; Austin and Moalem-Taylor, 2010]. In generale, l'attivazione della cascata 
infiammatoria, l'up-regolazione pro-infiammatoria delle citochine e le vie di comunicazione neuro-
immuniche svolgono un ruolo fondamentale nel danno strutturale e funzionale dei nervi periferici che 
conducono alla neuropatia periferica diabetica. Purtroppo, la maggior parte dei farmaci analgesici 
disponibili sembra essere relativamente inefficace nel controllo del dolore neuropatico diabetico, sia per 
insufficienza di efficacia che per gli effetti collaterali [Galer et al., 2000; Kapur 2003]; pertanto, vi è una 
chiara necessità di nuovi approcci terapeutici che vadano a modificare la patologia.  
Le cellule staminali/ stromali mesenchimali (MSC) potrebbero offrire una nuova opzione terapeutica per 
il trattamento della neuropatia diabetica. Le MSC sono in grado di modulare l'ambiente lesionato del 
sistema nervoso e promuovere la riparazione in quanto in grado di secernere molecole anti-
infiammatorie, anti-apoptotiche e fattori trofici che sostengono la crescita assonale, 
l'immunomodulazione, l'angiogenesi, la rimielinizzazione e la protezione dall’apoptosi [Ma et al., 2014]. 
Quindi, le MSC trapiantate inoltre non solo differenziano direttamente nelle cellule endogene ma 
secernono anche un'ampia gamma di fattori biologicamente attivi, generalmente definiti come secreto 
MSC o secretoma; infatti anche se inizialmente le MSC sono state proposte per la terapia cellulare 
basata sul loro potenziale di differenziazione, la mancanza di correlazione tra il miglioramento 
funzionale e l'assunzione o la differenziazione cellulare nel sito di lesione ha portato a supporre che le 
MSC esercitino i loro effetti non attraverso il potenziale di differenziazione ma attraverso i prodotti 
secreti [Makridakis, 2016; Blaber et al., 2012]. 
Per queste ragioni, utilizzando un modello preclinico di diabete di tipo I, nel presente studio 
confrontiamo l'effetto terapeutico di hASC (cellule adipose umane / stromali) e del loro medium 
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condizionato (CM, secretoma), sull’allodinia, sull’iperalgesia, sull'espressione di citochine pro- e anti- 
infiammatorie nelle principali stazioni nervose coinvolte nella trasmissione del dolore e nelle risposte 
immunitarie periferiche. Il diabete di tipo 1 è stato indotto nei topi mediante iniezione intraperitoneale 
(i.p.) di basse dosi di streptozotocina (STZ, 80 mg / kg, una volta al giorno per tre giorni consecutivi), 
mentre gli animali controllo sono stati iniettati con veicolo (buffer citrato). In tutti i gruppi sperimentali, 
l'allodinia meccanica è stata valutata con il test di Von Frey prima dell'induzione del diabete ed ogni 
settimana dopo STZ fino alla fine del protocollo (14 settimane da STZ). Quando l’allodinia si è instaurata 
(2 settimane dopo STZ) gli animali sono stati trattati per via endovenosa (i.v.) con 106 hASC o con il 
secretoma ottenuto da 2x106 hASC (CM-hASC), cellule e secretoma prima di essere iniettati sono stati 
risospesi in PBS con eparina al 2,5%. Gli animali controllo sono stati iniettati con il veicolo. I nostri dati 
hanno dimostrato che i trattamenti con hASC e CM-hASC erano in grado di ridurre l'allodinia, anche se 
l'effetto delle hASC era significativamente superiore a quello ottenuto dal CM-hASC. L’effetto di 
entrambi i trattamenti è stato molto veloce, infatti una significativa riduzione dell'allodinia meccanica 
era già evidente 3 ore dopo l'iniezione; mentre il massimo effetto antiallodinico è stato raggiunto tra la 
prima e la seconda settimana dopo il trattamento. Inoltre l’effetto osservato è estremamente duraturo, 
infatti 12 settimane dopo un unico trattamento l’effetto antiallodinico risulta ancora evidente. 
Successivamente, 4 settimane dopo il primo trattamento (6 settimane dopo STZ) abbiamo deciso di 
ritrattare un gruppo di animali diabetici con hASC e CM-hASC; il trattamento ripetuto con hASC non è 
stato in grado di migliorare ulteriormente allodinia; mentre poche ore dopo la seconda iniezione il 
trattamento ripetuto con CM-hASC ha potenziato significativamente l'effetto antiallodinico. Al fine di 
capire se i trattamenti con hASC e CM-hASC potessero essere efficaci anche in una fase più avanzata 
della patologia, 6 settimane dopo l’induzione del diabete un gruppo di animali STZ è stato trattato per la 
prima volta con hASC o CM-hASC. Anche in questa situazione entrambi i trattamenti sono stati efficaci 
nel fornire un effetto antiallodinico veloce ed irreversibile. Inoltre, per verificare se la staminalità fosse 
un prerequisito fondamentale per ottenere sollievo dal dolore, un gruppo di animali STZ è stato trattato 
con il secretoma ottenuto da 2x106 fibroblasti umani (CM-hF). La somministrazione di CM-hF non ha 
esercitato alcun effetto sull’allodinia meccanica, dimostrando che solo il secretoma derivante da cellule 
staminali è biologicamente attivo. Molto importante risulta essere anche la metodica di preparazione 
del secretoma stesso, perché il CM-hASC se liofilizzato non è in grado di fornire nessun sollievo dal 
dolore, questo ci fa ipotizzare che durante il processo di liofilizzazione dei fattori bioattivi essenziali 
vengano persi.  
Poiché nei pazienti le alterazioni sensoriali associate alla neuropatia diabetica sono molteplici abbiamo 
valutato l'iperalgesia termica ed abbiamo iniziato a valutare l'allodinia termica, rispettivamente 
mediante plantar test e test dell’acetone. Gli animali STZ sono sensibili all’allodinia termica ed entrambi 
i trattamenti sono stati in grado di ridurre in modo significativo questa ipersensibilizzazione. Negli 
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animali diabetici abbiamo osservato che l’iperalgesia termica in risposta a stimoli caldi è presente fino a 
3 settimane dopo la somministrazione di STZ e che successivamente i topi diabetici sono caratterizzati 
da ipoalgesia, entrambi i trattamenti sono stati in grado di evitare il passaggio da iper- a ipo- algesia. 
Questi test comportamentali dimostrano la capacità delle cellule staminali e del loro secreto di alleviare 
l'ipersensibilità a diversi tipi di stimoli, caratteristici del dolore diabetico.  
Allo scopo di valutare l'impatto dei trattamenti sulle citochine pro- e anti- nfiammatorie, gli animali sono 
stati sacrificati in momenti diversi: 2 settimane dopo STZ, cioè 3 ore dopo trattamento con hASC /CM-
hASC; 3 settimane dopo STZ, cioè 1 settimana dai trattamenti e 14 settimane dopo STZ, cioè 12 o 8 
settimane dai trattamenti. Da ogni animale è stato prelevato il nervi sciatici, i gangli della radice dorsale, 
il midollo spinale e gli splenociti. I livelli delle citochine IL-1β, TNF-α, IL-6, IL-10 sono stati valutati nei 
tessuti nervosi mediante saggio ELISA. Tre settimane dall’induzione della neuropatia, negli animali 
diabetici, le citochine pro-infiammatorie IL-1β, TNF-α e IL-6, risultano over-espresse sia a livello del 
sistema nervoso periferico (nervo sciatico e DRG) che a livello del sistema nervoso centrale (midollo 
spinale). Entrambi i trattamenti sono stati in grado di ripristinare i livelli delle citochine pro-
infiammatorie, infatti dopo una settimana dai trattamenti sono tornate ai livelli basali; mentre i livelli 
della citochina anti-infiammatoria IL-10, in tutti i tessuti nervosi, sono apparsi significativamente ridotti 
negli animali diabetici, e sia il trattamento con hASC che con CM-hASC hanno significativamente 
aumentato le concentrazioni di IL-10. Quattordici settimane dopo STZ, i livelli di IL-1β, TNF-α e IL-6 nel 
midollo spinale erano ancora significativamente elevati e i livelli di IL-10 erano ridotti rispetto ai topi non 
diabetici, indicando la persistenza della neuro-infiammazione. Come osservato per l'effetto anti-
allodinico, anche la modulazione delle citochine indotta da hASC e CM-hASC è duratura, infatti 12 
settimane dopo i trattamenti effettuati a 2 settimane dalla STZ, i livelli di IL-1β, TNF-α e IL-6 erano 
ancora significativamente ridotti negli animali trattati con hASC e CM-hASC, mentre solo negli animali 
trattati con hASC abbiamo osservato una significativa normalizzazione dei livelli di IL-10. Effetti simili 
sono stati osservati anche nel doppio trattamento (2 e 6 settimane dopo STZ) ed entrambi i trattamenti 
hASC/CM-hASC sono stati efficaci anche quando le citochine sono state valutate in animali trattati in 
uno stadio avanzato della patologia (6 settimane dopo STZ).  
Inoltre, per valutare il possibile effetto acuto dei trattamenti, i livelli di IL-1β e IL-10 sono stati valutati 
dopo 3 ore dalla somministrazione di hASC e CM-hASC (2 settimane da STZ). Entrambi i trattamenti sono 
in grado di modulare positivamente tali livelli, alterati dalla patologia. 
I livelli proteici di CGRP sono stati misurati nei DRG e nel midollo spinale e abbiamo osservato che 
entrambi i trattamenti sono in grado di normalizzare i livelli di CGRP che risultano elevati negli animali 
diabetici. E’ stata valutata la perdita di fibre nervose e lo spessore della pelle a livello delle zampe 
posteriori, 1 e 12 settimane dopo una singola somministrazione di hASC/CM-hASC. Entrambi i 
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trattamenti sono stati in grado di contrastare la perdita di fibre nervose e di prevenire l’assottigliamento 
della pelle, anche se il trattamento con hASC si è dimostrato più efficace.  
Il protocollo utilizzato, ovvero la somministrazione di basse dosi ripetute di STZ, è in grado di sviluppare 
una risposta autoimmune contro il tessuto pancreatico sostenuto da un modello di attivazione T-helper 
1. Abbiamo quindi studiato se una polarizzazione di T-helper fosse presente negli splenociti dei topi 
diabetici e se il trattamento con hASC o con il loro secretoma fosse in grado di esercitare un'attività 
immunomodulatoria. Due settimane dopo la somministrazione di STZ, gli splenociti stimolati con Con-A 
hanno rilasciato livelli più elevati di IFN-γ mentre il rilascio di IL-10 è stato significativamente ridotto; 
entrambi i trattamenti con hASC e CM-hASC, 3 ore dopo la somministrazione sono stati in grado di 
aumentare i livelli di IL-10. Tre settimane dopo STZ, lo sbilanciamento Th1/Th2 appare molto più 
evidente ed entrambi i trattamenti hASC e CM-hASC sembrano in grado di ristabilire i corretti livelli di 
IFN-γ e IL-10. Quattordici settimane dopo STZ, è presente un chiaro passaggio verso un profilo Th1, 
caratterizzato da elevati livelli di IFN-γ e IL-2 e bassi livelli di IL-4 e IL-10; il trattamento con hASC o CM-
hASC è stato in grado di normalizzare i livelli di tutte le citochine in esame. Nel complesso, i dati indicano 
che entrambi i trattamenti sono in grado di bloccare la polarizzazione Th1 che si sviluppa in questo 
modello sperimentale di diabete. Inoltre nel corso dell’intero esperimento sono stati monitorati i livelli 
di glucosio nel sangue ed il peso corporeo degli animali. Gli animali trattati con STZ sono caratterizzati da 
una graduale perdita di peso, che diventa significativa (vs. animali controllo-non diabetici) 3 settimane 
dopo la STZ; la somministrazione di hASC o CM-hASC, 2 settimane dopo l'induzione del diabete ha 
significativamente impedito la perdita di peso corporeo. Né il trattamento con hASC nè quello con CM-
hASC è stato in grado di modificare i livelli di glucosio nel sangue che rimangono sempre elevati. Per 
meglio approfondire questo punto abbiamo eseguito anche un test di tolleranza del glucosio. 
Inoltre, gli animali STZ proprio come i pazienti sono caratterizzati anche da nefropatia ed entrambi i 
trattamenti sono stati in grado di migliorare tale condizione, indicando che i trattamenti sono efficaci 
anche nel contrastare anche altre complicazioni diabetiche.  
I nostri risultati dimostrano che il trattamento con hASC può controllare complicazioni diabetiche come 
il dolore neuropatico, agendo su diversi meccanismi periferici e centrali coinvolti nello sviluppo e nel 
mantenimento di questa condizione, sia a livello neurale che immunitario. Inoltre, i risultati positivi 
osservati anche con il secretoma suggeriscono l’ effetto delle hASC è probabilmente mediato dai loro 
prodotti secreti. 
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Diabetes mellitus is one of the most common and serious chronic disease in the world. Although the 
number of available agents to manage diabetes continues to rapidly expand, treatment of diabetes 
complications, such as neuropathy that is one of the most frequent complication of diabetes mellitus, 
remains a substantial challenge [Aring et al., 2005]. Pathophysiology of diabetic neuropathy is complex 
and not fully elucidated; it has multipathogenic mechanisms that cause a diversity of physical 
symptoms: allodynia, hyperalgesia, numbness and cutaneous ulceration [Vinik et al., 1995]. Persistent 
Neuropathic Pain (NP) interferes significantly with quality of life, impairing sleep, and emotional well-
being, and is a significant causative factor for anxiety, loss of sleep, and non-compliance with treatment. 
Recent advances in the mechanisms involved in NP have demonstrated that pro- and anti-inflammatory 
cytokines produced by immune cells as well as by glia and microglia in nerve, dorsal root ganglia (DRG) 
and spinal cord are common denominators in neuropathic pain [Sacerdote et al., 2013; Old et al., 2015]. 
These start a cascade of neuroinflammation-related events that may maintain and worsen the original 
injury, participating in pain generation and chronicization [Valsecchi et al., 2011; Sommer and Kress, 
2004; Austin and Moaelem-Taylor, 2010]. Activation of inflammatory cascade, pro- inflammatory 
cytokines upregulation, and neuroimmune communication pathways play a vital role in structural and 
functional damage of the peripheral nerves leading to the diabetic peripheral neuropathy. 
Unfortunately, most of the available analgesic drugs appear to be relatively ineffective in controlling 
diabetic neuropathic pain, both for insufficient efficacy and side effects [Galer et al., 2000; Kapur, 2003]. 
Thus, there is a clear need for new disease-modifying therapeutic approaches. 
Mesenchymal stem/stromal cells (MSCs) may offer a novel therapeutic option to treat diabetic 
neuropathy. MSCs modulate the nervous system injured environment and promote repair as they 
secrete anti-inflammatory, anti-apoptotic molecules, and trophic factors to support axonal growth, 
immunomodulation, angiogenesis, remyelination, and protection from apoptotic cell death [Ma et al., 
2014]. Transplanted MSCs not only directly differentiate into endogenous cells on administration, but 
also secrete a broad range of biologically active factors, generally referred to as the MSCs secretome; in 
fact even if initially MSCs were proposed for cell therapy based on their differentiation potential, the 
lack of correlation between functional improvement and cell engraftment or differentiation at the site 
of injury has led to the proposal that MSCs exert their effects not through their differentiation potential 
but through their secreted products [Makridakis, 2016; Blaber et al., 2012]. 
For these reasons in the present study we analyze in a Streptozotocin mouse model of type 1 diabetes 
the therapeutic effect of hASC (human adipose stem/stromal cells) and their conditioned media (CM-
hASC/ secretome) on allodynia and hyperalgesia, on pro- and anti- inflammatory cytokines expression in 
the main tissue stations involved in nociception transmission as well as in peripheral immune responses. 
Type 1 diabetes was induced in mice by intraperitoneal (i.p.) injection of moderate low doses of 
Streptozotocin (STZ, 80 mg/kg, daily for three consecutive days) while control mice were injected with 
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vehicle (citrate buffer). In all groups, mechanical allodynia was evaluated by Von Frey test before 
diabetes induction and every week after STZ until the end of protocol (14 weeks after STZ). When 
allodynia was established (2 weeks after STZ) animals were treated with 106 hASC that have been 
mechanically dissociated to a single cell suspension in PBS solution with 2.5% heparin; CM-hASC from 
2x106 cells was also re-suspended in PBS solution with 2.5% heparin and both hASC and CM-hASC were 
intravenously injected in the tail vein to mice. Animals injected with vehicle only were considered as 
controls. Our data demonstrated that hASC and CM-hASC treatments were able to reduce allodynia, 
although the effect of hASC was significantly higher than that elicited by CM-hASC. The effect of both 
hASC and their secretome was very fast, since a significant reduction of mechanical allodynia was 
evident already 3 hours after the injection. The antiallodynic effect was maximal beetwen 1 and 2 weeks 
after treatments and it was extremely long lasting: a significant reduction of allodynia was still present 
12 weeks after a single hASC and CM-hASC treatment.  
Moreover, 4 weeks after the first hASC/CM-hASC treatment (6 weeks after STZ) we decided to treat 
again a group of diabetic animals with hASC or CM-hASC; repeated hASC treatment did not further 
ameliorate allodynia. On the other hand, already few hours after the second CM-hASC injection, the 
antiallodynic effect was significantly potentiated and it completely mimicked the effect evoked by hASC. 
In order to discover whether hASC and CM-hASC treatments were effective also in a more advanced 
stage of the disease, when a severe loss of nerve function is reported, we treated animals 6 weeks after 
diabetes induction. Also in this situation both treatments were efficacious in providing a fast and 
irreversible antiallodynic effect. Futhermore, in order to verify whether stemness is a fundamental 
prerequisite for obtaining pain relief a group of STZ-mice was treated with CM obtained from 2x106 
human fibroblasts (CM-hF). CM-hF did not exert any effect on mechanical allodynia, demonstrating that 
only secretome from stem cell cultures is biologically active. It is very important also to consider 
preparation method of secretome, because lyophilized CM-hASC was unable to provide pain relief, 
suggesting that during the lyophilization process some essential bioactive factors may be lost. 
Moreover, since in patients sensory alterations associated to diabetic neuropathy are often diverse in 
order to ascertain whether the effects of hASC and CM-hASC were limited only to mechanical allodynia, 
we evaluated thermal hyperalgesia (hot stimuli) and thermal allodynia (cold stimuli) by plantar test and 
acetone test, respectively. In STZ-mice cold allodynia was present and both treatments were able to 
significantly reduce it. As regards to heat hyperalgesia, it was present in diabetic mice until 3 weeks from 
STZ administration, but subsequently we observed hypoalgesia appearance and both treatments were 
able to avoid hypoalgesia development; these results demostrate the ability of stem cells and their 
secretome to relieve and prevent the typical diabetic hypersensitivity in response to different types of 
stimuli.  
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In order to evaluate the impact of treatments on pro- and anti- inflammatory cytokines, animals were 
sacrificed at different time points: 2 weeks after STZ, i.e. 3 hours after hASC/CM-hASC treatment; 3 
weeks after STZ, i.e. 1 week from treatments and 14 weeks after STZ, i.e. 12 or 8 weeks from 
treatments. From each animal, sciatic nerves, dorsal root ganglia, spinal cord and spleens were 
collected. IL-1β, TNF-α, IL-6 and IL-10, were evaluated as protein in nervous tissues by ELISA assay. 
Three weeks after neuropathy induction pro-inflammatory cytokines IL-1β, TNFα and IL-6 resulted 
overexpressed in peripheral (sciatic nerve and DRG) and central (spinal cord) nervous system of diabetic 
mice, both hASC and CM-hASC were similarly able to restore pro-inflammatory cytokine levels that 1 
week from treatments were back to basal levels; while in all nervous tissues IL-10 levels appeared 
instead significantly reduced in diabetic animals and both hASC and CM-hASC significantly increased IL-
10 concentrations, reaching physiological levels in DRG and spinal cord, while it exceeded basal levels in 
the sciatic nerve, indicating a switch towards an anti-inflammatory environment in all these tissues. 
Fourteen weeks after STZ, spinal cord IL-1β, TNF-α and IL-6 levels were still significantly elevated and IL-
10 levels reduced in comparison to non diabetic mice, indicating the persistence of neuroinflammation. 
As observed for the antiallodynic effect, also cytokine modulation induced by hASC and CM-hASC was 
long lasting. Twelve weeks after treatments performed 2 weeks from STZ, IL-1β, TNF-α and IL-6 levels 
were still significantly reduced by hASC and CM-hASC treatments, while hASC-treated mice showed a 
significant normalization of IL-10 levels. Similar effects were observed also in double treatments (2 and 6 
weeks after STZ) and both treatments were effective in modulating cytokine levels also when they were 
administered in an advanced pathological state (6 weeks after STZ). Moreover, to investigate the timing 
of cytokines modulation exerted by both treatments IL-1 and IL-10 levels in scatic nerves, DRG and 
spinal cord were measured. Two weeks after diabetic induction, STZ mice were characterized by pro- 
inflammatory profile and only 3 hours after hASC and CM-hASC administration , both treatments were 
able to modulate cytokines levels. 
To further demonstrate the modulation of treatments on pain-related mediators we demonstrated the 
ability of hASC and CM-hASC to normalize calcitonin gene related peptide level (CGRP), that was 
elevated in DRG from diabetic animals. Moreover, we evaluated loss of nerve fibers and skin thickness 1 
and 12 weeks after a single hASC/CM-hASC administration at 2 weeks after STZ. Both treatments were 
able to contrast loss of nerve fibers and skin thickness, although hASC treatment was more effective. 
Since STZ multiple low-doses protocol that we utilized is able to develop an autoimmune response 
against pancreatic tissue sustained by a T-helper 1 pattern of activation, we studied whether a T-helper 
polarization was present in splenocytes from diabetic mice and whether hASC or their secretome did 
exert any immunomodulatory activity.  
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 Summary 
Two weeks after STZ, Con-A stimulated splenocytes released higher levels of IFN-γ, while IL-10 release 
was significant reduced; both hASC and CM-hASC treatments 3 hours after administration were already 
able to augment IL-10 levels. Th1/Th2 cytokines unbalance was more evident 3 weeks after STZ and 
both tretaments appeared able to restablish a correct IFNγ/IL-10 balance. When cytokine levels were 
measured at longer time from diabetes induction, i.e. 14 weeks after STZ, a clear shift toward a Th1 
pattern, characterized by higher IFN-γ and IL-2 secretion and lower levels of IL-4 and IL-10, was present 
and both hASC/CM-hASC treatments were able to normalize cytokine levels. In the whole, the data 
indicate that both hASC and CM-hASC treatments are able to block Th1 polarization that develops in this 
experimental model of diabetes. Moreover, throughout the experiment, blood glucose levels and weight 
were monitored. In respect to non-diabetic control animals, a significant body weight loss was observed 
in diabetic mice, that started to be significant 3 weeks after STZ. In STZ-mice the administration of hASC 
or CM-hASC, 2 weeks after diabetes induction significantly prevented the loss of body weight. Neither 
treatments did modify blood glucose levels that were elevated in STZ-mice nor glucose tolerance test 
response.   
Moreover both hASC and CM-hASC did ameliorate nephropathy that was present in diabetic animals, 
indicating that the treatments may be useful for treating also other diabetes complications. 
Our results demonstrated that hASC can control diabetic complications such as neuropathic pain, acting 
on several peripheral and central mechanisms involved in development and maintenance of this 
condition, such as neural and immune elements. Moreover the significant new positive results observed 
also with hASC conditioned medium strongly suggest that their effect is likely to be mediated by their 
secreted products. 
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1.1 Anatomy and physiology of pain 
In the 1979, the International Association for the Study of Pain (IASP) defined pain as “an unpleasant 
sensory and emotional experience associated with actual or potential tissue damage, or described in 
terms of such damage” [Merskey, 1979]. This definition takes into consideration two important concepts 
concerning the phenomenon of pain: its subjectivity and its manifestation also in absence of real tissue 
damage.  
Pain experience is in fact complex and highly variable between individuals. It involves an intricate 
neurobiological apparatus consisting of dynamic excitatory and inhibitory nervous circuits, deputed to 
the transmission and elaboration of painful perception. Moreover the presence of modulatory pathways 
controlling the emotional state (fear, anxiety, attention and distraction) and the cognitive functions 
(past experiences, memories of pain) can in turn either enhances or diminishes the individual pain 
experience [Ossipov et al., 2010].  
Pain can last for a short (acute pain) or long (chronic pain) period, it can be caused by several conditions 
and its processing can imply different neuronal mechanisms. Given the complexity and the 
heterogeneity of pain manifestation, the distinction of the pathways and molecules implicated in the 
several types of pain processing is fundamental in order to target the treatments at the mechanisms 
responsible.  
According to Woolf classification, pain can be broadly divided into three main types: nociceptive, 
inflammatory and pathological pain [Woolf, 2010].  
Nociceptive pain is protective and needful for maintaining body integrity as it represents a primitive 
defence mechanism evolved for warning us about the presence of potential dangerous stimuli and for 
minimizing tissue injury. It follows that the absence of nociceptive pain sensitivity has a negative impact 
on health; congenital insensitivity to pain due to mutations of genes encoding for channels or molecules 
involved in pain processing or lacking the ability of pain perception due to a sensory damage for 
instance, typically results in bone fractures, self-mutilation, maintaining of unrealized infections and a 
reduction of the life span [Axelrod and Hilz, 2003; Raouf et al., 2010].  
Also the inflammatory pain is physiological and protective. This kind of pain takes place in presence of 
tissue injuries or infections and is associated to an inflammatory state caused by the activation of the 
immune system. However the increased pain hypersensitivity is functional because it protects the 
injured tissue site until healing occurs, by minimizing contact with stimuli potentially able to provoke 
other pain. 
Usually, both nociceptive and inflammatory pain trigger adaptive responses and last until the resolution 
of the initial injury. The switch from a physiological to a pathological condition occurs in presence of 
damage (neuropathic pain) or an abnormality functioning (dysfunctional pain) of the nervous system. In 
these cases pain is maladaptive, not protective and is maintained for a long period ranging from weeks 
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to years. In other words, pathological pain is not a symptom of some disorders but rather a disease of 
the nervous system [Woolf, 2010]. 
 
1.1.1 Pain pathways 
Nociception is the neuronal process that allows the people to experience pain. Four distinct steps occur 
along the pain pathways:  
 
I.  Transduction of noxious stimuli (mechanical, thermal or chemical stimuli) in neural electrical 
activity by the activation of ion channels, including transient receptor potential channel 
subtypes (TRPA, TRPM and TRPV), sodium channel isoforms (Nav), potassium channels subtypes 
(KCNK) and acid-sensing ion channels (ASICs), clustered on nociceptors [Grace et al., 2014]; 
moreover, kinin peptides, in particular bradykinin, are released from kininogen precursors at 
the site of tissue injury and inflammation by protease kallikreins and kininases and act on 
constitutively expressed B2 and injury-induced B1 G-protein-coupled receptors (GPCRs) 
expressed on primary sensory neuron peripheral terminals [Prado et al., 2002], to contribute to 
nociception [Rueff and Dray, 1993; Couture et al., 2001]. 
II.  Transmission of nerve impulses from the site of transduction to spinal cord, brainstem, 
thalamus, and central structures in the brain; 
III.  Modulation of nociceptive signals through endogenous mechanisms of pain control (spinal 
inhibitory interneurons and descending pain modulatory circuits); 
IV.  Perception of pain as the end result of nociceptive stimulus travelling through the entire 
nervous system, including the supra-spinal structures involved in memory, cognition and 
emotion, which contribute to the neuronal network of conscious experience of pain [Fields and 
Basbaum, 1999]. 
 
Nociceptive ascending pathway begins in periphery with the activation of the nociceptors, sensory 
neurons able to detect dangerous or potentially damaging stimuli for the organism.  
Nociceptors are pseudounipolar neurons with a single axon that forks into peripheral and central 
processes. The afferent branch projects to skin, mucosa, blood vessels and connective tissue of visceral 
organs, while the other runs to Central Nervous System (CNS). Specialized structures at the terminal end 
of nociceptors, once coming in contact with noxious stimuli, convert painful messages in electrical 
signals that propagate along this axonal pathway from periphery to the spinal cord or hindbrain. From 
here the signals reach the supraspinal structures and, finally the cortical and subcortical regions, where 
painful information is interpreted and perceived.  
Unlike to other classes of sensory fibers, nociceptors have high activation thresholds; in fact in normal 
conditions, they can be excited only by stimuli enough intense to cause a real tissue damage, but not by 
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innocuous stimulations such as light touch, vibrations or warning. High threshold stimuli for nociceptors 
activation include extreme temperatures, intense pressure and irritant chemicals [Dubin and 
Patapoutian, 2010].  
The main primary afferent fibers that convey noxious stimuli to CNS arise from nociceptive neurons 
having a small or medium-diameter cellular body located in the dorsal root ganglia (DRG). They 
comprehend the thinly myelinated, mostly mechanosensitive A fibres and the unmyelinated, 
polymodal, i.e. able to detect mechanical, thermal and chemical stimuli, C fibers [Julius and Basbaum, 
2001].  
All A fibres respond to intense mechanical stimulations but depending on their responsiveness to 
noxious heat, they can be divided in type I and type II fibres. The first type includes capsaicin-insensitive 
fibres responding to high temperatures (52-56 °C), while the type II population comprehends capsaicin-
sensitive fibers responsive to noxious heat of 40-45 °C [Giordano, 2005]. 
Unmyelinated C fibers represent the majority of the primary afferents fibers and, according to ability of 
synthesizing neuropeptides, mostly Substance P (SP) and Calcitonin Gene Related Peptide (CGRP), are 
broadly divided in two main populations, the peptidergic and the non-peptidergic fibers.  
 
A and C nociceptive fibers differ also in terms of conduction velocity. When activated, A fibers 
transmit nociceptive potentials with a velocity ranging to 12-30 m/s leading to a rapid pain sensation, 
while C fibers propagate noxious information more slowly (0.5-2 m/s) inducing a second, delayed 
response to pain. The different pattern of signal propagation results in two successive and qualitatively 
Image 1|Nociception.  
[Image modified from Milligan and Watkins, 2009] 
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distinct pain sensations: brief, pricking, and well localized “first pain” and a longer-lasting, burning, and 
less well localized “second pain” [Ploner et al., 2002].  
Another group of nociceptors is represented by C nociceptive fibers known as “silent” or “sleeping” 
nociceptors which respond to noxious stimuli only when sensitized by tissue injury or inflammation. 
Peripheral primary afferents also include myelinated, fasting conducting (30-100 m/s) A fibers arising 
from DRG large-diameter neurons, responsive to mechanical innocuous stimuli. Normally they don’t 
contribute to pain sensation but in some cases they begin to signal pain in response to non-noxious 
stimuli.  
Information transmit by A fibers can be in fact greatly altered during disease conditions or after tissue 
damage has resolved, leading to abnormal pain signalling [Milligan and Watkins, 2009].  
The information collected in periphery by nociceptive fibers reach the spinal cord via the dorsal roots. 
Here (spinal cord) their central processes form synapses with different populations of second-order 
neurons mostly distributed in the superficial layers of the dorsal horns (Rexed laminae I and II). 
Nociceptors also synapse in some deeper laminae such as Rexed laminae V and X. Dorsal horns neurons 
include Nociceptive Specific (NS) neurons, exclusively responsive to nociceptive input conveyed by Aδ 
and C fibres, Wide Dynamic Range (WDR) neurons that respond to both nociceptive and non-nociceptive 
stimuli coming from Aδ, C and A central axons and Non-Nociceptive (N-NOC) neurons responding to 
innocuous stimulations mostly propagated by A fibers [Almeida et al., 2004].  
Nociceptive fibers transmit the nociceptive message through the release of glutamate, as the primary 
neurotransmitter, and of neuropeptides (SP,CGRP), which have the potential of exciting second-order 
nociceptive projection neurons [Grace et al., 2014].  
The excitatory amino acid binding to postsynaptic glutamate AMPA and kainate receptors is responsible 
for a fast synaptic transmission and a rapid, short-term depolarization of second-order neurons. On the 
contrary a slow and long-term synaptic transmission is mediated by SP and CGRP release. 
Spinal projection neurons relay the nociceptive signals received to higher centres of the CNS following 
the ascending spinal tracts. Secondary afferents decussate and pass up the spinal cord to midbrain via 
the spinothalamic, spinoreticular and spinomesencephalic tracts to the thalamus and to sensory cortex, 
but also have other links, such as to reticular formations, limbic and hippocampal areas [Farquhar-Smith, 
2008].  
Cortical and supra-spinal areas form the “pain matrix”, i.e. a collection of brain regions involved in 
neurological functions, including cognition, emotion, motivation and sensation, as well as pain, which 
acting together in pain modulation context lead to the conscious experience of pain [Tracey and Johns, 
2010; Ossipov et al., 2010]. 
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As mentioned above the three main ascending pathways linking the dorsal horns to brain are: 
 
 Spinothalamic tract (STT) 
This tract originates from spinal WDR, NS and N-NOC neuron types propagating noxious and 
innocuous signals that are related to pain, temperature and touch. Before ascending, secondary 
axons decussate transversely through the anterior commissure of the spinal cord. During its 
passage through the brain stem, STT originates collateral branches destined to reticular 
formation of the medulla, pons and midbrain, periaqueductal grey matter (PAG), hypothalamus 
and medial and intralaminar thalamic nuclei [Almeida et al., 2004]. 
 
 Spinoreticular tract (SRT) 
This tract mostly originates from spinal WDR and NS neurons. It presents two components in the 
brain stem; one is directed at the precerebellar nucleus in the lateral reticular formation 
involved in motor control, while the other is directed to the medial pontobulbar reticular 
formation involved in mechanism of nociception [Millan, 1999]. SRT is an important pathway for 
the modulation of the nociceptive segmental pathway by activating brain stem structures 
responsible for descending suppression [Almeida et al., 2004].  
 
 Spinomesencephalic tract (SMT) 
As SRT, this tract is highly involved in the mechanisms of pain modulation. This tract originates 
from spinal WDR and NS neurons and projects to different regions of PAG. The projections to 
the midbrain PAG matter from spinal neurons are functionally distinct; those the reach the PAG 
in the portion more dorsal to the limiting sulcus have excitatory characteristic in afferent 
nociceptive transmission, while those that project more ventral to the limiting sulcus activate 
mechanisms responsible for the inhibition of the afference of this same pathway [Almeida et al., 
2004]. 
 
1.1.2 Pain modulation  
The sensory experience of pain extends beyond the activation of nociceptors as it involves an intricate 
neuronal network consisting of dynamic excitatory and inhibitory nervous circuits which modulate pain 
experience enhancing or inhibiting pain sensation.  
In the dorsal horn of spinal cord local GABAergic and glycinergic interneurons have a functional role of 
inhibition of pain information processing. As described by Melzack and Wall’s in the Gate Control Theory 
of Pain [1978], these inhibitory interneurons function as a gate in spinal cord regulating the transmission 
of pain message from primary afferents to the spinal second-order projection neurons. Aβ non-
nociceptive fibers activity inhibits (or “closes”) the gate inducing the activation of local inhibitory 
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interneurons, while the activity of small nociceptive C and Aδ fibres facilitates (or “opens”) the gate 
[Moayedi and Davis, 2013]. The balance between the inputs from nociceptive and non-nociceptive 
primary afferents which is controlled by the complex spinal inhibitory interneuron circuits determines 
the status of this gate, i.e. whether and how strong the nociceptive signal will be transmitted, via 
secondary projection neurons, to the higher brain centers [Guo and Hu, 2014]. Descending fibers 
originating from supra-spinal regions which project to the spinal dorsal horns are also implicated in the 
modulation of this gate [Moayedi and Davis, 2013].  
Pain modulation exists in fact also in the form of descending inhibitory and facilitatory pain pathways 
which involve different regions within CNS, including cortex, thalamus and brainstem.  
The midbrain periaqueductal grey region (PAG) and the rostral ventromedial medulla (RVM) are 
particularly important in the endogenous modulation of pain. These regions are known to be involved in 
endogenous pain control through PAG-RVM-spinal cord descending inhibitory pain pathway [Fields, 
2006].  
These supra-spinal sites exert influences on the perception of pain either directly, sending projection 
neurons to the spinal cord, or indirectly, sending projection neurons to other regions in the brainstem 
that send projections to the spinal cord. These modulatory effects are predominantly mediated by 
descending pathways that utilize serotonin, norepinephrine and endogenous opioids.  
Monoamines and endogenous opioids modulate the release of neurotransmitters from nociceptive 
afferents and the excitability of dorsal horn neurons by binding to different receptor subtypes. 
Stimulation of PAG and RVM was found to cause release of serotonin in spinal cord [Cui et al., 1999]; at 
this level serotonin has either inhibitory or facilitatory role of pain transmission which is dependent on 
the receptor subtype activated [Suzuki et al., 2004; Dogrul et al., 2009]. 
Norepinephrine also strongly contributes in anti-nociceptive mechanisms associated to descending 
inhibition. PAG and RVM communicate with an important noradrenergic site to pain modulation, the 
locus coeruleus (LC), which is one of the major source of direct noradrenergic projections to spinal cord 
involved in the inhibition of presynaptic and post-synaptic spinal pain transmission neurons [Fields et al., 
2005; Proudfit, 1992]. 
Descending pain inhibition from PAG was also observed after direct microinjection of opiods [Fang et 
al., 1989; Ossipov et al., 2010].   
“On-cells” and “off-cells” are two classes of pain modulatory neurons identified in the RVM and PAG 
[Fields et al., 1991; Mason, 1999]. “Off-cells” are excited by opioids and inhibit ascending noxious stimuli 
from the periphery by triggering descending inhibition. On the contrary, “on-cells” are thought to trigger 
descending facilitation [Fields and Basbaum, 1999; Mason, 1999; Fields, 2000].  
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1.1.3 Mechanisms involved in the transition from physiological to pathological pain 
processing  
 
1.1.3.1 Peripheral sensitization  
Tissue injury and nerve damage produce pain hypersensitivity inducing molecular and cellular changes in 
the primary afferent neurons. This neuronal plasticity manifests through an increased responsiveness 
and reduced activation threshold for thermal and mechanical stimuli of nociceptors and is referred as 
peripheral sensitization. 
These electrophysiological phenomena correlate to behavioral phenomena which include spontaneous 
pain, hyperalgesia (increased responses to noxious stimuli) and allodynia (nociceptive response to 
innocuous stimuli) [Cheng and Ji, 2008].  
The capacity to produce increases in sensitivity after injury is functional and protective in physiological 
pain; however peripheral sensitization can be a leading cause for the development of persistent 
pathological pain. Increases in pain sensitivity are mediated by the local release of inflammatory 
mediators (collectively referred as “inflammatory soup”) from primary afferents terminals and different 
non-neuronal cells, including fibroblasts, mast cells, neutrophils, monocytes and platelets. After nerve 
damage, these mediators can also be released by Schwann cells and damaged neurons [Campana, 
2007]. “Inflammatory soup” includes prostaglandins E2 (PGE2), bradikinin, ATP, protons, nerve growth 
factor (NGF) and pro-inflammatory cytokines (TNF-α and IL-1β) [Julius and Basbaum, 2001].  
These mediators stimulate/activate nociceptors directly (e.g. protons, ATP and 5-hydroxytryptamine (5-
HT)) or by increasing sensitivity to subsequent stimuli (e.g. bradikinin, prostaglandins, leukotrienes and 
NGF) via receptor-mediated second messenger action.  
Cyclic AMP, Protein Kinase A (PKA) and specific subtypes of Protein Kinase C (PKC) such as PKCε are 
important second messenger and effectors involved in nociceptor sensitization, which may be at least in 
part caused by changes to ion channels. Ion channels, including voltage-gated sodium ion channels, acid-
sensing ion channels and the heat and capsaicin receptor, the Transient Receptors Potential channel V1 
(TRPV1), give a significant contribution to activation, sensitization and consequently hyperalgesia and 
allodynia development, and their sensitivity is strongly regulated by inflammatory mediators [Farquhar-
Smith, 2008].  
Beyond to activate PKC and PKA pathways, the inflammatory mediators released after injury also 
activate MAPK signalling in nociceptive primary sensory neurons. Activation of this pathway results in 
the regulation of transcriptional and translational factors which ultimately lead to increased synthesis of 
gene encoding for ion channels (such as TRPV1, TRPA1, tetrodotoxin-resistant (TTX-R) sodium and 
calcium channels), neuromodulators (BDNF, SP and CGRP) and pro-inflammatory cytokines TNF-α and IL-
1β. Persistent increase in the synthesis of these pro-nociceptive mediators in primary sensory neurons 
maintains hypersensitivity of these neurons and persistent pain [Cheng and Ji, 2008]. 
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In addition, nociceptors activation not only results in the transmission of pain message to spinal cord 
(and from here to brain), but is also responsible for the initiation of neurogenic inflammation. 
The antidromic release of peptides and neurotransmitters, notably substance P and CGRP, from 
activated nociceptors induces in fact vasodilation, plasma extravasation and activation of immune cells, 
which in turn contribute additional elements to the inflammatory soup [Julius and Basbaum, 2001].  
 
1.1.3.2 Central sensitization 
Several chemical signals in the spinal cord trigger pain transmission in response to incoming noxious 
stimuli, including SP, glutamate, CGRP and many others neuromodulators. Under normal, non-
pathological condition, low-frequency activation of Aδ and C fibre nociceptors leads to glutamate 
release from the central presynaptic afferent nerve terminals in the spinal cord dorsal horn, where the 
excitatory amino acid induces a short-term activation of glutamate AMPA/kainate receptor subtypes. 
Although glutamate also binds the NMDA ionotropic glutamate receptor (NMDAR) present on the pre- 
and postsynaptic neurons, the receptor remains silent, i.e. it does not lead to changes in membrane 
potential and subsequent pain-projection neuron excitation, because it is plugged by Mg2+ [Milligan and 
Watkins, 2009]. 
Intense, repeated and sustained activity of primary sensory neurons elicits changes in neuronal and 
biochemical processing at central synapses and descending projections, transitioning these sites into a 
pain facilitatory state [Basbaum and Scherre,2009; Ossipov et al., 2010]. In the spinal dorsal horn, these 
changes are collectively known as central sensitization and windup.  
These processes involve the phosphorylation of a range of receptors, including AMPA and/or kainate 
receptors, which increases synaptic efficacy by altering channel opening time, increasing burst firing, 
removing the Mg2+-mediated channel blockade at the NMDA receptor, and promoting trafficking of 
receptors to the synaptic membrane [Latremoliere and Woolf, 2009]. 
As a consequence of central sensitization, spinal dorsal horn neurons increase ongoing activity, expand 
their receptive field and increase their responsiveness by lowering of excitation thresholds [Farquhar-
Smith, 2008]. 
During this time, altered low-threshold non-nociceptive Aβ sensory fibers activate spinal pain-projection 
neurons, contributing to development of allodynia. SP and CGRP released from primary afferent 
neurons also contribute to central sensitization by the activation of the NMDA receptor in persistent 
pain states. Neurokinin A and B acting on neurokinin receptors may influence the NMDA receptors 
directly by inducing a slow depolarization (by decreased potassium ion conductance). 
Nerve growth factor (NGF) induces stimulation of neuropeptide formation and release, which contribute 
to the development of central sensitization and hyperalgesia. Brain-derived neurotrophic factor (BDNF) 
is produced by NGF-dependent nociceptors, and its synthesis is increased with inflammation. BDNF 
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augments spinal neuron excitability by phosphorylation-mediated stimulation of the NMDA receptor 
[Farquhar-Smith, 2008].  
Sustained nociceptor activation caused by peripheral nerve injury and inflammation leads to central 
sensitization, where enhanced responsiveness of neurons in the spinal dorsal horn is thought to underlie 
chronic hyperalgesia and allodynia [Chapman et al., 1998; Kidd and Urban, 2001].  
 
1.2 Neuropathic pain 
Neuropathic pain is a pathological pain that occurs secondarily to injury of the central and/or peripheral 
nervous system. The International Association for the Study of Pain (IASP) has recently modified its 
definition as “pain caused by a lesion or disease of the somatosensory system” to emphasize that the 
injury in the nervous system has to be within the somatosensory system [Treede et al., 2008]. 
Neuropathic pain is an emerging pathology affecting million people in the world and can be classified as 
an incurable disease for the lack of valid treatments. In fact it is partially unresponsive to classical 
analgesics and its treatment with adjuvant drugs, i.e. antidepressant or anticonvulsive, provides only a 
temporary relief of pain in a small percentage of patients.  
This chronic pain is highly invalidating because it directly impacts on lifestyle of sufferers who very often 
are forced to leave their work influencing the social life and psychological and emotional condition 
characteristic of the individual. This obviously poses enormous costs to society in terms of healthcare 
and social care.  
For these reasons, nowadays, the development of new and efficacious therapies to contrast painful 
neuropathy represents a priority. 
Neuropathic pain arises from lesions to both the central and peripheral nervous system and in the 
human many etiologies have been recognized, including [Sacerdote et al., 2013]:  
- mechanical nerve injuries/compression; 
- spinal cord injuries; 
- metabolic diseases (e.g. diabetes); 
- viral diseases (e.g. herpes zoster, HIV); 
- inflammatory/immunological mechanisms (e.g. Multiple sclerosis); 
- alcoholism (vitamin B12 deficiency); 
- iatrogenic: cancer chemotherapy(e.g. cis-platinum), anti-viral treatmets (AIDS) or anti-tuberculosis 
medications (isoniazide)  
- vascular lesions of the hypothalamus; 
- congenital (e.g. Charcot-Marie-Tooth); 
- aging.   
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Whatever the cause, neuropathic patients typically exhibit a mixture of sensory loss with ongoing 
spontaneous pain and enhanced sensitivity to innocuous stimuli, i.e. mechanical allodynia. Mechanical 
and thermal hyperalgesia (increased pain response to painful stimuli) are also frequent and classical 
symptoms [Treede et al., 2008; Zimmermann, 2001; Colleoni and Sacerdote, 2010].  
Much of the initial research on the pathophysiological basis of neuropathic pain focused on the plasticity 
properties of neurons following a nerve injury, leading to the proposal of both peripheral and central 
sensitisation as important disease mechanisms [Sacerdote et al., 2013]. 
Peripheral and central amplification is mediated by changes in the expression and distribution of ion 
channels (sodium and calcium channel); expression of receptors and neurotransmitters; increased 
neuronal excitability and ectopic generation of action potentials; axonal atrophy, degeneration or 
regeneration (Wallerian degeneration); damage to small fibers; neuronal cell death and reorganization 
of central nociceptive circuits [Costigan et al. 2009; Latremoliere and Woolf, 2009]. Loss of spinal 
inhibitory control and changes in the balance of facilitation/inhibition within descending pain 
modulatory pathways are other mechanisms which contribute to neuropathic pain development 
[Tesfaye et al., 2013]. 
Recently it has emerged that neuropathic pain pathogenesis and maintenance also involve a 
pathological interaction between neurons, inflammatory immune cells and glia cells, as well as a wide 
cascade of pro- and anti- inflammatory cytokines [Austin and Moalem Taylor, 2010; Calvo et al. 2012]. 
Neuronal injury therefore, not only results in profound modifications of the activity of sensory neurons 
and their central projection pathways, but is also coupled to a sustained immune-inflammatory 
response at different anatomical locations associated to chronic pain processing, i.e. nerve, DRG, spinal 
cord and brain [Calvo et al., 2012]. 
 
1.2.1 Neuropathic pain triad (neurons, immune cells and glia) 
Peripheral nerve injury 
provokes the recruitment 
of immune cells as well 
as the activation of 
resident cells at the site 
of injured nerve, in the 
DRG, and in the spinal 
cord. Communication among immune cells and immune-like glial cells along the way of pain 
transmission is driven by a plethora of immune cell-derived inflammatory cytokines and chemokines, 
which are crucial mediators for the development and maintenance of persistent pain state. 
 
Image 2| Peripheral nerve injury. [Image modified from Scholz & Woolf, 2007] 
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1.2.1.1 Neuroimmune interactions in injured nerve 
Macrophages act as pivotal mediators in the peripheral inflammatory reactions to nerve lesion. 
Immediately after nerve injury, resident macrophages rush to the lesion site like a rapid-response team 
[Mueller et al., 2001]. 
Neutrophils also participate in the very early immune response to nerve injury, particularly during the 
first 24 hours after injury, reinforcing macrophage recruitment through the release of chemoattractans 
and cytokines [Perkins and Tracey, 2000].  
 
Activated macrophages and Schwann cells produce matrix metalloproteases that interrupt blood-nerve 
barrier [Shubayev et al., 2006]. In addition, vasoactive mediators including CGRP, SP, bradykinin and 
nitric oxide released from injured axons promote further invasion of monocytes and lymphocytes at site 
of injury by increasing vascular permeability. As results of these vascular changes, two days after injury, 
a dense cellular infiltrate predominantly composed by macrophages, T lymphocytes and mast cells, 
forms at the lesion site [Scholz and Woolf, 2007].  
Resident and infiltrating immune cells as well as Schwann cells release pro-inflammatory cytokines, such 
as TNF-α, IL-1β, IL-6 that contribute to axonal damage, and several other factors including chemokines, 
PGs and NGF, responsible for the initiation and maintenance of sensory abnormalities after injury.  
Macrophages and Schwann cells are also implicated in the Wallerian degeneration of axotomized nerve 
fibers distal to nerve lesion. Macrophages remove by phagocytosis dead or dying remnants of injured 
Schwann cells, axotomized axons and myelin debris [Bruck, 1997], thus facilitating the reorganization of 
Schwann cells in order to activate axonal repair.  
Schwann cells, in turn, release chemical signals, such as NGF and GDNF, that promote axonal growth and 
remyelination [Esper and Loeb, 2004]. However, these growth factors induce pain initiation directly 
activating and sensitizing nociceptors [Malin et al., 2006].  
 
 
Image 3| Inflammatory 
changes associated with 
wallerian degeneration. 
[Image modified from Scholz & 
Woolf, 2007]  
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The inflammatory responses to nerve injury driven by resident and infiltrating cells, particularly by 
macrophages, directly contribute to pain hypersensitivity. Hyperalgesia is delayed in genetically 
manipulated WLDs mice, in which Wallerian degeneration and the recruitment of macrophages in 
response to nerve injury are delayed [Myers et al., 1996; Araki et al., 2004]. Moreover, systemic 
depletion of macrophages reduces mechanical hypersensitivity after peripheral nerve injury in animal 
models, revealing their crucial role in the generation of neuropathic pain [Liu et al., 2000]. 
Uninjured fibers also contribute to the development of pain. Crossing the degenerating environment 
they change their biologic properties with increased spontaneous activity and up-regulate nociceptive 
molecules like TRPV1, cytokines and chemokines. They also develop an enhanced responsiveness to pro-
inflammatory cytokines. 
 
1.2.1.2 Neuroimmune interactions in DRG 
Normally, macrophages and few T 
lymphocytes reside in DRG. Their 
numbers increase after nerve damage. In 
parallel satellite glia cells begin to 
proliferate.  
These resident immune and glia cells 
strongly react to nerve injury and their 
response is reinforced by invading 
macrophages and T cells. Injury-induced 
macrophage invasion appears to be 
triggered by the release of chemokines 
from DRG neurons [Zhang and 
DeKoninck, 2006]. The accumulation of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and chemokines 
in the DRG after injury contributes to the sensitization of sensory neurons [Levin et al., 2008; Uceyler et 
al., 2007]. 
TNF-α acts to increase the density of tetrodotoxin-resistant (TTX-R) sodium channel currents within DRG 
neurons [Jin and Gereau, 2006], while other cytokines such as IL-6 regulate the synthesis of 
neuropeptide transmitters. The resultant changes in the phenotype of sensory neurons is likely to alter 
the efficacy of their synaptic input to the spinal cord [Scholz and Woolf, 2007]. 
Moreover, it was found that deletion of IL-1β receptor or IL-1RA overexpression inhibit the development 
of spontaneous sensory neuron firing, and blocking IL-1β or IL-6 mediated signalling attenuates 
neuropathic pain-like behavior [Arruda et al., 2000; Wolf et al., 2006]. 
 
Image 4|Immune response in DRG. 
[Image modified from Scholz & Woolf, 2007] 
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1.2.1.3 Neuroimmune interactions in spinal cord 
Spinal cord glia activation is a common underlying mechanism that leads to development and 
maintenance of chronic pain. Microglia and astrocytes have in fact a well-documented role in pain 
facilitation, modulating neuronal synaptic function and excitability by various mechanisms [Halassa et 
al., 2007; Pocock and Kettenmann, 2007]. In spinal cord and supra-spinal sites within CNS microglia 
predominate in the early glial response, subsequently followed by activation and proliferation of 
astrocytes. CGRP, SP, glutamate and ATP released from the presynaptic terminals of the primary 
afferents after nerve injury determine the activation of spinal microglia and astrocytes.  
Once become activated, these cells release immune mediators which diffuse and bind to receptors on 
presynaptic and postsynaptic terminals in the spinal dorsal horn to modulate excitatory and inhibitory 
synaptic transmissions, resulting in nociceptive hypersensitivity.  
The release of inflammatory mediators, such as TNF-α, IL-1β, IL-6, nitric oxide, ATP and prostaglandins 
initiates in fact a self-propagating mechanism of enhanced cytokines expression by microglial cells. The 
production and subsequent release of pro-inflammatory cytokines from activated microglia cells leads 
to further activation of neighboring astrocytes [Watkins and Maier, 2003]. The activation of astrocytes 
results in the prolongation of a pain state [Dinarello, 1999]. 
TNF-α, IL-1β and IFN-γ, chemokines and reactive oxygen species (ROS) directly modulate excitatory 
synaptic transmission at central terminals by enhancing glutamate release. Their effect is partly due to 
the activation of transient receptor potential channel subtypes (TRPV1 and TRPA1), and the functional 
coupling between IL-1β receptor and NMDAR [Grace et al., 2014]. 
TNF-α and IL-1β from astrocytes increase neuronal excitability and synaptic strength by increasing the 
conductivity of glutamate AMPA and NMDA receptors, as well as by increasing the trafficking and 
surface expression of glutamate AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid) 
receptors, which render neurons vulnerable to excitotoxicity [Beattie et al., 2002; Stellwagen and 
Malenka, 2006]. IL-1β also induces the phosphorylation of specific NMDA receptor subunits (i.e. NR1 
and NR2A or NR2B subunits) leading to its activation [Stellwagen et al., 2005; Zhang et al., 2008; Viviani 
et al., 2003]. NMDA receptor channel opening leads to the influx of calcium and to increased production 
of NO and PGE2, which are involved in amplifying the excitability of pain-projection neurons [Milligan 
and Watkins, 2009].  
Excitatory synaptic transmission is further indirectly enhanced as the spinal astrocyte glutamate 
transporters, Excitatory Amino Acid Transporter 1 (EAAT1) and EAAT2 are persistently downregulated 
after peripheral nerve injury, leading to excitotoxicity and nociceptive hypersensitivity [Xin et al., 2009; 
Ramos et al., 2010]. 
Cytokines, chemokines and ROS also decrease GABA and glycine release from interneurons and 
inhibitory descending projections, leading to spinal cord pain circuits disinhibition, phenomenon known 
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to be implicated in the genesis of central sensitization and chronic pain [Latremoliere and Woolf, 2009]. 
Brain-derived neurotrophic factor (BDNF) released as a consequence of microgliosis, also contributes to 
pain inhibition/ disinhibition by causing a depolarization shift that inverts the polarity of currents 
activated by the inhibitory neurotransmitter GABA in spinal second-order nociceptive projection 
neurons [Milligan and Watkins, 2009].  
It is also important to highline that either in peripheral nerve and DGR or in CNS a complex network of 
regulatory circuits controls immune signalling after neuronal insult. These mechanisms include the 
production of anti-inflammatory mediators and the polarization of specialized immune and glia cells 
with an anti-inflammatory phenotype to prevent uncontrolled inflammation [Grace et al., 2014]. 
 
Alternatively activated microglia (also known as M2 macrophages), sub-populations of T lymphocytes 
(i.e. Th2 and Treg cells) as well as macrophages contribute to the resolution of nociceptive 
hypersensitivity after nerve injury, by releasing naturally anti-inflammatory mediators which include IL-
10, IL-4 and IL-1RA. 
IL-10 and IL-4 cytokines indirectly inhibit the synthesis of pro-inflammatory/pro-nociceptive cytokines 
and chemotactic factors by microglia, T-cells and macrophages regulating and promoting the 
differentiation of immune-like cells towards an anti-inflammatory profile.  
Intrathecal IL-1RA administration and the elevation of IL-10 and IL-4 levels in spinal cord result in 
attenuated nociceptive hypersensitivity associated to gliosis [Watkins et al., 1997; Leger et al., 2011]. 
 
 
Image 5| Recruitment and activation of spinal microglia and astrocytes. 
Image modified from Scholz & Woolf, 2007] 
 
[Image modified from Scholz & Woolf, 2007]  
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1.2.2 Pharmacological considerations: present and future 
Pain processing involves multi-pathways and dynamic systems in the periphery, spinal cord and brain 
which expose potential pharmacological targets for analgesia. Some of these are already exploited in 
clinic by existing analgesics [Farquhar-Smith, 2008]. 
Opioids are among the most powerful analgesics. Their efficacy can be explained by the large 
distribution of opioids receptors in the spinal cord and in areas of brain associated to descending pain 
modulatory pathways as locus coeruleus and PAG. Thus, opioids induce analgesia acting both on 
transmission and pain perception. 
The fact that most of pain inhibitory pathways are noradrenaline/serotonin-based pathways indicate 
why the antidepressants (inhibitor of noradrenaline/serotonine re-uptake) may be effective in 
controlling pain.  
Anticonvulsants induce analgesia acting on neuron excitability through the blocking of sodium and 
calcium channels; similarly capsaicin exerts its analgesic effect binding to TRPV1 channel. Non-steroidal 
anti-inflammatory drugs (NSAID), that prevent the formation of prostaglandins by inhibiting 
cyclooxygenase (COX), are generally not efficacious in neuropathic pain treatment . 
Moreover, considering the key role of the neuroimmune interface in chronic pain there is great interest 
in targeting immune and glia functions for pain management. Several promising strategies to target the 
neuroimmune interface include the direct inhibition of pro-inflammatory signalling, the stimulation of 
local protective anti-inflammatory mechanisms and inhibition of specific immune mediators [Grace et 
al., 2014].  
In this direction, a better knowledge of the mechanisms underlying neuropathic pain could lead to the 
identification of novel promising targets for the development of more efficacious analgesic therapy. 
 
1.2.3 Classical pharmacological treatments 
Pain has a very complex nature. Nowadays there are no drugs for neuropathic pain treatment acting in a 
complete and definitive way. 
Currently, lidocaine, lamotrigine, acetaminophen, dextromethorphan, carbamazepine, gabapentin, 
valproic acid, opioid analgesics, tramadol hydrochloride, and tricyclic antidepressants are used for the 
classical pharmacological treatment of neuropathic pain; but neuropathic pain responds poorly to 
classical analgesics (acetaminophen, NSAIDs and opioids) and the reference treatments are only partially 
effective. Three molecules have specific authorization in this indication: calcium channels α2 δ subunit 
ligands, gabapentin and its successor pregabalin; and duloxetine, a serotonin and norepinephrine 
reuptake inhibitor (SNRI). 
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1.3 Diabetes 
Diabetes mellitus (DM) is a group of metabolic disorders characterized by chronic hyperglycaemia with 
impaired metabolism of carbohydrate, fat and proteins as a result of endogenous insulin deficiency 
and/or resistance [Davey et al., 2014].  
Polydipsia, polyphagia, polyuria, blindness, weight loss or gain, burning and tingling sensation are some 
of distinct symptoms associated to diabetic status and are common for the two main forms of diabetes: 
type 1 (DMT1) and type 2 (DMT2) diabetes.  
Both types of diabetes are characterized by a progressive failure of pancreatic β-cells but the 
mechanisms leading to pancreatic cell death are quite different in the various forms of the disease 
[Cnop et al., 2005]. In type 1 diabetes β-cell destruction arises from an autoimmune assault against 
pancreatic cells by autoreactive T lymphocytes resulting in chronic pancreatic inflammation (process 
known as insulitis) which culminates with an absolute insulin deficiency. During insulitis, invading 
immune cells, including Th1 (CD4 and CD8) lymphocytes, macrophages and dendritic cells, participate to 
destruction of pancreatic β-cells by directly triggering cytotoxic processes or releasing pro-inflammatory 
cytokines.  
IL-1β, IFN-γ and TNF-α are important pro-inflammatory mediators. These cytokines induce β-cell 
apoptosis via the activation of pancreatic cell gene networks under the control of different transcription 
factors, including Nf-kB. The activation of Nf-kB leads to nitric oxide and chemokines production and 
depletion of endoplasmatic reticulum calcium, which ultimately contribute to pancreatic cell 
destruction. Parallel, anti-inflammatory cytokines, such as IL-4 and IL-10, produced by activated Th2 
lymphocytes, prevent β-cell destructive insulitis, indicating that an imbalance between pro- and anti-
inflammatory cytokines could be essential for the development of type 1 diabetes [Amirshahrokhi and 
Ghazi-Khansari, 2012]. 
The pathogenesis of type 2 diabetes is more variable than that of type 1 diabetes as it is linked to a 
combination of genetic and lifestyle factors that result in different degrees of insulin resistance and 
deficiency. Chronic exposure to elevated glucose and free fatty acids causes β-cell dysfunction and may 
induce β-cell apoptosis in type 2 diabetes [Cnop et al., 2005]. Islet cell inflammation as result of altered 
immune activation has since long time been recognized in type 1 diabetes, and now it is increasingly 
implicated in the pathogenesis of type 2 diabetes leading to defects in β-cell secretion (Das and 
Mukhopadhyay, 2011). 
Inflammation and alteration in immune system thus result as common underpinning mechanisms in the 
pathophysiology of type 1 and type 2 diabetes as well as of their complications [Agrawal and Kant., 
2014]. 
Elevation of systemic inflammatory mediators was found in patients with type 1 and type 2 diabetes 
[Agrawal and Kant, 2014; Davey et al., 2014].  
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COMPLICATIONS 
OF DIABETES 
MELLITUS
DIABETIC
RETINOPHATY
LEADING CAUSE OF BLINDNESS 
IN ADULTS 
(Fong et al., 2003)
DIABETIC 
NEUROPATHY
LEADING CAUSE OF NON-
TRAUMATIC LOWER EXTREMITY 
AMPUTATIONS                                   
(Gray et al., 1997)
DIABETIC 
NEPHROPATHY
LEADING CAUSE OF ENDSTAGE 
RENAL DISEASE 
(Molitch et al., 2003)
CARDIOVASCULAR 
DISEASE
8/10 INDIVIDUALS WITH DIABETES 
DIE FROM CV EVENTS 
(Gray et al., 1997)
STROKE
2- TO 4-FOLD INCREASE IN cv 
MORTALITY AND STROKE
(Kannel et al., 1990)
OTHER
ACUTE DIABETIC COMPLICATIONS: 
DIABETIC KETOACIDOSIS, 
HYPEROSMOLAR HYPERGLYCAEMIC 
SYNDROME AND DIABETIC LACTIC 
ACIDOSIS. 
(Wu et al., 2017)
The establishment of a persistent hyperglycaemic state in diabetes causes a series of physiological 
dysfunctions in the organism which, over time, turn into very serious complications responsible of the 
high rate of morbidity and mortality in diabetes sufferers. 
These complications are associated to a progressive, dramatic failure and dysfunction of the vascular 
system. They are grouped in “macro-vascular complications” and “micro-vascular complications” 
depending on the vascular district which is affected. 
Macro-vascular complications result from damage to arteries that supply the heart, brain, and lower 
extremities and include accelerated cardiovascular disease, peripheral arterial disease, myocardial 
infarction, stroke and limb amputation [Hofmann and Brownlee, 2004; Forbes and Cooper, 2013].  
The complications resulting from damage to small blood vessels are grouped as microvascular 
complications. Persistent chronic hyperglycemia resulting in the development of diabetes-specific 
microvascular complications in the retina, renal glomerulus, and peripheral nerves are characteristic of 
all forms of diabetes. Microvascular complications are classified into retinopathy, nephropathy, and 
neuropathy [Davey et al., 2014]. 
 
1.3.1 Diabetes complications 
As reported above, diabetes mellitus (DM) 
is a complex metabolic disorder that is 
associated with insulin resistance (IR), 
impaired insulin signalling, β-cell 
dysfunction, abnormal glucose levels, 
altered lipid metabolism, sub-clinical 
inflammation and increased oxidative 
stress [Testa et al., 2016]. Acute diabetic 
complications occur in the early stage of 
diabetes and include hyperglycaemia, 
diabetic ketoacidosis, hyperosmolar 
hyperglycaemic syndrome and diabetic 
lactic acidosis. Chronic diabetic 
complications that occur in the later 
developmental stage of diabetes include cerebral vascular disease, diabetic coronary artery disease 
(CAD), diabetic peripheral neuropathy (DPN), diabetic retinopathy (DR), diabetic nephropathy (DN), 
lower extremity vascular disease and diabetic foot disease . 
 
 
Image 6| Diabetic             
                 complications 
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1.3.1.1 Painful diabetic neuropathy 
Diabetic neuropathy is one of the most frequent long-term complications of diabetes. It affects about 
60% of diabetic population and is a source of morbidity and mortality in diabetic patients [Aslam et al., 
2014]. This type of peripheral nervous disorder is characterized by a progressive neuronal death, 
dymyelination and suppression of the nerve regeneration mechanisms, resulting in an impaired nerve 
functioning.  
Nerve damage can involve both the autonomic and the sensorimotor divisions of the nervous system, so 
every nerve fiber in the body is potentially vulnerable.  
Diabetic neuropathic patients typically experience lack of sensibility in several areas of the body and lose 
the capacity to perceive the temperature or even painful stimuli, with a consequent impairment of the 
quality of life. Further, the progressive loss of innervations can lead to atrophy of essential pedal 
muscles, resulting in deformities that predispose the patient to ulceration and in the more severe cases 
to lower extremities amputation [Duby et al., 2004]. Severity of symptoms increases gradually over time 
and correlate with the degree of hyperglycaemia [Han et al., 2013]. 
There are many types of diabetic neuropathy. Depending on the organ systems the types of nerves 
affected and the entity of the nerve damage, which can be diffused or well localized, diabetic 
neuropathies are classified in: diffuse somatic neuropathy, autonomic neuropathy and focal neuropathy. 
Among these, the sensorimotor neuropathy or distal symmetrical polyneuropathy (DSPN) is the most 
common form.  
DSPN affects both large and small sensory fibres resulting in a mixture of symptoms and sensory loss. 
The onset of the neuropathy is usually gradual and insidious and is heralded by sensory symptoms that 
start from the most distal extremities of the limbs (toes and fingers) and progress proximally in a 
symmetrical “glove and stocking” distribution [Tesfaye et al., 2013]. The syndrome involves initially the 
lower limbs.  
Approximately 50% of patients with DSPN exhibit neuropathic pain symptoms, which include 
uncomfortable tingling in the lower limbs (dysesthesia), spontaneous and evoked pain and numbness. 
Unusual sensations such as feeling of swelling of the feet or severe coldness of the legs when clearly the 
lower limbs look and feel fine, odd sensations on walking likened to “walking on pebbles” or “walking on 
hot sand” are other characteristic clinical manifestations of the disease [Tesfaye et al., 2013]. The pain is 
often worse at night and interferes with normal sleep causing tiredness during the day. The constant 
unremitting pain negatively impacts on the quality of life of diabetic patients resulting in form of 
depressions; in some cases patients experience loss of appetite and body weight known as “diabetic 
neuropathic cachexia” [Aslam et al., 2014].  
The exact pathophysiology of diabetic neuropathic pain is not fully understood. However, the 
abnormalities of pain processing in the peripheral and central nervous system which are supposed to 
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contribute to the development and maintenance of neuropathic pain could be related to 
hyperglycaemia, as this is the classic metabolic abnormality of diabetes [Aslam et al., 2014]. 
 
1.3.1.1.1 Pathogenesis of diabetic neuropathy 
Despite decades of intensive researches, the pathogenesis of the diabetic neuropathy has not been yet 
fully elucidated. Hyperglycaemia is considered to be one of the major pathophysiological determinants 
of the disease. However, the cause of this syndrome is more complex than dysregulated glucose levels 
alone [Han et al., 2013]. Several factors have been postulated to participate in the diabetic neuropathy 
pathogenesis, including microcirculatory dysfunction, impaired insulin signalling, growth factor 
deficiency and inflammation.  
All these abnormalities are intertwined through numerous competing or parallel pathways and are 
supposed to contribute to a pathological self-perpetuating cycle of oxidative stress, inflammation and 
cellular dysfunction ultimately resulting in the progression of neurovascular disease associated to loss of 
nerve fibers.   
Polyol pathway, advanced glycation end-product (AGE) production, poly-ADP ribose polymerase (PARP) 
over activation, protein kinase C (PKC) and altered Na+/K+ ATPase activity are some of the molecular 
mechanisms underlying diabetic neuropathy [Sandireddy et al., 2014].  
 
 Hyperglycaemia 
Prolonged hyperglycaemic state contributes to cell damage and thus to neuropathy, through the 
generation of oxidative stress, as the final result of increased glycolysis, polyol pathway activity and 
generation of AGE products. Excess of glycolysis overloads the mitochondrial electron transport 
chain promoting the production of reactive oxygen species (ROS), while the abnormal high rate 
glucose “flux” through the polyol pathway leads to NAPDH depletion causing oxidative stress. 
Accumulation of reactive oxygen species (ROS) increases lipid, DNA and protein peroxidation, 
induces cellular apoptosis, reduces nerve blood flow (NBF) and induces impairment of vasodilation 
of epineural blood vessels, which results in ischemia to the neural tissue. Oxidative stress also leads 
to deterioration of Schwann cells, which play a key role as a provider of insulation for neurons, 
immunologic perineurial blood nerve barrier, and effector of nerve regeneration [Han et al., 2013]. 
The production of AGEs can impair cellular function by altering the structure and so the biological 
function of essential proteins. Moreover, binding to receptors (RAGE), AGEs can trigger an 
inflammatory cascade that involves the activation of MAPK and PKC pathways and that ultimately 
generate oxidative stress [Duby et al., 2004].  
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 Impaired insulin signalling 
Insulin is essential for general neuronal function as it promotes neuronal growth and survival. Insulin 
receptors are present in DRG sensory neurons and in peripheral axons sustaining epidermis and 
after physical injury of peripheral nerves they increase [Guo et al., 2011].  
In diabetic mice, local or intranasal insulin administrations improve sensory nerve fiber density in 
the plantar foot pad and mechanical sensation [Francis et al., 2009].  
In DMT1 patients, the reduction of C-peptide, marker for pancreatic β-cells functionality, contributes 
to nerve dysfunction by reducing the activity of Na+/K+ ATPase and eNOS and the endoneurial blood 
flow.  
Treatment with C-peptide can slow down the progression of neuropathy [Ekberg and Johansson, 
2008]. Tight glucose control with insulin supply can also reduce neuropathy in DMT1 patients. 
However, the reduction of glucose levels is not enough to block the vicious cycle of oxidative stress, 
inflammation and cellular damage triggered by hyperglycaemia [Han et al., 2013]. 
 
 Vascular and growth factor deficiency 
Various studies report a major pathophysiological role of vascular and neurotrophic supply in 
diabetic neuropathy. 
Maintaining adequate blood supply to nerves is crucial for maintaining nerve structure and function 
[Han et al., 2013]. Deficiency in the nerve blood perfusion resulting in ischemic hypoxia largely 
contributes to pathogenic mechanisms of diabetic neuropathy as it determines malnourishment of 
nerve and thus neuronal dysfunction.  
Pathologies of nervous and vascular system are highly intertwined in diabetes. As the disease 
progresses, neuronal dysfunctions correlate closely with the development of vascular abnormalities. 
Diabetic foot is a common complication for diabetic people associated with epidermal thickness 
alteration, recent studies demostrated that in pure diabetic patients the average epidermal 
thickness of plantar skin was increased (capillary basement membrane thickening and endothelial 
hyperplasia) while was decreased in people with diabetic neuropathy [Chao et al., 2011; Duby et al., 
2004]. Impaired vasodilation in diabetic epineurial arterioles (caused by ROS) decreases nerve 
conduction velocity.  
Neurotrophic support has also an important role in diabetic neuropathy. Reduced neurotrophic 
supply in experimental diabetes was found to contribute to nerve malnourishment and neuronal 
dysfunction [Ekberg and Johansson, 2008].  
Many growth factors exert both neurotrophic and angiogenic effects. In ischemic tissues, VEGF 
induces angiogenesis by stimulating the proliferation and migration of endothelial, thus improving 
tissue ischemia. It also promotes axonal outgrowth and survival of neurons and Schwann cells in 
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DRG. Like VEGF, IGF induces vessel remodelling and has neurotrophic effect. It also stimulates 
Schwann cell mitogenesis and myelinisation. NGF, a well-known neurotrophic factor, promotes 
survival and differentiation of sensory and sympathetic neurons [Han et al., 2013]. Moreover it 
provides neuroprotective and repair functions. In addition to these neurotrophic effects, NGF 
directly induces angiogenesis [Kim et al., 2012].  
 
 Neuroinflammation 
Oxidative stress in combination with the activation of the classic metabolic pathways mentioned 
above, especially the MAPK signalling and the increased production of AGEs, can directly or 
indirectly initiate and progress the production of inflammatory mediators leading to 
neuroinflammation and thus nerve damage. 
Activation of RAGE on microglia and macrophages initiates an inflammatory cascade through the 
activation of the transcriptional factor Nf-kB, a potent inducer of the inflammatory processes [Yan et 
al., 1994]. The activation of this transcriptional factor results in the up-regulation of genes encoding 
for pro-inflammatory cytokines (IL-1β, TNF-α and IL-6) and chemokines, induction of neuronal 
apoptosis, and suppression of antioxidant genes with a consequent weakening of the innate 
antioxidant defence [Ganesh et al., 2013]. 
A persistent hyperglycaemic state also induces neuroinflammation by affecting the structural 
features of neurons; the glycosylation of myelin proteins alters their antigenicity and causes the 
infiltration of monocytes, macrophages, neutrophils from the blood circulation as well as the 
activation of glia cells [King, 2001; Shi et al., 2013].  
Moreover, NADP depletion mediate by PPARs (Peroxisome proliferator-activated receptors) 
overactivation leads to bioenergic failure driving the cells towards necrosis. This mechanism 
contributes to neuroinflammation as the release of cellular debris by necrotic cells determines the 
recruitment of further inflammatory cells to injury site which enhance the local inflammatory 
response [Szabò, 2003].  
Inflammatory cytokines released by either resident or infiltrating cells mediate damages to myelin 
sheets and increase nerve excitability leading to edema and neuroinflammation. Moreover, 
inflammatory cells have a vicious positive feedback loop for increasing further production of 
inflammatory mediators thus potentiating nerve derangement [Sandireddy et al., 2014]. 
Hypoxia and ischemia created in diabetes aggravate the neuroinflammation by inducing iNOS 
activity, which is responsible for the release of nitric oxide (NO), another important mediator of 
inflammation. 
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1.3.1.2 Diabetic nephropathy 
In the diabetic milieu, metabolic derangements and hemodynamic alterations, particularly activation of 
the renin–angiotensin system, trigger a number of cell signaling cascades, including the MAPKs (p38 and 
JNK) and PKC-β, which mediate a cellular response through activation of key transcription factors such 
as NF-κB. In response to such signals, renal cells such as tubular epithelial cells, podocytes, and 
mesangial cells can produce chemokines, growth factors, and profibrotic cytokines. CSF-1 and MCP-1 
function as chemotactic molecules and promote the recruitment of monocytes from the circulation. 
Upregulation of ICAM-1 on endothelial cells – a key leukocyte adhesion molecule - facilitates infiltration 
of circulating mononuclear cells into the kidney. CSF-1 also promotes monocyte/macrophage 
differentiation, proliferation, and activation. MIF functions to retain macrophages at sites of 
inflammation and has counter-regulatory functions against the anti-inflammatory actions of 
glucocorticoids. Activated macrophages can produce proinflammatory and profibrotic cytokines, 
reactive oxygen species, and antiangiogenic factors and contribute to a cycle of inflammation, oxidative 
stress, cellular injury, progressive fibrosis, and loss of glomerular filtration rate. Podocyte loss, 
endothelial dysfunction, alterations in the tubular injury contribute to increasing proteinuria during the 
development and progression of diabetic nephropathy. Diabetic nephropathy or diabetic kidney disease 
is a syndrome characterized by the presence of pathological quantities of urine albumin excretion, 
diabetic glomerular lesions, and loss of glomerular filtration rate (GFR). This diabetes complication is 
characterized by structural and functional changes: in glomeruli, there is mesangial expansion, 
thickening of the basement membrane, and, characteristically, nodular glomerulosclerosis (Kimmelstiel–
Wilson nodules). Initially tubular hypertrophy is present but eventually interstitial fibrosis with tubular 
atrophy develops, along with arteriolar hyalinosis. In advanced cases, there is an infiltrate of 
macrophages and T-lymphocytes. Ultrastructurally, there is podocyte loss and reduced endothelial cell 
fenestration [Toyoda et al., 2007]. Functionally, there is early glomerular hyperfiltration and increased 
albumin excretion; and with advancing nephropathy, increasing proteinuria and declining GFR. Pathways 
that promote this pathology are many, complex, overlap and interact with one another and enhance 
one another’s biophysiological effects.  
 
 Hemodynamic factors  
There is an imbalance in afferent and efferent arteriolar resistance, resulting in increased glomerular 
hydrostatic pressure and hyperfiltration. Activation of the renin–angiotensin system (RAS) increases 
angiotensin II levels, leading to efferent arteriolar vasoconstriction and production of 
proinflammatory and profibrotic molecules through multiple mechanisms. High angiotensin 
converting enzyme (ACE) levels are associated with greater albuminuria and nephropathy in diabetic 
mice and humans [Huang et al., 2001]. Increased levels of endothelin-1 and urotensin II also 
  
   34 
  Chapter 1: Introduction
contribute to vasoconstriction. Various dysregulation of nitric oxide and nitric oxide synthase has 
been described in DN. Nitric oxide mediates endothelium-dependent vasodilatation, and is formed 
from L-arginine by endothelial nitric oxide synthase. Diabetic endothelial nitric oxide synthase 
knockout mice develop more severe glomerular lesions and proteinuria compared to wild-type mice 
[Kanetsuna et al., 2007]. 
 
 Metabolic factors  
Oxidative stress and generation of reactive oxygen species (ROS) damage DNA and protein, or 
function as signaling amplifiers to activate cellular stress pathways such as PKC, MAPK, and                                         
NF-κB [Haneda et al., 1997; Ha and Lee, 2000]. Activation of the polyol pathway, with aldose 
reductase converting excess glucose to sorbitol, and subsequent conversion to fructose by sorbitol 
dehydrogenase contributes to oxidative stress by increasing the NADH/NAD+ ratio [Srivastava et al., 
2005; Williamson et al., 1993]. A recently described novel mechanism of injury also involves 
endogenous fructose production with activation of fructokinase in the proximal tubule [Lanaspa et 
al., 2014]. The formation of advanced glycation end-products (AGE) by nonenzymatic binding of 
glucose to proteins, lipids, and nucleic acids can lead to alteration of protein structure and function, 
oxidative stress, and expression of proinflammatory cytokines and growth factors [Sheetz and King, 
2002]. 
 
 Growth factors/cytokines  
Activation of TGF-β and its downstream cytokine, CTGF (Connective tissue growth factor), induce 
extracellular matrix formation and fibrosis. In kidney biopsies, glomerular expression of TGF-β1 and 
CTGF were higher in diabetics compared to controls, and correlated with albuminuria. PDGF 
expression is also increased in DN, which can modulate chemotaxis, vascular tone, and platelet 
aggregation. VEGF is crucial in angiogenesis but also mediates vasodilatation and leukocyte 
trafficking in DN [Lim, 2014]. 
 
 Cell signaling and transcription factors 
Increased renal gene transcription of PKC-β showed a strong relationship with glycemic control 
[Langham et al., 2008]. PKC activation has wide ranging effects, including enhancing angiotensin II 
actions, nitric oxide dysregulation, endothelial dysfunction, and activation of MAPK and NF-κB [Noh 
and King, 2007; Derubertis and Craven, 1994]. MAPKs are intracellular kinases which integrate cell 
signaling into cellular responses. MAPKs activate a number of nuclear transcription factors, including 
NF-κB, which then regulates the gene expression of various cytokines, chemokines, and adhesion 
molecules. The activation of p38α isoform of the p38 MAPK pathway is most strongly associated 
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with renal inflammation and DN [Sakai et al., 2005; Adhikary et al., 2004]. There may also be a role 
for toll-like receptors (TLR2, TLR4) and B7-1 costimulatory signaling in modulating inflammation and 
injury in DN [Fiorina et al., 2014; Mudaliar et al., 2013]. Finally, transcription factors bind to the 
promoter regions of genes and modulate transcription of messenger RNA. NF-κB has been the best 
studied in DN. Activation of NF-κB in both human peripheral blood mononuclear cells and kidney 
biopsies correlate with severity of proteinuria and glycemic control [Schmid et al., 2006; Hofmann et 
al., 1998]. A review of transcription factors in DN is provided by Sanchez and Sharma [Sanchez and 
Sharma, 2009]. 
 
 Inflammation 
In diabetic nephropathy, there is recruitment and activation of innate immune cells and elaboration 
of proinflammatory cytokines [Lim and Tesch, 2012]. Macrophages and T-lymphocytes are 
prominent in early diabetic glomeruli while an interstitial infiltrate develops later. Strategies 
impairing kidney leukocyte recruitment, proliferation, or activation have demonstrated that 
macrophages mediate DN [Chow et al., 2007; Lim et al., 2009]. In humans, kidney macrophage 
accumulation is associated with the severity of glomerulosclerosis [Furuta et al., 1993]. 
Accumulation of interstitial macrophages correlated strongly with proteinuria, interstitial fibrosis, 
and GFR decline [Nguyen et al., 2006]. The role of lymphocytes is less clear. A higher circulating level 
of activated T-cells is associated with DN [Bending et al., 1988]. A kidney T-cell influx is common in 
early type 1 diabetes, and correlates with renal function and albuminuria [Moriya et al., 2004]. 
However, absence of lymphocytes did not prevent fibrosis and declining renal function in 
experimental DN [Lim et al., 2010]. Recent attention has focused on the subset of regulatory T-cells 
(Treg), which may play a protective role in DN. Treg numbers are increased in diabetic mice [Lim et 
al., 2010]. Treg depletion in diabetic mice exacerbated albuminuria and hyperfiltration, while 
adoptive transfer of Treg improved DN [Eller et al., 2011]. In type 2 diabetics, the number of Tregs as 
determined by flow cytometry showed an inverse correlation with albuminuria, particularly in 
patients with macroalbuminuria [Xu et al., 2009]. Treg also demonstrated an anti-inflammatory 
function, which reduces the metabolic abnormalities and insulin resistance in a mouse model of 
type 2 diabetes [Ilan et al., 2010]. The main proinflammatory cytokines implicated in DN are TNF-α, 
MCP-1, ICAM-1, IL-1, IL-6, and IL-18. These cytokines are increased in diabetic patients and show 
correlation with albuminuria and glomerular pathology [Lim and Tesch, 2012]. 
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1.4 Rodent models of painful diabetic neuropathy  
Although intensive researches over the last decades have contributed to make light of some of 
molecules, receptors, channels and pathways mainly associated to diabetic neuropathy, a clear 
comprehension of the mechanisms underlying the development and maintenance of neuropathic pain is 
unfortunately far. Important advances in the study of neuropathic pain have been achieved using animal 
models, excellent systems to simulate the clinical pain conditions observed in human and to test novel 
therapeutic agents for contrasting this intractable pain. Even if most of animal models of neuropathic 
pain were initially generated in rats as preferred species, now the majority of pain models have been 
transposed in mice for the availability of genetically characterized or manipulated inbred strains in 
which specific proteins or signal transduction components have been altered throughout genetic 
knockout technology [Colleoni and Sacerdote, 2010].   
According to the huge ethiology of human diabetic neuropathy different types of well-characterized 
animal models have been developed over time in order to resemble as closely as possible the 
heterogeneity of the pain manifestations. 
 
1.4.1 Models of diabetes-induced peripheral neuropathic pain 
Experimental models of diabetes exhibit behavioural responses similar to those present in diabetic 
neuropathic patients, including spontaneous pain, decrease in mechanical nociceptive thresholds and/or 
hypoalgesia characterized by decreased responses to mechanical and thermal stimuli [Colleoni and 
Sacerdote, 2010]. 
 
Experimental rodent models of diabetes include [Leither and Herrath, 2004; Roep et al., 2004]: 
 Spontaneous diabetes: T1DM insulinopenic BB /Worchester rats, T2DM hyperinsulinemic BBZDR / 
Worchester rats, NOD mice, LETL rats, Akita mice spontaneous T1DM;  
 Diabetic animals obtained by dietary manipulations: overeating, fasting, shift from a high fat diet 
to a high carbohydrate diet and High-fat diet-fed Mice; 
 
 Diabetic animals obtained by genetic manipulations: Zucker diabetic fatty rat, Obese leptin-
deficient (ob/ob) Mice, Leptin receptor deficient (db/db) mice, nonobese diabetic mice (NOD);  
 
 Chemo-induced pancreatic toxicity: streptozotocin (STZ) and alloxan (ALX) - induced diabetes.  
 
1.4.1.1 Experimental Models of T1DM Induced by Chemical Pancreatectomy 
Two agents can be used to induce chemical pancreatectomy, both are glucose analogs: ALX, a 
pyrimidine derivative (synthesized in 1938) and STZ, an alkylating and antimicrobial agent. Chemical 
properties of these compounds are crucial for their ability to induce diabetes [Lenzen, 2008]. Both are 
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hydrophilic and cannot cross plasma membrane. They use the glucose transporter GLUT2, which is 
expressed by the pancreatic β-cells. Cytotoxic effects of ALX are due to its reduced reaction product, 
dialuric acid, and to the production of reactive oxygen species (ROS) [Szkudelski, 2001] while STZ exerts 
its toxicity through DNA alkylation [Szkudelski, 2001]. Protein glycosylation is an additional deleterious 
factor. STZ induces ADP polymerase over-stimulation leading to a decrease in NAD+ as well as in ATP 
concentration and leads to the activation of apoptotic program that destroys β-cells and all the cells 
expressing the GLUT2 transporter (including cells from the kidney and liver). By performing a 
bibliography research using the database MEDLINE (PUBMED) and the following keywords: “diabetes” 
and “alloxan” or “streptozocin” and “neuropathy” during the last 30 years (i.e. 1982 to 2012), 298 
studies used the antimicrobial agent STZ and only 48 used ALX to induce diabetes. During the last 10 
years (i.e. 2002 to 2012) the ratio ALX:STZ was 9:139 probably due to the poor specificity of alloxan 
compared to STZ against pancreatic β-cells. Indeed STZ generally produces greater cytotoxicity due to its 
conversion to anionic radicals. STZ is more commonly used because of its greater stability and relative 
lack of extrapancreatic toxicity [Lee et al., 2010]. Thus, we focused on STZ-induced diabetic neuropathy 
in mice. 
 
1.4.1.1.1 Clinical signs of STZ-induced diabetes in experimental models 
After STZ administration, hyperglycemia and 
hypoinsulinemia appear in the first days and persist, 
attesting to an irreversible toxicity. A halt in weight 
growth or a weight loss are also observed, moreover 
sometimes decreased weight of the internal organs 
(such as kidney, liver and pancreas) has been 
observed [Brini et al., 2017; Courteix et al., 1994; 
Zafar and Naeem-ul-hassan Naqvi, 2010]. 
Hyperglycemia is concomitant with polydipsia (water 
intake 10-times higher), polyuria and polyphagia [Rondon et al., 2010]. While most morphological, 
histological and electrophysiological studies show that diabetic neuropathy is accompanied by nerve 
structural changes (segmental demyelination and axonal degeneration) and functional changes 
(assessed by nerve conduction velocity) in diabetic patients [Said, 2007], structural changes are rarely 
reported in STZ-induced diabetic mice or appear slowly and later. Tibial nerve biopsies from diabetic rats 
[Walker et al., 1999] reported the lack of abnormal nerve tissue regarding the distribution of 
unmyelinated axons, diameter of myelinated axons, fascicular area, absence of Wallerian degeneration. 
However, abnormalities in the structure of endoneural capillaries presented increased luminal surface 
and decreased endothelial cells size, related to impairment in vaso nervorum.   
Image 7| Streptozotocin 2D structure [PubChem]. 
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1.4.1.1.2 Hypersensitivity in STZ-induced diabetic models 
Behavioral studies assessed in STZ-diabetic model often focus on their response to nociceptive or non-
nociceptive stimuli, because of the absence of quantifiable signs of spontaneous pain. These tests 
consist in measuring time latency or withdrawal thresholds of an animal whose paw or tail is exposed to 
a thermal, mechanical or tactile stimulation. 
Among these behavioural tests, an interesting one consists in placing the animal on plates where the 
animal can spontaneously choose between two temperatures [Moqrich et al., 2005]. This test presents 
the advantage of getting rid of animal handling, therefore allowing the assessment of spontaneous 
behavior towards a range of thermal stimuli, leaving the animal free to stand on one of the two plates of 
different temperatures.  
The use of this test has allowed to reveal the presence of a thermal hypersensibility/hyperalgesia (for a 
temperature > 45°C) in STZ animals [Pichon et al., 2010]. However, thermal hyperalgesia to high 
temperatures is not a common painful symptom in diabetic patients, which makes difficult the 
extrapolation of these results toward clinic [Gold et al., 2006]. Some authors, using the thermal ramp 
test that consists in placing the animal on a surface where the temperature increases of 1°C/sec from 
30°C to 50°C, have observed hypersensitivity during the first few weeks of diabetes, but a 
transformation into a hypoalgesia 1 to 3 month later, signing an evolution of neuropathy toward an 
insensitive neuropathy to hot stimuli, similarly to what can be found in humans [Guy et al., 1985], and 
consistent with the loss in thermal nociceptors that was reported in diabetic patients [Kennedy and 
Wendelschafer-Crabb, 1996].  
Altered perception of tactile stimuli (light touch) and mechanical (pressure) are principal symptoms in 
diabetic patients. In STZ mice, the application of a von Frey filament, producing a light static touch, 
causes a paw withdrawal induced by the inappropriate activation of Aδ and C fibers, signing a tactile 
allodynia. Cotton swabs or brushes also have been used to measure dynamic tactile allodynia by 
caressing the plantar surface of the hind paw of the animal, which evokes a paw withdrawal if Aβ fibers 
are impaired. The comparison of the two different symptoms reveals that dynamic allodynia has a later 
onset than static allodynia and both painful symptoms worsen over time in STZ rats [Brini et al., 2017; 
Castelli et al., 2016; Fields and Basbaum, 1999]. The search for a chemical sensitivity (such as formalin) 
in diabetic mice, that could, at best, mimic human inflammatory hypersensitivity observed in clinic, 
revealed an increase in the tonic response while the phasic response is not altered by the chemical 
agent [Calcutt et al., 1996]; moreover diabetic patients are hypersensitive to cold stimuli [Ziegler et al., 
1988] and recent studies demostrated that also this parameter may be to evaluated in STZ-mice by 
aceton test, since this behavioural test showed that STZ-mice had elevated sensitivity threshold to the 
cold stimuli [Flatters and Bennett, 2004; Brini et al., 2017]. 
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1.4.1.1.3 Pathophysiology of STZ-induced neuropathic pain  
Pain associated with nerve damage from diabetes initially involves peripheral mechanisms causing 
sensory fibers hypersensitivity, which secondarily leads to central rearrangements responsible for 
central nociceptive system hyperexcitability. In this section, we discuss the main peripheral and central 
mechanisms of diabetic neuropathic pain in STZ-mice model [Lim, 2014].  
 
 Peripheral changes:  
Involvement of voltage-dependent calcium channels Cav. The T-type Cav channels (“LVA” low 
voltage activated) or CaV 3.1, 3.2 and 3.3 are localized in cell bodies and dendrites of primary 
afferent fibers, and play an important role in modulating the neuronal excitability [Cao, 2006]. Their 
involvement in the pathophysiology of neuropathic pain has also been demonstrated, particularly in 
models of diabetes and traumatic neuropathies by sciatic nerve ligation, where current density of 
type T is greatly increased [Jagodic et al., 2007]. The “knockdown” strategy by CaV3.2 isoform 
antisense but not the CaV3.1 or CaV3.3 isoforms, suppresses thermal (Hargreaves test) and 
mechanical hypersensitivity (applying a von Frey filament # 4.93) in STZ-diabetic model. 
Electrophysiological recording from small cells (C fibers) of dorsal root ganglia (DRG) and spinal cord 
(whole cell voltage-clamp) shows that the same strategy inhibits the “up-regulation” of T-type 
currents induced by diabetes [Messinger et al., 2009]. Finally, over- expression of the α2δ subunit of 
L-type calcium channels belonging to the family of “HVA” (high activation threshold) in the DRG of 
diabetic mice is contemporary with the development of tactile allodynia appreciated by the test of 
von Frey filaments [Yusaf et al., 2001]. This α2δ subunit is also the pharmacological target of certain 
antiepileptic drugs such as gabapentin and pregabalin. 
 
 Involvement of voltage-dependent sodium channels NaV:  
Peripheral nerve injury can alter the expression and function of NaV channels α subunits which 
results in a change in neuronal excitability [Dickenson and Bee, 2010]. It has been showed that four 
weeks after induction of diabetes by STZ, the NaV currents sensitive (S) and resistant (R) to 
tetrodotoxin (TTX) increased in small diameter DRG [Hong et al., 2004]. Quantification by Western 
blotting of different types of sodium channels showed an increased expression of NaV1.3 and 
NaV1.7 (TTX-S) channels and a decreased expression of NaV1.6 (TTX-S) and NaV1.8 (TTX-R) channels 
in DRG of diabetic mice (four weeks post-STZ). These authors also reported that phosphorylation of 
Thr / Ser residues of NaV1.8 and NaV1.6 channels, and Tyr residues of NaV1.7 and NaV1.3 channels 
is increased by diabetes. Sensitive or resistant TTX Nav channels play an important role in the 
pathophysiology of neuropathic pain of all etiologies, including diabetic, by changing the electrical 
properties of the membrane, thus contributing to the genesis of ectopic discharges. These channels 
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are also the target of different molecules (tricyclic antidepressants, anticonvulsants, local 
anesthetics etc.) whose therapeutic efficacy in the treatment of neuropathic pain is established. 
 
 Involvement of Transient Receptor Potential (TRP) channels:  
Thermal sensitivity observed in STZ-treated animals [Pichon et al., 2010] is probably due to the 
sensitization of cutaneous nociceptors associated with Aδ and C fibers. TRPV1 channel (Transient 
Receptor Potential Vanilloid type 1), is a major actor in thermal sensitivity, predominantly present in 
C fibers and, to a less extent, in Aδ fibers [Kamei et al., 2001; Pabbidi et al., 2008b; Rashid et al., 
2003]. TRPV1 is a non-selective calcium/sodium-permeable channel activated by temperatures up to 
43°C, capsaicin (extracted from red pepper), protons (pH < 5.9), metabolites of arachidonic acid etc; 
TRPV1 can be sensitized by phosphorylation, by prostaglandins, bradykinin, glutamate, histamine, 
serotonin, ATP or NGF. Any change in TRPV1 expression, associated with changes in intracellular 
signal transduction, may lead to spontaneous neuronal activity induced by normal body 
temperature; this is the case if the response threshold of TRPV1 is lowered below 38°C [Biggs et al., 
2008]. The expression of TRPV1 channels in Aδ and C fibers of STZ-treated mice was increased in 
those presenting hyperalgesia, and reduced in hypoalgesic mice. The same team also showed that 
thermal hypersensitivity developed by diabetic wild-type mice is abolished when the gene coding for 
TRPV1 channel is disabled (TRPV1-/- mouse). Finally, treatment with anti-vanilloid VR1 receptor 
antiserum abolishes thermal hyperalgesia in STZ-treated mice [Kamei et al., 2001]. In physiological 
conditions, it was shown that insulin positively modulates the activity and expression of TRPV1 
channels via protein kinase C (PKC) [Pabbidi et al., 2008a]. It is therefore possible that the sudden 
decrease in insulin levels induced by STZ is indirectly responsible for a decrease in TRPV1 activity, 
which would lead to a compensatory increasing of the expression of these channels. Another 
hypothesis suggests a direct action of STZ onto sensory neurons, involving the ROS-p38 MAPkinase 
pathway, thereby altering expression and function of TRPV1 [Pabbidi et al., 2008b]. 
A second TRP channel, TRPA1 (Transient Receptor Potential Ankyrin type 1) seems to be involved in 
DPN, since some studies showed that TRPA1 antagonists changed mechanical thresholds in STZ-
treated animals [Koivisto et al., 2012; Wei et al., 2009]. Moreover, the TRPA1 channel can be 
activated in sensory neurons by ROS, alkenyl aldehydes and 15-deoxy-prostaglandin J2, which are 
generated during oxidative stress leading to intracellular calcium rise [Andersson et al., 2008; 
Nishikawa et al., 2000]. Hence, TRPA1 receptor through indirect activation by metabolites from 
oxidative stress seems to be an important molecular protagonist in mechanical hypersensitivity of 
diabetic neuropathy. 
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 Involvement of HCN channels:  
Described for the first time in pacemaker cells of the heart sinus node, HCN (hyperpolarization 
activated cyclic nucleotide-gated cation) channels were discovered in neurons and responsible for Ih 
currents (Hyperpolarization-activated current) [Jiang et al., 2008]. HCN channels open when the 
membrane is hyperpolarized (-60 to -50 mV, i.e. to the rest potential) and generate a mixed Na+, K+ 
cationic current. Four genes coding for HCN channels have been identified (HCN1-4). The most 
abundant in neurons of DRG are the HCN1/2 type. The Ih current generated is of greater amplitude, 
faster and more frequent in neurons of large and medium diameter (type A) than in small diameter 
neurons (type C). The administration of a HCN channel blocker, the ZD7288, suppresses tactile 
allodynia in STZ-induced diabetic rats (three weeks post-STZ) and reduces mechanical 
hypersensitivity as well [Wattiez et al. 2011], whereas ivabradine, a more selective blocker of HCN 
channels, suppresses cold allodynia in a model of toxic neuropathy induced by oxaliplatin [Descoeur 
et al., 2011]. 
 
 Central changes 
Involvement of N-Methyl-D aspartate (NMDA) receptors: dizocilpine, memantine or D-CPP, NMDA 
receptor non-competitive and competitive antagonists respectively induce analgesic effects in vivo, 
on mechanical hypersensitivity in STZ rats [Chen et al., 2009; Courteix et al., 2007; Malcangio and 
Tomlinson, 1998] NMDA receptor phosphorylation would be involved in the development of tactile 
allodynia, mechanical and thermal hypersensitivity [Rondon et al., 2010]. It has been also 
demostrated the importance of the specific activation of certain isoforms of MAPKinases in painful 
hypersensitivity in STZ animals, as well as the need for NMDA receptor activation for the 
phosphorylation activity of these kinases [Wattiez et al., 2011; Daulhac et al., 2006], opening new 
prospects for a more targeted drug therapy, thus better tolerated for diabetic neuropathic pain. 
 
Alteration of descending systems: One of the pathophysiological mechanisms involved in the 
pathogenesis of chronic pain including neuropathic pain is a loss of the inhibitory role of serotonin 
on persistent pain, as evidenced by (i) the nearly ineffectiveness of selective serotonin reuptake 
inhibitors (SSRIs) in neuropathic pain patients [Finnerup et al., 2010] and, (ii) results obtained in 
STZ-induced diabetic rats showing an alteration of spinal 5-HT2A receptor-mediated analgesic 
effect, usually involved in the analgesic effect of serotonin [Pichon et al., 2010]. These receptors 
have the particularity to be associated with specific multiprotein complexes, consisting in part of 
proteins containing PDZ domains, which can modulate signal transduction of receptors to which 
they are associated [Becamel et al., 2004]. In STZ animals, administration of a cell-penetrating 
peptidyl mimetic of the 5-HT2A receptor C-terminus ending, which disrupts their interaction with 
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PDZ proteins, induces antihyperalgesic effect per se and enhanced the analgesic effect of 
fluoxetine, a SSRI [Pichon et al., 2010]. 
Most of peripheral and central abnormalities in the transmission and modulation of nociception 
that have been described in STZ mice were also found in other neuropathic pain models, especially 
traumatic peripheral nerve injury (CCI or SNL) showing the lack of specificity of the model.  
It would be over simplistic to associate a pathophysiological mechanism to an etiology because the 
same mechanism can be found in neuropathies of different etiologies [Baron et al., 2010], and a 
given injury may involve several mechanisms. 
 
1.5 Mesenchymal Stem Cells (MSCs)  
The first isolation from bone marrow of stromal multilineage 
progenitor cells giving rise to mesodermal cells was carried out 
by Friedenstein more than 50 years ago, opening a field of 
research in continue expansion [Friedenstein et al., 1976]. 
Successively, Caplan named them “Mesenchymal Stem Cells” 
(MSCs) because of their ability of self-renewal and 
differentiation [Caplan, 1991].  
Nowadays, MSCs can be isolated nearly from all adult human 
tissues and organs: liver, kidney, spleen, pancreas, lungs, 
brain,   adipose tissue, dermis, dental pulp and periodontal 
ligaments. Interesting sources of MSCs are discarded tissues, such as fat from liposuctions, deciduous 
teeth, placenta and umbilical cord blood [de Girolamo et al., 2013]. Because of their broad distribution 
in the body, MSCs are thought to play a central role in maintaining tissue homeostasis.  
Isolated MSCs share common features: fibroblastoid morphology, clonogenic ability (Colony Forming 
Unit- Fibroblasts, CFU-F), self-renewal and multipotential differentiation. However, a considerable 
variability exists among MSC populations [Dominici et al., 2009]. For this reason, these progenitor cells 
are now generally termed “multipotent Mesenchymal Stromal Cells”, while the definition of 
“Mesenchymal Stem Cells” should be applied only if specific criteria are satisfied. In 2006, the 
International Society for Cellular Therapy (ISCT) proposed three minimal criteria to define Mesenchymal 
Stem Cells:  
i) purification by plastic adherence,  
ii) differentiation towards adipogenic, osteogenic and chondrogenic lineages under standard in vitro 
specific stimuli,  
Image 8| MSCs human niche. 
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iii) antigen surface expression of CD105 (endoglin, SH2), CD73 (ecto-5’-nucleotidase) and CD90 (Thy1), 
while absence of the hematopoietic markers CD45, CD34, CD14 or CD11b, CD19 or CD79α and HLA-DR 
[Dominici et al., 2006].  
Despite these common markers, MSC populations are phenotypically characterized by the expression of 
variable set of surface proteins [Mafi et al., 2011].  
The variability in surface antigen expression, biological functions and activities is not surprising, since 
MSC populations derive from different tissues and each tissue possesses its own unique progenitor 
niche. Recently it has been proposed that surface marker expression could be influenced not only by the 
source but also by the method of isolation and stage of culture. This observation highlights the 
possibility that MSCs express markers in vitro which not necessarily correspond to their in vivo patterns 
[de Girolamo et al., 2013].  
MSC populations can be isolated from almost all adult vascularized tissues, where they are localized in a 
vascular niche probably in the wall of large and medium-size vessels. This localization originates during 
embryogenesis and persists in adult body presumably with the role of controlling vessel integrity by 
secreting factors that promote vasculogenesis, thus stabilizing endothelial tissue and immune system 
homeostasis during physiological and pathological conditions. For these reasons, some authors have 
proposed that MSCs could represent a subset of precursor cells in close relationship with pericytes or 
even that MSCs identify with them [Caplan and Correa, 2011].  
 
1.5.1 Adipose-derived Stem/Stromal Cells (hASCs)  
Like bone marrow, adipose tissue has a mesenchymal origin. It is composed by different cell populations 
at various stages of differentiation, mainly mature adipocytes, pre-adipocytes, fibroblasts, vascular 
smooth muscle cells, endothelial cells and Adipose-derived Stem/Stromal Cells (ASCs). Adipose tissue 
represents an ideal source of MSCs because it can be obtained by discarded lipoaspirates from aesthetic 
surgery, with the advantages of large availability, easy accessibility and minimal discomfort for the 
patient [Yu et al., 2011]. ASCs can be isolated by a simple collagenase digestion, followed by 
centrifugation to separate floating adipocytes from ASC-containing stromal vascular fraction (SVF). ASCs 
are then purified by plastic adherence. The frequency of stem cells in SVF is approximately 2500-fold 
that of bone marrow (up to 0.002%) [Fraser et al, 2008].  
ASCs share the main properties of MSCs: fibroblastoid morphology, self-renewal and clonogenic ability, 
differentiative potential towards several mesodermal lineages (adipocytes, osteoblasts, chondrocytes) 
but also trans-differentiative potential towards endodermic (i.e. hepatocytes and endocrine pancreatic 
cells) and ectodermic lineages (i.e. epithelial and neuronal-like cells) [Zuk et al., 2001].  
Despite these general properties, ASCs show slight differences in surface antigen expression respect to 
other MSCs. For example, the hematopoietic marker CD106 is expressed by BMSCs (Bone Marrow-
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derived Stem Cells) while it is absent in ASCs. SVF-isolated populations are often a non-uniform subset 
of stem and precursor cells lacking an unique marker that allows the identification of ASCs without 
ambiguity. Furthermore, it is known that ASC phenotype has a dynamic profile that changes during cell 
culture and overall in different in vitro conditions. Donor characteristics are another important source of 
variability (i.e. age, body mass index, gender and health conditions) [Baer, 2014].  
In 2013, International Fat Applied Technology Society (IFATS) published a revised statement to point out 
the minimal phenotypic criteria to define Adipose-derived Stem/Stromal Cells: “in the SVF, cells are 
identified phenotypically by the following markers: CD45-, CD235a-, CD31-, CD34+. The fibroblastoid 
colony-forming unit assay permits the evaluation of progenitor frequency in the SVF population. In 
culture, ASCs retain markers in common with other mesenchymal stromal/ stem cells (MSCs), including 
CD90, CD73, CD105, and CD44 and remain negative for CD45 and CD31. They can be distinguished from 
bone marrow-derived MSCs by their positivity for CD36 and negativity for CD106. The CFU-F assay is 
recommended to calculate population doublings capacity of ASCs. The adipocytic, chondroblastic and 
osteoblastic differentiation assays serve to complete the cell identification and potency assessment” 
[Bourin et al., 2013].  
 
1.5.2 MSCs as therapeutic tool  
MSCs are thought to be an excellent candidate for cell therapy because they exert many beneficial 
effects, are available in large amounts, can be cryopreserved and their use arises fewer ethical concerns 
than that of embryonic stem cells (ESCs). In recent years it has become evident that their therapeutic 
effect is related not only to their stemness features of self-renewal and differentiation. Indeed, MSCs, in 
response to the cross-talk with micro-environmental cells, act mainly through the secretion of a wide set 
of molecules that have both paracrine immunomodulatory and trophic activities [Figure 1]. Recently, 
Caplan suggested to modify the acronym of MSC in “Medicinal Signaling Cells”, highlighting that the 
peculiar ability of these cells is to produce bioactive factors [Caplan, 2010]. In 2001, the European 
Directive 2001/83/CE declared that products for advanced medicinal therapy (AMT, i.e. gene therapy, 
cell therapy and tissue engineering) are considered drugs because of their pharmacologic, metabolic and 
immunologic activities, useful in the potential treatment of many disorders. For this reason, stringent 
requirements of safety and efficacy are applied to AMT cellular products, which should be manipulated 
according to Good Manufacturing Practices (GMP) and tested in approved clinical trials before being 
commercialized [European Commission, 2011]. The design of appropriate clinical trials needs to consider 
many important factors: source (i.e. tissue origin), isolating methods, expansion culture conditions (e.g. 
medium and oxygenation), cryopreservation procedures, quality controls, doses and administration 
routes. Furthermore, cells have to be administered at early passages in culture (<4) to avoid the risk of 
cellular senescence or the accumulation of genetic instability [Keating, 2012].  
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Safety represents a significant barrier to the successful translation of MSCs into an acceptable clinical 
therapeutic tool. Preclinical studies on immuno-suppressed mice have highlighted the possibility of long-
term risks associated to MSCs therapy, which are mainly related to immunosuppression and tumor 
formation. However it is not sure that these effects could appear also in immune-competent hosts 
[Huang et al., 2013]. In recent years efficacy and safety of MSCs are under investigation in many clinical 
trials of cardiovascular, neurological and immunological disease with encouraging preliminary results. (It 
has been reported no apparently association between MSC treatment and the development of acute 
infusional toxicity, organ system complications, infections, malignancy or death [Lalu et al.,2012]. For 
this reason, MSCs transplantation is considered safe, even if continuous and rigorous reporting of 
adverse events is required to further define their safety profile.  
Nowadays the use of allogeneic rather than autologous MSCs is considered preferable because the host 
immune system would be able to eliminate possible transformed cells, avoiding the risk of tumor 
formation.  
 
1.5.3 Current clinical trials  
In recent years, MSCs have been worldwide applied to treat a broad spectrum of human diseases, 
including bone-articular, immune, neurological, cardiovascular, gastrointestinal and blood pathologies 
[Murphy et al., 2013]. Entering the keyword “stem cells”, the NIH website on November 2014 produced 
a lists of 4714 stem cell-based current clinical trials, 440 of them employing MSCs 
[http://clinicaltrials.gov]. The clinical appeal of MSCs is due to their wide biological functions, mainly 
differentiation ability, immunoregulatory properties and production of multiple paracrine trophic 
factors. Moreover, MSCs are tested in a wide variety of experimental applications, such as myocardial 
infarction, acute kidney failure, liver fibrosis, amyotrophic lateral sclerosis, cerebral palsy, traumatic 
brain injury, stroke and inherited metabolic disorders [Daley, 2012]. Giving their ability to mitigate 
autoimmunity, MSCs have been tested as cellular approach for graft-versus-host disease (GVHD) after 
allogeneic transplantation and autoimmune conditions (e.g. Crohn’s disease, multiple sclerosis and 
systemic lupus) [Shi et al., 2011]. MSCs are also being tested for orthopedic applications (e.g. bone 
fracture, joint cartilage repair, osteoporosis, osteoarthritis and rheumatoid arthritis) because of their in 
vitro potential to form bone and cartilage [Griffin et al., 2011].  
Among MSCs, ASCs are largely applied in different medical fields, such as plastic, orthopedic, oral 
maxillofacial and cardiac surgery, mainly thanks to their ability of soft-tissue regeneration and wound 
healing [Tobita et al., 2011]. Collectively, ASC-based clinical trials are focused on digestive, autoimmune, 
cardiovascular, skeletal and neurologic pathologies and disorders [Gir et al., 2012].  
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Since now, clinical trial outcomes showed encouraging, although often moderate or short-termed, 
clinical benefits. These observations highlight the need of a rational optimization of therapeutic 
strategies with an adequate assessment of risk-benefit factors [Pacini, 2014].  
 
1.5.4 Homing and engraftment  
One of the most persistent paradoxes in MSC therapy is that systemically administered MSCs are able to 
exert their beneficial effects in the absence of stable engraftment in target tissues [Parekkadan & 
Milwid, 2010].  
 
Indeed, most homing and engraftment studies indicated that less than 1% of systemically administered 
MSCs persist for longer than a week after the injection [Image 9]. Immediately after administration, the 
majority of MSCs (>80%) accumulate in the lungs and are cleared with a half-life of 24 hours [Lee et al., 
2009]. Trafficking studies have reported that systemically administered MSCs fail to engraft in most 
tissues and that engrafted cells may eventually be rejected, resulting in immunological memory to 
subsequent treatments [Zangi et al., 2009].  
The most used tracking approach is the detection of MSCs expressing a reporter gene (mainly green 
fluorescent protein, GFP), even if it is unclear whether the transfection could modify cell behavior 
[Dominici et al., 2008]. A more powerful approach is magnetic resonance imaging (MRI) of MSCs labeled 
by traceable iron particles [Salamon et al., 2014]. However, the development of new and more accurate 
cell tracking techniques is a fundamental requisite to assess safety and efficacy of administered MSCs, in 
the light of their possible future clinical application.  
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Image 9| In vivo distribution of MSCs upon systemic administration. Whole-organism distribution 
of intravenously (i.v.) injected hMSCs in mice tissues.  
[Image modified from Parekkadan et al., 2012] 
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One of the major characteristics of MSCs is that they have migratory abilities, [Nagyova et al., 2014] and 
after administration, they specifically migrate to the sites of inflammation and tissue damage which is 
typically associated with cytokine outburst [Eggenhofer et al., 2014; Sohni and Verfaillie, 2013], though 
the mechanism by which MSCs home to tissues is still not completely clear. However, it seems that 
injured tissues express specific receptors or ligands that allow MSC migration across endothelium, 
similarly to the way leukocytes are recruited to inflammation sites [Katsuda et al., 2013]. BMSCs, the 
most characterized MSCs, express on their surface different integrins (e.g. integrin α4/β1), which 
mediate cell-cell and cell-extracellular matrix interactions by binding to the vascular cell adhesion 
molecule 1 (VCAM-1) and to the V-region of fibronectin. In damaged tissues there is an increase of 
fibronectin V-region exposure that allows MSCs to adhere and transmigrate into the extracellular 
matrix. Moreover, MSCs are able to secrete different metallo-proteinases (e.g. MMP-2 and MT1-MMP) 
which degrade the extracellular matrix barriers allowing extravasation [Ebrahim and Leach, 2014].  
 
1.5.5 Paracrine action of MSCs  
Although traditionally MSCs regenerative ability was associated to their stemness features, it is now 
clear that MSCs therapeutic effects are overall due to the secretion of a broad range of bioactive 
molecules, that mediate immunomodulation, chemo-attraction, angiogenesis, trophic support, anti-
apoptosis and anti-scarring properties [Lavoie and Rosu-Myles, 2013]. In response to local micro-
environmental cues, MSCs secrete variable concentrations of soluble factors that promote 
differentiation and survival of resident cells, remodeling of extracellular matrix and formation of new 
blood vessels [Meirelles et al., 2009]. The secretion of this wide variety of factors (growth factors, 
cytokines, chemokines, metabolites and bioactive lipids) 
has the role to coordinate multiple interactions with the 
surrounding micro-environment. Beside known 
paracrine and autocrine activities, there is the 
possibility that MSCs could mediate endocrine effects 
on endogenous cells in a remote location.  
The ability of MSCs to modulate the immune system 
seems to play a role in almost all MSCs treatment 
effects. The immunomodulatory action of MSCs is 
based mainly on cell-to-cell contact, production of 
inhibitory molecules and induction of regulatory T-cells. 
Interestingly, the release of soluble immunosuppressive 
factors seems to be specifically linked to the cause of 
inflammation. The modulation of the host immune 
Image 10| Paracrine effects of MSCs.  
[Lai et al., 2011] 
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response mediated by MSCs plays also a role in tissue repair, by reducing tissue damage and scarring, 
during the regeneration of damaged organs. MSCs secreted factors promote tissue regeneration and 
repair of damaged organs, despite the absence of stable engraftment. Studies on many disease models 
(e.g. lung injury, chronic kidney disease and liver injury) demonstrated that MSC-derived conditioned 
medium (CM) alone is sufficient to mediate lasting therapeutic effects. Thus the beneficial effects 
observed after MSC administration can be completely recapitulated by MSC secreted factors alone. 
Moreover, many recent works have demonstrated that also the extracellular vesicles (EVs) produced by 
MSCs participate in the process of tissue repair [Image 10].  
It is now evident that different paracrine actions of MSC secretome function in a co-operative manner to 
generate an advantageous microenvironment that allow tissue regeneration. Biological properties of 
MSCs and their ability to adapt to specific micro-environments define the new concept of “stem cell 
therapeutic plasticity” [Drago et al., 2013].  
The paracrine activity seems to be the main (even if not the only) mechanism by which MSCs exert their 
regenerative potential. Indeed, the often observed long lasting effects can’t be explained by MSC short-
lived engraftments after injection or transplantation. In this view, MSCs can be defined as drug delivery 
particles whose function follow a pharmacokinetic model: when administered they are subject to 
distribution and clearance similarly to other therapeutics.  
 
1.5.5.1 Immunomodulatory properties of MSCs  
Nowadays it is clear that MSCs action on tissue regeneration is only partially due to cell replacement, 
while the essential component is their ability to communicate with the inflammatory micro-
environment by modulating inflammation. In response to inflammatory cues, MSCs produce a large 
amount of immune-regulatory factors that together with growth factors stimulate resident cells to 
repair the damaged tissue.  
MSCs act on both the adaptive and innate immune systems and, depending on the type and intensity of 
inflammatory stimuli, these cells can have the ability to both suppress or enhance the immune 
response. For this reason, the type and the amount of cytokines released during the inflammatory 
process have a critical role in the influence and activation of immunoregulatory properties of MSCs 
[Wang et al., 2014].  
Many studies have demonstrated that MSCs can suppress the activation and function of various cells of 
the innate and adaptive immune systems, including macrophages, neutrophils, natural killer cells (NK), 
dendritic cells (DCs), T-lymphocytes and B-lymphocytes. MSCs act on T-cell inhibiting their 
differentiation into TH1 and TH17 types of helper T-cells and promoting the generation of regulatory T-
cells (Treg cells) [Figure 4]. In addition, MSCs mediate the switch of macrophages from a pro-
inflammatory type 1 to anti-inflammatory type 2 phenotype [Shi et al., 2012].  
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Immunosuppressive factors produced by MSCs are mainly: interleukin 6 (IL-6), interleukin 10 (IL-10), 
transforming growth factor-β (TGF-β), prostaglandin E2 (PGE2), human leukocyte antigens (HLA-A, HLA-
DR, HLA-G5), epidermal growth factor (EGF), fibroblast growth factor (FGF), platelet-derived growth 
factor (PDGF), vascular endothelial growth factor (VEGF), insulin growth factor (IGF), COX-2 (cyclo-
oxygenase 2), matrix metallo-proteinases (MMPs), tryptophan-catabolic enzyme IDO and nitric oxide 
(NO), a product of inducible nitric oxide synthase (iNOS) [Ma et al., 2014]. This great variety of 
mediators is probably due to the different tissue and micro-environment from which MSCs derive.  
An important issue is that MSCs probably aren’t able to elicit their immune-regulatory actions unless 
they are first in vivo activated by certain combinations of inflammatory stimuli, mainly interferon-γ (IFN-
γ) together with other cytokines (e.g. TNF-α, IL-1α or IL-1β). Upon stimulation, MSCs secrete large 
amounts of chemokines that attract T-cells. In this way, MSCs influence the inflammatory process both 
recruiting T-cells and producing immunosuppressive factors. Moreover, MSCs are poorly immunogenic 
because they express low levels of major histocompatibility complex class I and II (MHC I – II), which can 
be up-regulated by IFN-γ and IL-1β treatment [Schu et al., 2012].  
 
However, MSC plasticity makes these cells able to inhibit but also promote the immune response, 
dependently on various inflammatory stimuli and on the state of activation of the immune system. 
Indeed MSCs activation depends on type and concentration of inflammatory mediators present in the 
surrouding micro-environment. Essentially, inflammation status determines the immune-regulatory fate 
of MSCs [Ren et al., 2008].  
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Image 11| Immunomodulatory effects of MSCs on innate and adaptive immune cells. 
[Image modified from Yi et al., 2012] 
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During the pathogenesis of inflammatory diseases, high concentrations of inflammatory cytokines in the 
acute phase promote disease progression, while low concentrations of these factors in the chronic 
phase prepare the microenvironment to facilitate tissue repair. It is thought that MSCs exert their 
immunosuppressive effect in the presence of strong inflammation, while weak inflammation 
paradoxically causes MSCs to enhance the immune response [Wang et al., 2014].  
For example, it has been reported that graft-versus-host disease (GvHD) treatment is more successful if 
MSCs are administered some days after bone marrow transfusion, when the inflammation is already 
established [Bernardo and Fibbe, 2013].  
For this reason, a correct clinical design should consider the correct timing of MSC administration 
because the inflammatory status strongly influences the therapy outcome. Consistently, pre-treating 
MSCs with inflammatory cytokines before the administration could be a successful strategy to reinforce 
their immunosuppressive efficacy, while the concomitant application of immune-suppressants should 
be avoided.  
It’s still under debate the reason why endogenous tissue-resident MSCs aren’t able to elicit these 
immunomodulatory actions. A possible explanation is that MSCs, before being administered, are 
expanded in vitro and could acquire part of these properties during culture. Furthermore, it should be 
considered that MSC administration is performed with a high number of cells (1-2x106 cells/ kg).  
 
1.5.5.2 Role and biological functions of microvescicles, exosomes and miRNA  
                    Image 12| Microvescicles and exosomes. [Image modified from Raposo & Stoorvogel, 2013]  
 
Cell-based therapy is associated to many ethical and practical problems (i.e. cell senescence, genetic 
instability, loss of function, limited cell survival and possibility of malignant transformation). Most of 
these issues might be eluded with the use of MSC conditioned medium (CM), microvesicles (MVs) and 
exosomes, which act as delivery vehicles containing a complex mixture of bioactive molecules. These 
particles have peculiar characteristic that make them a possible useful tool for cell-free therapies. For 
example, it has been shown that vesicles are able to cross the blood brain barrier, an interesting aspect 
for the treatment of neurodegenerative diseases (e.g. Alzheimer, Parkinson and prion diseases). 
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Moreover, many studies have shown that MSCs contain microRNAs, 20-22 nucleotide long RNA 
molecules that target messenger RNA for cleavage or translational repression, thus suppressing protein 
synthesis. It has been recently shown that miRNAs play critical functions in MSCs survival, proliferation, 
differentiation and immunomodulatory actions [Clark et al., 2014]. Recent studies have also focused on 
the involvement of miRNAs in the paracrine action of MSCs. miRNAs can modulate the expression of 
MSC secreted proteins or alternatively they can be stored in microvesicles or exosomes and once 
secreted they exert their regulatory function in target cells.  
        
1.5.5.3 Soluble factors identification in secretome   
Recently, the conditioned medium (CM) of cultured MSCs has become the subject of intensive 
proteome profiling in the search for soluble factors which could be interesting for human regenerative 
medicine. Moreover, the proteomic study of extracellular vesicles (i.e. exosomes and microvesicles) is 
particularly attractive, since EVs are thought to be the real mediators of cell  communication and could 
represent both an useful tool for regenerative medicine and markers for certain pathologies [Skalnikova, 
2013].  
Up to now a variety of growth factors, angiogenic factors, cytokines, chemokines and extracellular 
matrix proteins have been identified in the mammalian mesenchymal stem cell and other stem cell 
secretomes [Table 1 - Skalnikova et al., 2011]. Other interesting studies are now focused on the 
secretome of conditioned medium obtained from cells cultured in hypoxic conditions, serum deprivation 
or inflammatory stimulation (e.g. TNF-α or lipopolysaccharide). Such conditions increase the amount of 
particular proteins and cytokines secreted into the culture media.  
Two major approaches are employed to analyze secreted proteins: targeted proteomic approaches 
(immunological assays) and shotgun broad range scanning (protein separation followed by protein 
identification by mass spectrometry).  
Target-based proteomic studies are based on the research of specific molecules with known biological 
roles (i.e. growth factors and hormones). This approach is based on immunological methods, mainly the 
Enzyme-Linked Immunosorbent Assay (ELISA).  
Interestingly, proteomic studies do not always agree on the exact content of the MSCs secretome. This 
is probably due to differences in the analytic techniques used but it could also depend on the fact that 
MSCs are highly sensitive to their environment, therefore different culture conditions can result in 
changes of molecule secretion.  
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Extracellular 
matrix proteins 
and proteins 
involved in cell 
adhesion  
Biglycan  
Cadherin 2-11-13  
Collagen α-1 and α-2 chains  
Decorin (Bone proteoglycan II)  
Dermatopontin  
Entactin (Nidogen 1)  
Extracellular matrix protein 1  
Fibrillin 1-2  
Fibronectin  
Fibulin 1-2  
Laminin γ1  
Lumican Osteoblast-specific factor 2 (Periostin)  
Serpin H1 (Collagen-binding protein)  
Tenascin  
Versican core protein  
Vitronectin  
 
Growth and trophic 
factors  
Bone-derived growth factor (BDFG)  
Brain-derived neurotrophic factor (BDNF)  
Connective tissue growth factor  
Epidermal growth factor (EGF)  
Fibroblast growth factors (FGF) 4-7-9-17  
Glial cell line-derived neurotrophic factor 
(GDNF)  
Hepatocyte growth factor (HGF)  
Insulin like growth factor 1 (IGF-1)  
Insulin-like growth factor-binding protein (IGFBP)                
2-3-4-5-6-7  
Nerve growth factor (NGF)  
Placental growth factor (PIGF)  
Platelet-derived growth factor (PDGF)  
 
Angiogenic factors  
   Angiogenin  
   Angiopoietin  
   Vascular endothelial growth factor (VEGF)  
Chemokines  
CCL1 (I309)  
CCL2 (MCP-1)  
CCL5 (RANTES)  
CCL7 (MCP-3)  
CCL8 (MCP-2)  
CCL11 (Eotaxin)  
CCL15 (MIP-1δ)  
CCL16 (HCC-4)  
CCL18 (PARC)  
CCL22 (MDC)  
CCL23 (Ckb8-1, MIP-3)  
CCL24 (Eotaxin-2)  
CCL26 (Eotaxin-3, MIP-4α)  
CX3CL1 (Fractalkine)  
CXCL1 (GROα)  
CXCL2 (GROβ, MIP-2α)  
CXCL3 (GROγ)  
CXCL5 (human ENA-78, mouse LIX)  
CXCL6 (GCP-2)  
CXCL8 (IL-8)  
CXCL11 (I-TAC)  
CXCL12 (SDF-1α)  
CXCL13 (BLC)  
XCL1 (Lymphotactin)  
 
Pro-inflammatory 
cytokines  
Interferon γ (IFN-γ)  
Interleukin-12 (IL-12)  
Interleukin-1α (IL-1α)  
Interleukin-2 (IL-2)  
Tumor necrosis factor α (TNF-α)  
 
Anti-inflammatory 
cytokines  
Interleukin-10 (IL-10)  
Interleukin-13 (IL-13)  
Macrophage migration inhibitory factor (MIF)  
Transforming growth factor β (TGF-β)  
 
Pleiotropic 
cytokines  
Interleukin-11 (IL-11)  
Interleukin-16 (IL-16)  
Interleukin-1β (IL-1β)  
Interleukin-6 (IL-6)  
Leukemia inhibitory factor (LIF)  
Oncostatin M (OSM)  
 
Hematopoietic 
cytokines  
Flt 3 ligand (FLT3LG)  
Granulocyte colony-stimulating factor  
(G-CSF)  
Granulocyte-macrophage colony-stimulating factor 
(GM-CSF)  
Interleukin-3 (IL-3)  
Interleukin-7 (IL-7)  
Macrophage colony-stimulating factor  
(M-CSF)  
Stem cell factor (SCF, Kit ligand, steel 
factor)  
Thrombopoietin  
 
Cytokine receptors  
   CXCR3 (IP-10 receptor, CD183)  
   Osteoprotegerin  
Enzymes and 
enzyme 
inhibitors/enhance
rs  
72 kDa type IV Collagenase  
Chitinase-3-like protein 1  
Glia-derived nexin  
Matrix metalloproteinase (MMP) 1-2-3  
Metalloproteinase inhibitor (TIMP) 1-2-
3  
Plasminogen activator inhibitor (PAI) 1-2  
Procollagen C-endopeptidase enhancer  
Serine protease HTRA1  
Serine protease inhibitor J6  
 
Other proteins  
Bone morphogenetic protein 1 
(BMP-1)  
Clusterin  
Cystatin B-C  
Dickkopf related protein-3  
Galectin 1-3  
Galectin-3-binding protein  
Gelsolin  
Granulins  
Latent-TGFβ-binding protein 1-2  
Myocilin  
Pentraxin-related protein 3 (PTX3)  
Pigment epithelium-derived factor (PEDF, serpin F1)  
Secreted protein acidic and rich in cysteine (SPARC, 
osteonectin)  
Stromal cell derived factor 4  
Sulphated glycoprotein 1 (prosaponin)  
TGFβ-induced protein ig-h3  
Thrombospondin 1-2  
 
Table 1| MSC secretome. [Table modified from Skalnikova et al., 2013] 
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1.6 Stem cell therapy in experimental models of neuropathic pain 
In recent years many preclinical studies have been carried out to assess the effects induced by several 
stem cells in different models of neuropathic pain. At the beginning, embryonic stem cells (ESCs) 
grabbed researchers' attention especially thanks to their wide differentiation potential, however they 
can easily induce tumor formation and are associated to ethical problems due to to their collection, so 
today there are three main types of adult stem cells used for experimental neuropathic pain treatment: 
neural stem cells (NSCs), bone marrow mononuclear cells (BMMCs) and mesenchymal stem cells (MSCs). 
Marrow mononuclear cells containing mixed stem cell populations have been intravenously used in 
neuropathic rats showing recovery from pain [Klass et al., 2007]; their implantation could be a possible 
solution for spinal cord injury; in fact BMMCs have the ability to be incorporate into spinal cord, 
differentiate, and to improve locomotor recovery [Schultz, 2005]. Klass et al. [Klass et al., 2007] 
described that BMMCs infusion in CCI rat model was able to induce neuropathic pain recovery (both 
hyperalgesia and allodynia). The authors did not investigate into the mechanisms involved in such 
modulations. These cells also injected into the hind limb skeletal muscles in STZ-rats [Naruse et al., 
2011] were able to ameliorate mechanical hyperalgesia and cold allodynia in the BMMCs-injected side. 
Furthermore, the slowed sciatic nerve conduction velocities and decreased sciatic nerve blood flow in 
diabetic rats were improved in the BM-MNC-injected side. 
It has been demonstrated that human NSCs can promote functional corticospinal axons regeneration 
and synapse reformation in the injured spinal cord of rats. The action is mainly through the nutritional 
effect of the stem cells on the spinal cord. Transplanted cells were found to migrate into the lesion, but 
not scatter along the route of axon grows. The cells differentiated into astrocytes or oligodendrocytes, 
but not into the neurons after transplantation [Liang et al., 2006]. Moreover, spinal progenitor cells 
intrathecally transplanted in neuropathic rats are able to alleviate neuropathic pain [Lin et al., 2002]. 
Murine neural stem cells (NSCs) grafted onto the injured spinal cord improved motor behaviour [Pallini 
et al., 2005]. In CCI model, NSCs systemic injection when the pathology was already established, induced 
a significant reduction in allodynia and hyperalgesia; moreover it was also present a reparative process 
and an improvement of nerve morphology [Franchi et al., 2014]. These positive results were observed 
also by Xu and colleagues [Xu et al., 2013], that used another route for NSCs administration; the authors 
described that an intrathecal administration of neural stem cells, 3 days after CCI injury in rat, was able 
to significantly attenuate mechanical and thermal hyperalgesia.  
Among stem cell population, mesenchymal stem cells (MSCs) rise probably best potential good results in 
pain-care research. One of the first groups to assess the effect of rat bone marrow stromal cells in an 
experimental CCI rat model was the group of Musolino [Musolino et al., 2007]. They demonstrated that 
an ipsilateral intraganglionic injection of rat stromal cells was able to prevent the generation of 
mechanical allodynia and to reduce the number of allodynic responses to cold stimuli [Musolino et al., 
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2007]. Rat bone marrow MSCs have also been used STZ diabetic neuropathy [Shibata et al., 2008]. MSCs 
were able to ameliorate all the alterations induced by diabetes such as hypoalgesia, delayed nerve 
conduction velocity, and decreased sciatic nerve blood flow. Moreover, MSC transplantation was able to 
normalize sural nerve morphometry restoring the axonal circularity, decreased in diabetic rats. The 
same positive effect on nerve conduction velocity amelioration was also reported by Kim and Jin [Kim 
and Jin, 2011]. The Maione's group is the main user of human BMSCs for treating experimental 
neuropathic pain due to the spared nerve injury (SNI), the hBMSC therapeutic administration was 
performed either in the mouse lateral cerebral ventricle [Siniscalco et al., 2010] or systemically into the 
caudal vein [Siniscalco et al., 2011]. In both studies, hBMSC reduced pain-like behaviors, such as 
mechanical allodynia and thermal hyperalgesia, with an effect which was evident one week after cell 
transplantation and was long lasting. When cells were injected into the caudal vein, their effect on pain 
relief was still present three months after transplant while when hBMSCs were intravenously injected, 
cells were able to home into the spinal cord and prefrontal cortex of SNI neuropathic mice. The authors 
described the capacity of these cells to reduce glial [Siniscalco et al., 2010] and macrophage activation 
[Siniscalco et al., 2011] switching to an anti-inflammatory phenotype by decreasing the proinflammatory 
cytokines (IL-1β and IL-17) and increasing the anti-inflammatory cytokine IL-10 [Siniscalco et al., 2010; 
2011]. The group of Waterman [Waterman et al., 2012] developed a method to optimize the anti-
inflammatory effects of hBMSC, skewing them in vitro, before their injections, towards a protective 
MSC2 phenotype. These BMSCs demonstrated a higher capacity to counteract mechanical allodynia and 
heat hypoalgesia induced in mice by STZ treatment. These cells were also able to decrease the serum 
level of pro-inflammatory cytokines and were described to be safe [Franchi et al., 2014].  
A recent study from our group evaluated the antinociceptive effect of hASC isolated from human 
adipose tissue intravenously injected in CCI model. Antihyperalgesic and antiallodynic effect was rapid, 
long lasting, and dose dependent, in fact 106 hASCs were able to completely abolish thermal 
hyperalgesia [Sacerdote et al., 2013a]. 
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Diabetes mellitus is one of the most common and serious chronic disease in the world. Although the 
number of available agents to manage diabetes continues to rapidly expand, the treatment of diabetes 
complications, such as neuropathy, remains a substantial challenge and diabetic peripheral neuropathy 
is one of the most frequent complication of diabetes mellitus. Pathophysiology of diabetic neuropathy is 
complex and not fully elucidated; it has multipathogenic mechanisms that cause a diversity of physical 
symptoms: allodynia, hyperalgesia, numbness and cutaneous ulceration. Persistent Neuropathic Pain 
(NP) interferes significantly with quality of life, impairing sleep, and emotional well-being, and is a 
significant causative factor for anxiety, loss of sleep, and non- compliance with treatment. Recent 
advances in the mechanisms involved in NP have demonstrated that pro- and anti-inflammatory 
cytokines produced by immune cells as well as by glia and microglia in nerve, dorsal root ganglia and 
spinal cord are common denominators in neuropathic pain. These start a cascade of neuroinflammation-
related events that may maintain and worsen the original injury, participating in pain generation and 
chronicization. By and large, activation of inflammatory cascade, proinflammatory cytokine 
upregulation, and neuroimmune communication pathways plays a vital role in structural and functional 
damage of the peripheral nerves leading to the diabetic peripheral neuropathy. 
Unfortunately, most of the available analgesic drugs appear to be relatively ineffective in controlling 
diabetic neuropathic pain, both for insufficient efficacy and side effects. Thus, there is a clear need for 
new disease-modifying therapeutic approaches. 
Mesenchymal stem/stromal cells may offer a novel therapeutic option to treat diabetic neuropathy; in 
fact in the last years the view of the biological action of Mesenchymal Stem Cells (MSCs) has been 
greatly changed. It has become evident that MSCs participate in tissue repair mostly by a paracrine 
mechanism through the release of soluble trophic and immunomodulatory factors.MSCs modulate the 
nervous system injured environment and promote repair as they secrete anti-inflammatory, anti-
apoptotic molecules, and trophic factors to support axonal growth, immunomodulation, angiogenesis, 
remyelination, and protection from apoptotic cell death. Transplanted MSCs not only directly 
differentiate into endogenous cells on administration, but also secrete a broad range of biologically 
active factors, generally referred to as the MSCs secretomeMany studies provided pivotal support for 
the paracrine hypothesis such that MSC therapy is increasingly rationalized on MSCs secretion rather 
than its differentiation potential. 
On these premises, the aim of my PhD project was to assess and  compare in the type 1 Streptozotocin 
mouse model of diabetes  the therapeutic effect of  hASC (human adipose stem/stromal cells) and their 
secretome (CM-hASC) on painful diabetic neuropathy, evaluating mechanical and cold allodynia,  and 
thermal hyperalgesia. In order to identify the mechanisms involved in the effect of hASC and CM-hASC 
we evaluated neuroinflammation, measuring pro- and anti- inflammatory cytokines expression in the 
main tissue stations involved in nociception transmission. Since hASC exert also an important 
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modulation of  peripheral immunity, we considered also the activation and cytokine production of T-
lymphocytes. We also evaluated the effect of both hASC and CM-hASC treatment on fiber loss and skin 
tickness, at the level of hind paws. Futhermore, to assess if treatments may be able to modify pathology 
development and progression, throughout the experiments blood glucose levels, body and organs 
weight were assessed. We also took into consideration the other important diabetes complication, i.e. 
nefropathy and measured kidney damage. 
Type 1 diabetes is induced in mice by administration of Streptozotocin, a β-cytotoxine and when 
allodynia is established animals are intravenously injected in the tail vein with 106 hASC or CM-hASC 
from 2x106 cells.  Behavioural measuremets, biochemical and immune evaluation are performed at 
different time points after diabetes induction. 
Moreover, in order to verify whether stemness is a fundamental prerequisite to obtain pain relief a 
group of STZ-mice is treated with CM obtained from 2x106 human fibroblasts (CM-hF). The present 
study will help to understand whether the hASC therapy may be effective for diabetes complication and 
whether eventually cells could be replaced by their conditioned medium, suggesting the chance to use a 
cell-free therapy. 
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3.1 Animals 
In all the experiments male mice of C57BL/6J strain, weighing 20-25g and 9 weeks old were used 
(Envigo, Italy). Animals were housed under controlled conditions with light/dark cycles of 12 hours, 
temperature of 22 ± 2 °C, humidity of 55 ± 10%, food and water ad libitum and they were acclimatized 
to the new environment for at least one week before being used. A total of 120 animals were used in 
the described experiments. Each experiment consisted of 6 mice per group. 
 
All animal care and experimental procedures complied with the International Association for the 
Study of Pain and European Community (E.C.L358/118/12/86) guidelines and were approved by the 
Animal Care and Use Committee of the Italian Ministry of Health guidelines (DL 116/92 and 
DL111/94-B). All efforts were made to minimize animal suffering and to reduce the number of 
animals used.  
 
3.2 Diabetic neuropathy induction 
Type 1 diabetes was induced in mice through chemical pancreatectomy by a repeated intraperitoneal 
(i.p.) administration of moderate low doses of streptozotocin (STZ, Sigma Aldrich, Italy), 80 mg/kg daily 
for three consecutive days (10μL/g), freshly prepared in citrate buffer 0.1 M, pH 4.55. Control mice 
were i.p. injected with citrate buffer [Castelli et al., 2016].   
STZ-mouse model is characterized not only by the development of neuropathic pain and 
hyperglycemia but also by other diabetic complications such as: body weight loss, fibers loss and skin 
thinning of the paws and, nephropathy as described below. 
 
3.3 Therapeutic treatments 
 Cells and substances used for therapeutic treatments were provided by the group of Dr. Brini 
(University of Milan, Department of Biomedical, Surgical and Dental Sciences; I.R.C.C.S Galeazzi 
Orthopedic Institute of Biotechnological Applications Laboratory) and are the following: 
 Human adipose-derived stem/ stromal cells (hASCs); 
 Conditioned Medium from hASC (CM-hASC); 
 Conditioned Medium from human Fibroblasts (CM-hF). 
 
3.3.1 Isolation and primary culture of hASC 
Cells were isolated from subcutaneous adipose tissue obtained as wasted material from plastic and 
cosmetic surgery of healthy donors (male and females, age range 26-53 y/o) after written consent and 
Institutional Review Board (IBR) authorization from IRCCS Galeazzi Orthopaedic Institute (procedure 
PQ 7.5.125, version 4, 22.01.2015).  
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Raw lipoaspirate (20-180mL) were mechanically dissected, washed 3-5 times in PBS (137mM NaCl, 
2.7mM KCl, 8.1mM Na2HPO4*2H2O, 1.7mM KH2PO4; pH 7.4) and centrifuged at 1300g for 2 minutes to 
remove precipitated erythrocytes and cell debris. Adipose tissues were then enzymatically digested in 
a PBS-collagenase solution with 0.75mg/mL type-I collagenase (250U/mg – Worthington Biochemical 
Corporation) in water bath at 37°C for 30 minutes, shaking manually every 5 minutes. After digestion, 
collagenase was neutralized by adding an equal volume of culture medium. Sample were centrifuged 
at 1300g for 10 minutes to isolate the stromal vascular fraction (SVF) from cellular debris and 
undigested tissue. SVF was then filtered using cell strainers (pore size: 100μm) to remove remaining 
undigested tissue residues. After centrifugation at 350g for 4 minutes, pellets were resuspended in 
culture medium consisting of DMEM high glucose (D5671, Sigma Aldrich) supplemented with 10% FBS 
(Thermo Scientific), 2mM L-glutammine (G7513, Sigma Aldrich), 100U/mL penicillin, 100μg/mL 
streptomycin (P4458, Sigma Aldrich) and if necessary 2.5μg/mL amphotericin B (A9528, Sigma Aldrich). 
Cells were counted using a modified Burker chamber (Improved Neubauer) and cell viability was 
assessed by Trypan Blue (T8154, Sigma Aldrich) exclusion. Counted cells were plated at density of 105 
cells/cm2 (passage 0) and maintained at 37°C in a humidified atmosphere with 5% CO2. After 48-72 
hours, non-adherent cells were discarded by washing with PBS. 
During all the period of culture, medium was changed three times a week. After reaching 80-90% 
confluence, cells were detached by incubation with 0.5% trypsin – 0.2% EDTA (T4174, Sigma Aldrich) at 
37°C for 3 minutes. hASCs were plated at density of 104 cells/cm2 for expansion. Cells were 
characterized as described below and they were administered between the third and seventh-passage.  
 
3.3.1.1 hASC characterization and flow cytometric analysis 
Characterization of hASCs for their immunophenotypic 
markers was carried out by flow cytometry (FACSCalibur, 
Becton Dickinson) using CellQuest Pro software. Cells were 
analyzed for MSC surface antigen profile, evaluating CD13, 
CD54, CD73, CD90, CD105, CD14 and CD45 expression. Cells 
(passage 3) were deached washed twice in PBS to completely 
remove culture medium, pelleted and resuspended in ice-cold 
FACS buffer (2% FBS in PBS). For each sample, 4x105 hASCs 
were aliquoted in polystyrene FACS tubes (352052, BD 
Falcon). Sample were incubated with monoclonal antibodies 
specific for CD13, CD73, CD90, CD14 or CD45 (Biolegend) 
conjugated with fluorescein isothiocyanate (FITC) or phycoerythrin (PE) on ice for 30 minutes at 4°C in 
the dark. Conversely, other samples were incubated with biotinylated monoclonal antibody specific for 
hASCs 
 %mean SEM + / - 
CD13 96.08 2.03 + 
CD54 83.34 7.26 + 
CD73 99.76 - + 
CD90 94.14 1.67 + 
CD105 94.77 3.13 + 
CD14 1.61 0.95 - 
CD45 0.8 0.37 - 
Table 2| hASC characterization.  
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CD54 or CD105 (Ancell) and then incubated with SA-PE (streptavidin, a biotin-binding protein 
covalently attached to phycoerythrin fluorescent label) secondary antibody on ice for 20 minutes at 
4°C in the dark. After washing with ice-cold FACS buffer, samples were analyzed by flow cytometry. 
Cells were first discriminated for cell size and granularity by forward and side scatter, vital cells were 
gated and further analyzed. 
From flow cytometric analysis, hASC populations showed positivity for surface antigen CD13, CD54, 
CD73, CD90 and CD105, while negativity for CD14 and CD45 [Table 2]. 
 
3.3.2 CM-hASC collection and concentration 
Upon reaching 80-90% confluence, hASCs were washed once and then incubated at 37°C with 5% CO2 
for 72 hours in serum-free medium containing DMEM high glucose (w/o phenol red) supplemented 
with 2mM L-glutamine, 50U/mL penicillin and 50μg/mL streptomycin. Starving medium was phenol 
red-free because the presence of this pH indicator could interfere with concentration step and 
because great part of collected CM had in vivo applications. 
Conditioned medium was collected, centrifuged once at 350g for 5 minutes to remove cell debris and 
then concentrated using Ultra-15 Centrifugal Filter Units with 3 kDA cut-off (Meck Millipore) by 
centrifugation at 4000g for 90 minutes [Cantinieaux et al., 2013]. After collecting the medium, cells 
were detached and counted to obtain a correspondence between CM/secretome volume and number 
of hASCs. hASC secretome was stored at -80°C or lyophilized. 
 
3.3.2.1 Lyophilization protocol 
Freeze-drying of concentrated conditioned medium was performed by using Lio5P freeze dryer (5 
Pascal) and RV8 vacuum oil pump/Oil Mist Filter (Edwards).  Following lyophilization, samples were 
stored at  -80°C, until use. Before in vivo administration samples were reconstituted in PBS + 2.5% 
heparin. 
 
3.3.3 Isolation of human Fibroblast and CM-hF collection and concentration 
Human dermal fibroblasts were collected from de-epidermized dermis obtained as wasted material 
from plastic and cosmetic surgery of healthy donors (male/females, age range 26-53 y/o). Tissue was 
mechanically minced and then fragments were enzymatically digested with 0.1% type I Collagenase at 
37°C for 6 hours. After collagenase digestion, samples were filtered, centrifuged and the pellet was 
resuspended in DMEM. Cells were cultered at the plate density of 5x103 cells/cm2  as reported above 
for hASC. Procedure for obtain CM-hF was the same used ti prepare CM-hASC. 
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3.4 Experimental design          
A sets of experiments were performed. Schematic experimental designs used throughout study are 
depicted in Scheme 1.  
For the treatments, 106 hASC and CM derived from 2x106 hASC or hF were resuspended in 200μL of 
PBS supplemented with 2.5% heparin. Animals were intravenously injected through the caudal vein, 
CTR mice were administered with the same volume of vehicle (PBS + 2.5% heparin). 
Moreover, to localize hASC both in diabetic and naïve mice 106 hASC were systemically administrated 
and Alu-sequences were identified.  
 
SINGLE TREATMENT  
Two weeks after STZ-injection (W2), mice were randomly allocated to different groups of treatment: 
 Control mice treated with vehicle (CTR) 
 Control mice treated with 106 hASC (CTR-hASC) 
 Diabetic mice treated with vehicle (STZ) 
 Diabetic mice treated with 106 hASC (hASC) 
 Diabetic mice treated with Conditioned Medium derived from 2x106 hASC (CM-hASC)  
 Diabetic mice treated with CM derived from 2x106 hASC lyophilized (Lyo CM-hASC)  
 Diabetic mice treated with Conditioned Medium derived from 2x106 hF (CM-hF) 
 
REPEATED TREATMENT 
Two weeks after STZ-injection (W2), mice were randomly separated to different groups of treatment: 
 Control mice treated with vehicle (CTR) 
 Diabetic mice treated with vehicle (STZ) 
 Diabetic mice treated with 106 hASC (hASC) 
 Diabetic mice treated with conditioned medium derived from 2x106 hASC (CM-hASC)  
Moreover, 6 weeks after STZ (W6), corresponding to 4 weeks after the first injection two groups of 
mice received a second hASC or CM-hASC treatment using the previously mentioned doses. 
 
SINGLE TREATMENT IN ADVANCED STAGE OF DISEASE 
Six weeks after STZ (W6), mice were divided into the following groups: 
 Control mice treated with vehicle (CTR) 
 Diabetic mice treated with vehicle (STZ) 
 Diabetic mice treated with 106 hASC (hASC) 
 Diabetic mice treated with conditioned medium derived from 2x106 hASC (CM-hASC)  
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Scheme 1| Experimental protocol schema. (A-a) STZ-mice treated once (W2) with hASC or CM-hASC; (A-b) STZ-mice treated once (W2) with CM-hASC 
lyo or CM-hDF and CTR-mice treated with hASC. (B) Reapeated treatment (W2+W6) with hASC or CM-hASC in STZ-mice. (C) Single hASC or CM-hASC 
treatment in advanced pathological state (W6). 
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3.5  Nociceptive behaviour test 
In order to characterize the nociceptive behaviour of neuropathic mice, two of the most frequent 
symptoms encountered in neuropathic patients were evaluated, i.e. allodynia (mechanical and 
thermal) and thermal hyperalgesia, monitoring over time the threshold responses of the animals to 
thermal and mechanical stimuli. Behavioural testings were performed before neuropathic induction 
(T0), i.e. before chemical pancreactomy with STZ, to establish a baseline for comparisons with post-
diabetic induction values, and at different successive times after diabetes induction, weekly or every 
two weeks respectively, for whole period of experimental study on both hind paws of animals. 
Thermal allodynia was determined before and after STZ-injection and 1 week after treatments. The 
acute effect of both treatments was studied in STZ-mice, evaluating the responses to mechanical and 
thermal stimuli 3, 24 and 72 hours after hASC or secretome administration. 
All behavioural tests were carried out in the morning in a stabulary-designed rooms  after a 
habituation period of 30 minutes that allows an “appropriate behavioural immobility” of the animals. 
The behavioural evaluations were always performed by researchers who were blind to treatments. 
 
3.5.1 Von frey test: mechanical allodynia evaluation 
Mechanical allodynia, painful response to 
innocuous mechanical stimuli, was 
monitored evaluating the mechanical 
touch sensitivity through a blunt probe 
(Von Frey filament, 0.5 mm diameter) on 
the mid plantar surface of the animal 
hind paw, using the Dynamic Plantar 
Aesthesiometer (Ugo Basile, Italy). This 
instrument consists of a moveable force 
actuator containing the Von Frey 
filament, placed below a metallic 
perforated platform upon which the researchers deposit the animals, whose mobility is restrained by a 
Perspex cage; two compartments, further subdivided by wooden structures in order to test at the 
same time more animals, divide the Perspex box and delimit the space within which the animals are 
free to move, helping the operator to carry out a rapid “testing” work. The moveable force actuator is 
a cylindrical vessel equipped with an adjustable angled-mirror in order to position the touch probe 
below the target area of the paw and start keys to actuate a vertical movement of the filament. A 
controller allows the setting of the force exerted by the filament on the mouse paw and the reading (in 
grams) of the paw withdrawal threshold (PWT).  
Image 13| Dynamic plantar Aesthesiometer. 
[www.ugobasile.com] 
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An increasing force (ranging up to 10 grams in 10 seconds) starting below the threshold detection is 
applied on the mid plantar surface of the hind paw; when animals feel pain they remove their paw and 
the PWT recorded. PWT was measured three times on both hind paws and the mean of the values was 
calculated. 
 
3.5.2 Acetone drop test: thermal allodynia evaluation 
Cold-allodynia was assessed by Acetone drop test; a 
drop of acetone (50μL) was placed, without touching 
the skin, in the middle of the ventral side of the 
hindpaw. Mouse was immediately placed  in a perspex 
box (size: 60cm × 40 cm × 15 cm) and  allowed  to 
move freely. A stopwatch was started. The response 
of the animal to acetone was monitored for 20s. If the 
mouse did not withdraw, flick or stamp its paw within 
this 20s period then no response was recorded for that trial (0, see below). However, if within this 20s 
period the animal responded to the cooling effect of the acetone, then the animal's response was 
assessed for an additional 20s, for a total of 40s from the application. The reasons why a longer period 
of time was needed to assess the acetone-evoked behaviour was to measure only pain-related 
responses and not startle responses that can occur immediately after acetone application. Moreover, 
painful responses evoked by acetone application is often an interrupted series of behaviours, thus it is 
important to give the animals enough time to see all pain-related behaviours. Responses to acetone 
were graded to the following 4-point scale:  
- 0, no response;  
- 1, quick withdrawal, flick or stamp of the paw;  
- 2, prolonged withdrawal or repeated flicking (≥ 2) of the paw;  
- 3, repeated flicking of the paw with licking directed at the ventral side of the paw.  
Acetone was applied alternately three times to each hindpaw, with a 5 minutes gap, between the 
applications. Mean values were then generated for each mouse [Flatters and Bennett, 2004]. 
 
 
 
 
 
 
 
Image 14| Experimental procedure of acetone 
drop test.  
  
   66 
 Chapter 3: Materials & Methods 
3.5.3 Hot plate test: thermal hyperalgesia evaluation 
Animals were placed individually into a perspex cilinder on a clean and dry aluminum hot plate 
maintained at 55 ± 1°C (Ugo Basile, Varese, Italy). This test measures the 
time that elapses before the mouse demonstrates hind paw 
licking/shaking and jumping, which indicate pain in response to the 
applied heat. Basically, each animal was placed on the heated surface, 
and the time (in seconds) between placement and pain response was 
measured. Exposure to heat continued until nociceptive reaction of 
either hind paws occurred. The latency of the withdrawal response was 
determined before induction of neuropathy and then every two weeks 
until the end of the experimental study (W14). The heat source was 
maintained at constant intensity. A maximal latency value (cut-off) of 
20s was set to avoid tissue damage, and the withdrawal latency was approximately 10-13s in naive 
mice. Animals were tested once at every time points to minimize skin damage and adaptation. Heat 
hyperalgesia was defined as the average-group of these measurements [Romanovsky et al., 2010; 
Alshahrani et al., 2012]. 
 
3.6 Blood glucose level and body weight reduction evaluations 
The development of diabetes was monitored every week from STZ administrations by evaluating the 
blood glucose levels and the body weight of each animal, parameters tipically altered also in diabetic 
patients. Blood samples were obtained from a small prick on the animals  tail  vein and glucose 
concentration was assessed using a glucometer (GLUCOCARD G+ meter, A. Menarini diagnostics, Italy).  
 
 
 
 
 
 
Only the animals with blood glucose values above 250 mg/dl were considered diabetic; mice with 
blood glucose values inferior to this concentration were excluded from the study. Animal body weight 
was monitored at T0 and weekly after STZ-injection throughout the experimental study using a digital 
scale (PE1600, Metler Toledo, USA); the evaluations were always performed in the morning. 
 
 
 
Image 15| Hot plate. 
[www.coulbourn.com] 
Image 16| Blood glucose levels 
evaluation. 
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3.6.1 Glucose metabolism: glucose tolerance test 
At W10 from STZ (8 weeks after treatments) 4 mice for each experimental group performed glucose 
tolerance test. This test was carried out in the morning after an overnight fast (14-18h) during which 
animals had access to drinking water. Basal blood glucose levels, before and after fasting, were 
recorded using a glucometer according to the previously mentioned protocol used for canonical 
glycemia measurement, subsequently animals were intraperitoneally injected with a D-glucose 
solution 2g/Kg . Blood was then sampled at 30, 60, 90, 120 and 180 minutes after the injection.  
After the first measure, bleeding is started by removing the scab of the first incision, massaging the tail 
in case the blood flow was not sufficient. Further loss of blood from the incision was minimized by 
apply pressure directly to the incision after each measurement. 
At the end of the experimental session, the mouse was placed in a clean cage with food and water ad 
libitum. Animals were monitored carefully to observe any abnormal behaviors. 
 
3.7 Biochemical evaluations 
Mice were killed by CO2 inhalation at different times: 
 3 weeks from STZ, one week after treatments (short time) 
 14 weeks from  STZ (long time): 
 mice treated 2 weeks from STZ (W2, single treatment); 
 mice treated after 2 and 6 weeks from  STZ (W6 + W2, repeated treatment); 
 mice treated after 6 weeks from STZ (W6, in advanced disease treatment). 
Other animals were also sacrificed in  other time points (see Table 3) 
 
3.7.1 hASC localization by Alu sequence detection 
Lungs, livers, pancreas and sciatic nerves of STZ and CTR mice were taken and immediately frozen at 
day 1, 3, 7, 14 and 21 after 106 hASC i.v. injection. Genomic DNA from organs was extracted following 
standard procedures. Briefly, 25 mg of each tissue (except for the sciatic nerve) were homogenized 
and lysed in 0.5 mL of lysis buffer (1% SDS, 400mM NaCl, 5mM EDTA [pH 8.0], 100mM Tris [pH 8.0]) 
containing 0.2 mg/mL of Proteinase-K (Sigma-Aldrich). Differently, both sciatic nerves from each 
mouse were lysed in 50µl of the same lysis buffer. Samples were incubated overnight at 56°C and 
following phenol/chloroform extraction, DNA was precipitated in 100% ethanol, washed with ice-cold 
70% ethanol and finally resuspended in MilliQ water. Primate specific ALU sequences were amplified 
by PCR using appropriate primers: (forward, 5’-TGGGCGACAGAACGAGATTCTAT-3’; reverse, 5’-
CTCACTACTTGGTGACAGGTTCA-3’) that produce DNA amplicons of 224bp [Yu et al., 2012]. Human 
DNA isolated from hASC was used as positive control. The PCR products were analysed by agarose gel 
electrophoresis and images were captured using SyngeneGBox-HR Gel Doc System. 
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Table 3| In vitro analysis scheme. 
 
Times of biochemical 
evaluations 
Animals/ 
treatments 
Tissue/ cells Methods Target 
3 hours after 
treatment 
CTR 
STZ 
STZ + hASC                             
STZ + CM- hASC 
Splenocytes ELISA IFN-γ, IL-2, IL-4 and IL-10 
Nervous tissues  ELISA IL-1β, IL-10 and CGRP 
3 weeks after STZ 
(short time) 
CTR 
STZ 
STZ + hASC 
STZ + CM- hASC 
Splenocytes 
RT-PCR IFN-γ and IL-10 
ELISA IFN-γ, IL-2, IL-4 and IL-10 
Nervous tissues  ELISA 
IL-1β, IL-6, TNF, IL-10 
and CGRP 
Pancreas ELISA IL-1β and IL-10 
Plasma ELISA insulin 
Epidermal paws 
Immunohistochemistry PGP9.5 (% nerve fibers) 
Morphology/ hIstology  Epidermis thickness 
14 weeks after STZ 
(longer time) 
W
2 
CTR 
STZ 
STZ+hASC 
STZ+CM-hASC 
Splenocytes 
ELISA IFN-γ, IL-2, IL-4 and IL-10 
RT-PCR IFN-γ and IL-10 
Spinal cord (L4-L6) ELISA 
IL-1β, IL-6, TNF, IL-10 
and CGRP 
Plasma ELISA insulin 
Pancreas ELISA IL-1β and IL-10 
Epidermal paws 
Immunohistochemistry PGP9.5 (% nerve fibers) 
Morphology/ hIstology   Epidermis thickness 
Kidney Morphology / hIstology Bowman’s space area 
W
2
 +
 W
6 CTR 
STZ 
STZ+hASC 
STZ+CM-hASC 
Splenocytes ELISA IFN-γ, IL-2, IL-4 and IL-10 
Spinal cord (L4-L6) ELISA IL-1β, IL-6, TNF, IL-10 
Plasma ELISA insulin 
Pancreas ELISA IL-1β and IL-10 
Kidney Morphology/hIstology  Bowman’s space area 
W
6 
CTR 
STZ 
STZ+hASC 
STZ+CM-hASC 
Splenocytes ELISA IFN-γ, IL-2, IL-4 and IL-10 
Spinal cord (L4-L6) ELISA IL-1β, IL-6, TNF, IL-10 
Plasma ELISA insulin 
Pancreas ELISA IL-1β and IL-10 
Kidney Morphology/ hIstology Bowman’s space area 
1 and 3 days  and         
1, 2, 3 weeks after 
treatments 
CTR 
STZ+hASC 
CTR+hASC 
Lungs, liver, pancreas and sciatic 
nerves 
PCR Alu-sequences 
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3.7.2 Tissues collection   
 Nervous tissues/ pancreas and serum collection for cytokines and insulin assay respectively  
At different time points (reported in Table 3) Pancreas, DRG, spinal cord and sciatic nerves were 
rapidly dissected from diabetic neuropathic mice treated with hASC, CM-hASC, saline and their 
controls, immediately frozen in liquid nitrogen and  conserved at -80°C until cytokine protein 
content assay. Nervous tissues were homogenized in 0.3 ml of ice-cold PBS containing a 
protease inhibitor cocktail (lysis buffer) (Roche Diagnostics, Italy). Pancreatic tissues were 
homogenized in 2 ml of the same lysys buffer.  All samples were centrifuged at 13000 rpm for 15 
minutes at 4 °C. Supernatants were collected and used to measure pro- and anti- inflammatory 
cytokines levels and total protein content (Lowry’s method, see paragraph 3.7.3). In order to 
evaluate CGRP concentration spinal cord and DRG were homogenized in 2 N acetic acid (250µL), 
heated at 90°C for ten minutes, centrifuged, supernatant was dried, and then dissolved in EIA 
buffer. Before proceeding at tissues removal, a small aliquot of blood from all each mice was 
collected in tubes for plasma insulin dosage. 
 
 Spleen cells collection and stimulation for cytokine assay  
Spleen cells collection was performed 2, 3 and 14 weeks from STZ. At these time points mice 
were killed and their spleens rapidly and aseptically removed. Splenocytes were spilled out from 
an incision on spleen cuticle made with 20-gauge needles, adjusted in 24-well plates at the final 
concentration of 4x106 cell/ml of culture medium (complete RPMI, i.e. RPMI 1640 supplemented 
with 10% FCS, 1% glutamine, 2% antibiotics and 0.1% 2-mercaptoethanol) and incubated at 37 
°C in 5% CO2 and 95% air with or without 10 μg/ml Concanavalin A (ConA) for Th1 and Th2 
cytokines stimulation. The stimulus was added to the cell cultures in a final volume of 1 ml/well 
in complete RPMI.  After 24 (for IFN-γ and IL-2) or 48 hours (for  IL-4 and IL-10) of culture, times 
of maximum cytokines release [Sacerdote et al., 2000; Martucci et al., 2007], the supernatant 
was collected and stored frozen at -80 °C for cytokine assay. Moreover, 4x106 cells were pelleted 
for mRNA evaluation (see 3.7.4) and stored at -80 ° C.  
 
3.7.3 Enzyme-Linked Immune-Sorbent Assay (ELISA) 
Cytokine concentration was determined by Enzyme-Linked Immuno-Sorbent Assay (ELISA) using ultra-
sensitive ELISA kits according to the manufacturer’s instruction. DuoSet® ELISA development system 
for mouse IL-2, IFN-γ and IL-4 was purchased from R&D Systems (Minneapolis, USA) while mouse IL-10, 
IL-1β, TNF- and IL-6 ELISA Ready-SET-Go! from eBioscience (San Diego, CA). CGRP EIA Kit was 
purchased from Cayman. Serum insulin dosage was performed using a specific ELISA kit provided by 
Mercodia (Uppsala, Sweden). Sensitivity of the kits are reported in Table 4.  
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Table 4|  ELISA Kits 
 Sensitivity Kit 
Interleukin 1β (IL-1β) 8 pg/mL eBioscience 
Interleukin 2 (IL-2) 15.6 pg/mL R&D 
Interleukin 4 (IL-4) 15.6 pg/ mL R&D 
Interleukin 10 (IL-10) 32 pg/ mL eBioscience 
Interferon γ (IFN-γ) 31.2 pg/mL R&D 
Tumor Necrosis Factor (TNF-α) 8 pg/mL eBioscience 
Interleukin 6 (IL-6) 4 pg/mL eBioscience 
Calcitonin Gene Related Peptide (CGRP) 3.91 pg/mL Cayman 
Insulin 0.2 ng/mL Mercodia 
 
Briefly, a first primary anti-cytokine monoclonal antibody (Ab-I) was seeded onto a polystyrene plate 
with U bottom 96 wells. Ab-I adhesion to the plastic polymer was favoured by basic pH and occurred 
during an over-night incubation at 4 °C (eBioscience kit) or at room temperature (R&D kit). In the 
insulin kit (Mercodia), wells were already  Ab-I pre-coated. Several washes were then carried out to 
eliminate antibody excess that was not bound. The nonspecific sites of the plate were blocked a with 
blocking buffer solution; samples and standards were subsequently added. Plates were incubated to 
ensure that any cytokine present in the sample bound to the antibody already attached to the wells. 
After several washes, secondary anti-cytokine biotinylated monoclonal antibody (Ab-II) was added: 
this bound the immobilized cytokine already linked to Ab-I.  
 
Therefore a "sandwich" was formed with the substance in the center and on the sides the antibodies. 
After another series of washes, avidine peroxidase, which has the task of binding the biotinylated 
antibody, was added. 
Finally, enzyme substrate was added: a colored complex was formed the intensity of which was 
proportional to the amount of cytokine present in the sample; color development was stopped with 
Image 17| Illustration of sandwich ELISA method 
[http://www.leinco.com/sandwich_elisa] 
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H2SO4 [1M] addition. Results were obtained by reading the absorbance of each well in a 
spectrophotometer, using a specific wavelength to each cytokine studied. In cell coltures (splenocytes 
and macrophages) released cytokine concentrations were determined by interpolation with standard 
curve assayed the same plate (response pg/mL); for tissues (nervous tissues and pancreatic tissues) 
ELISA obtained values were then normalized considering the total protein content in of each sample. 
 
3.7.4  Determination of total protein concentration 
Total protein concentration is necessary to compare the quantity of cytokines obtained with ELISA to 
the total quantity of proteins present in the samples. It was evaluated according to the Lowry method 
which uses bovine serum albumin (BSA) as a standard. 
A standard curve was prepared as follows: BSA powder was dissolved in distilled water and diluted to a 
concentration of 1 mg/mL. In each standard test tube: 5, 10, 20, 40, 60, 80, 100 µL of BSA (1mg/mL) 
were added and brought them to a final volume of 100 µL with distilled water. Blanks were obtained 
substituting albumin with 100µL of distilled water.  All standards, and samples, were made in 
replicates of 2. 
Samples were diluted, depending from the tissue of origin, such that they would fall within the BSA 
standard range (0-100 μg/μL) and a total volume of 100 μL was placed in each tube.  Then 200µL of 
NaOH 1N and 2mL of Cooper Reagent1 were added to each test tube. Samples were incubated without 
light for 10 minutes and then 100µL of Folin Ciocalteau reagent were added to each one of them. A 
second incubation without light for 45 minutes was needed to proceed to the reading of absorbance 
through a spectrophotometer (Uvicon 941 PLUS, Kontron Instruments), with a wavelength of 750nm.  
Samples were obtained with analogous procedure of that used for the standard straight line using a 
fixed quantity of sample, instead of albumin, by adding distilled water we reached the final volume of 
100µL. 
 
 
 
 
 
 
 
 
 
                                                          
1
 composed of 2% Na2CO3, 1% CuSO4 and 2% Na K-tartrate dissolved in distilled water in a proportion of 100:1:1 
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3.7.5 Evaluation of mRNA levels of IL-10 and IFN-γ in spleen cells 
Every manipulations was done with the use of RNAse-free material and sterile solutions in order to 
avoid any contaminations of samples. 
 
3.7.5.1 Homogenization of samples and total RNA extraction 
To evaluate levels of mRNA of Th1 (IFN-γ) and Th2 (IL-10) cytokines, a part of isolated spleen cells were 
homogenized with turrax in 1 mL of Trizol® (Trifast Eurogold®, Euroclone, Italy), which is a monophasic 
solution of phenol and guanidine isothiocyanate that destroys cell membrane allowing leak from cells 
of RNA. Using insulin syringes (one for each sample to avoid contamination) they were transferred in a 
new series of tubes and 200µL of chloroform (Serva) were added to each one. Samples were manually 
shaken for 30 seconds and then they were incubated for 5 minutes at room temperature.  
After this pause they were centrifuged at 13000 rpm for 15 minutes at 4°C. At this point there is a 
separation of the solution in three different phases: 
 
 
 on the surface: aqueous solutions composed of RNA  
 
  interphase: white matt which contains DNA and proteins 
 
 at the bottom: pink phase composed of phenol and chloroform 
 
 
The superficial phase was transferred in a new series of tubes and then 500µL of Isopropanol (Sigma 
Aldrich) were added to each sample to allow the precipitation of the RNA. Test tubes are then 
manually shaken for 30 seconds, incubated at room temperature for 10 minutes and centrifuged at 
13000rpm for 15 minutes at 4°. At the end of this centrifugation step, the bottom of the tube 
contained a pellet of RNA. Supernatant was eliminated and pellet was washed with 1mL of ethanol 
75%. Samples were subjected to another centrifugation step at 13000rpm for 10 minutes at 4°C, 
ethanol was eliminated and the pellet dried in the air. At the end dry RNA pellet was resuspended in 
20µL of DEPc water (Fluka) and stored at -80°C to avoid degradation of the sample. 
 
3.7.5.2 Digestion of genomic DNA 
Before proceeding to the quantification of total mRNA contained in samples and to the 
retrotranscription to cDNA which is the final substrate for the PCR reaction, samples were incubated in 
a thermostate bath for 10 minutes at 55-60°C. To avoid any contamination of genomic DNA, samples 
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underwent to DNase treatment2 (DNA-free™ DNase kit Treatment and Removal Reagents, Ambion, 
Applied Biosystem, Italy) to avoid false-positive results. At the end of this treatment, they were 
incubated in a thermocycler (T100™, BioRad) for 40 minutes at 37°C. Subsequently, a quantity of 0,1 of 
the final volume (in our case 2 µL) of DNase Inhibitor Reagent, which inactivates DNAse, was added to 
each sample. Samples were left for 3 minutes at room temperature. They were finally centrifuged at 
12000 rpm for 3 minutes and then the supernatant (which contained total RNA) was transferred to 
another series of test tubes. 
Samples could now be used for quantification of the total mRNA or can be conserved at -80°C until 
use. 
 
3.7.5.3 Quantification of total mRNA 
Total RNA concentration was determined using spectrophotometer U.V. (Biophotometer, Eppendorf). 
From each sample a rate of 1µL was taken and diluted with 49µL of DEPc water. The total volume was 
transferred in uvette for the reading at the spectrophotometer set to a wavelength of 260 nm. Total 
concentration of RNA for each sample was calculated whereas OD260=1 is equal to 40 ng/µL, using the 
following formula: 
[ ] total RNA= OD x 40 ng/µL x FD 
To test the purity of extracted mRNA the ratio between absorbance of RNA (OD260) and absorbance 
of proteins (OD280) is evaluated. This ratio, in absence of contamination, has to be between 1,8 and 2. 
 
3.7.5.4 Retrotrascription of mRNA 
Extracted RNA is converted in cDNA. This is done thanks to the use of random primers, commercial 
exanucleotide that pair to the isolated RNA giving the docking (represented by an initial oxidrile group) 
for the activity of the reverse transcriptase enzyme. After the quantification of the total RNA, 1000ng 
were taken from each sample and a fixed quantity of 4µL of Mix for retrotranscription, Iscript RT 
supermix 5X (BioRad)3 was added to the RNA.  Final volume of reaction was reached through the add 
of a quantity of DEPc water of:  20µL - (4µL RT Supermix + µL sample) 
Samples are then incubated in thermocycler for 40 minutes with the following procedure: 5 minutes at 
25°C (priming), 30 minutes at 42°C (Reverse Transcription) and the last 5 minutes at 85°C (RT 
inactivation). 
Samples of cDNA obtained were preserved at -80°C for further analysis, RT-PCR. 
                                                          
2
 DNA-free
™ 
kit contains Dnase-I Buffer (10X) and rDNase. In our case Vf = 20µL, for each sample 2µL of DNase-I 
buffer (10X) and 1µL of rDNase were added (the latter quantity is independent from Vf). 
3
 5x RT supermix with iScript MMLV-RT (RNase H
+
), RNase Inhibitor, dNTPs, oligo (dT), random primers, Buffer, 
MgCl2 and stabilizer 
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3.7.5.5 Real Time-PCR 
Real Time-PCR is a semi-quantitative technique that allows the study of gene expression. Amplification 
of cDNA is monitored during all the exponential phase of growth. 
The amplification reaction, through Real Time-PCR, was performed using ABI PRISM 7000 system 
(Applied Biosystem, Foster City, CA) and carried out in a final volume of 25µL constituted by: 
- 2 µL of cDNA obtained from previously retrotranscription of mRNA 
- 1,25µL of TaqMan primers/probe 
- 10 µL of Real Master Mix Probe Rox (Eppendorf) containing Taq-polymerase enzyme 
- 11,75 µL of RNase-free water  
Specific TaqMan primers/probe for cytokines of interest, IL-10 (Mm00439616_m1) and IFN-ƴ 
(Mm01168134_m1), were used. As endogenous control gene GAPDH (Mm99999915_g1) (Taqman® 
Assay-on-Demand™ Gene Expression Products, Applied Biosystem) was used. 
All Real Time PCR assays were performed in duplicate. Before using the ∆∆Ct method for relative 
quantification, a validation experiment was performed in order to demonstrate that the efficiencies of 
targets and reference were approximately equal. As controls reaction mix without cDNA was used. 
The reaction conditions were as follows: 95°C for 2 minutes (Initial Denaturation), followed by 45 
cycles at 95°C for 15 seconds (Cycled Template Denaturation) and at 60°C for 60 seconds (Annealing 
and Extension).  
Relative quantification was performed using the comparative threshold method. Threshold cycle 
numbers (CT) of the specific gene of interest and the endogenous control gene GAPDH were 
determined by ABI PRISM 7000 Sequence Detection System. 
Gene expression values, of each gene, were standardized on correspondent values of the endogenous 
control gene GAPDH and relate as relative values of calibrator sample using the following formula: 
2 -∆∆CT 
 Briefly, ∆CT value was calculated subtracting GAPDH CT to target gene of interest CT (∆CT); while ∆∆CT 
was calculated subtracting the GAPDH CT average of saline treated healthy control group (non-diabetic 
mice) to ∆CT value of each sample. 
 
3.8 Skin immunohistochemistry and morphometry 
Mice plantar skin was collected and fixed in 10% buffered formalin for 24 hours. Skin was embedded in 
paraffin according to standard procedures and cut at 8 μm by a microtome (Microm HM 325). 
Alternate paraffin sections from the middle part of plantar skin were processed by 
immunohistochemistry. The sections were deparaffinised, rehydrated and subjected to antigen 
retrieval in 0.05M sodium citrate buffer (pH 6.0) in hot water bath (98°C for 20’). Endogenous 
peroxidase activity was blocked by incubation with a solution of 3% hydrogen peroxide. Sections were 
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immunostained with the monoclonal antibody anti-mouse PGP9.5 (protein gene product 9.5, dilution 
1:250, EMD Millipore, Darmstadt, Germany), a marker of nerve fibers. All sections were processed 
using UltraVision Quanto Detection System horseradish Peroxidase (HRP; ThermoScientific, Bio-Optica, 
Milan, Italy), followed by development with diaminobenzidine (Amresco, Prodotti Gianni, Milan, Italy). 
Finally, the sections were dehydrated and mounted and some of them were previously counterstained 
with  hematoxylin. Immunohistochemical control was performed by omitting the primary antibody, in 
presence of isotype matched IgGs and performing pre-adsorption assay using the related peptide and 
gave negative results. 
 
3.8.1 Quantification of epidermal innervation 
Digitally fixed images of slices were analyzed using an image analyzer (Image Pro-Premier, Immagini e 
Computer, Milan, Italy). The density of nerve fibers was evaluated measuring the percent area 
occupied by positive PGP9.5 nerve fibers in epidermal area including the sub-basal one. The data of all 
animals were analyzed at a final 400X magnification measuring three randomly collected fields for 
each section.  
 
3.8.2 Morphological evaluation of epidermal thickness  
Digitally fixed images of slices were analyzed using an image analyzer (Image Pro-Premier, Immagini e 
Computer, Milan, Italy). Epidermal thickness was evaluated by means of the distance (in μm) between 
basal membrane and stratum granulosum at a final 400X magnification measuring three randomly 
collected fields for each section by researcher unaware of the animal group assignment. 
 
3.9 Kidney histological analysis 
Kidneys were fixed in 10% buffered formalin (Sigma-Aldrich) for 24 hours at RT and then processed for 
paraffin embedding through a graded ethanol series through STP 120 Spin Tissue Processor (Bio 
Optica). Morphological analysis was performed on 2-3μm Harris’ hematoxylin and eosin (Bio Optica) 
stained sections (images acquired by Olympus BX51, Japan). Bowman's space area (73,74) in at least 
five randomly collected fields were quantified by ImageJ software at a final 200X magnification, by 
researchers unaware of the animal group assignment. At least 30 glomeruli/ group were analyzed. 
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3.10 Data analysis 
Statistical analysis were performed using GraphPad Prism 5 Software (San Diego, CA, U.S.A). Data were 
tested for equal variance before choosing statistical analysis. 
Data from mechanical allodynia measurements were analyzed by mean of Two-Way ANOVA 
considering the type of treatment and the time as factors. Baseline values, i.e. responses before STZ 
injection, were not included in the analysis. If an overall test comparing group was significant, 
Bonferroni’s test was used for between-group comparisons in the post hoc analysis. Cold allodynia 
scores were compared with Mann–Whitney U-test. 
Cytokines results were analyzed using One-Way ANOVA or Two-Way ANOVA, followed by Bonferroni’s 
post hoc test for multiple comparison. Body weight and blood glucose levels were statistically 
evaluated by Two-way ANOVA considering the type of treatment and the time as factors. If an overall 
test comparing group was significant, Bonferroni’s test was used for between-group comparisons in 
the post hoc analysis. 
Data from histological experiments (skin thickness and kidney damage) and of immunohistochemistry  
(PGP9.5) were analyzed and compared by analysis of variance (One-Way ANOVA) and by a Bonferroni’s 
multiple comparison test. 
The overall significance level was 0.05 for each hypothesis. Each group consisted of 6 animals. The 
group size was chosen on the basis of the results obtained in our previous studies. For antiallodynic 
response, considering an expected difference in means of 40%, SD of 10%, number of treatments 4, 
power 0.95 and α 0.05, a number of 3 animals for group could have been enough. However, 
considering also cytokines as important outcome, where the SEM can be estimated in 30%, the 
number must be increased to 6 animals. Results are expressed as mean ± SEM. 
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4.1 Effect of therapeutic treatments on allodynia, hyperalgesia and 
hyperglycemia 
In order to study whether hASC and CM-hASC treatments were effective in alleviating diabetic 
neuropathic pain we performed a series of experiments using a mouse model of diabetes induced by 
chemical destruction of pancreatic insulin-secreting β-cells; animals were injected with multiple low 
doses of β-cell toxin, streptozotocin (STZ, 80 mg/kg, i.p.; daily for three consecutive days).  
STZ administration induced in animals a rapid establishment of hyperglycaemic state associated to the 
development of painful symptoms. As depicted in Figure 1 (panel A), blood glucose levels of STZ mice 
strongly increased after 2 weeks from diabetes induction and were still significantly higher on weeks 14 
compared to normo-glycaemic values of controls; no treatments modified blood glucose levels that 
were always elevated in STZ mice over time. 
 A marked reduction of paw withdrawal thresholds (PWT) of mice it is observed one week after STZ 
(panel B). Pain thresholds to mechanical stimuli of STZ mice remained significantly lower than those of 
controls, i.e. non-diabetic mice, for the entire period of observation, i.e. up to 14 weeks. 
Two weeks after STZ, when mechanical allodynia was fully developed, hASC or CM-hASC were i.v. 
injected. As reported in Figure 1 - panel B, both treatments were able to significantly reduce mechanical 
Figure 1| Effects of a single hASC and CM-hASC treatment on hyperglycemia and mechanical allodynia. Mice received a 
single hASC (106) or CM-hASC (obtained from 2 × 106 cells) treatment, 2 weeks after STZ, and the effects on hyperglycemia (A) and 
mechanical allodynia (B, C) were monitored up to 14 weeks after STZ (long-lasting effects, B) and few hours (3 to 72 h) after the injection 
(short-term effects, C). Data represent mean ± SEM of 6 mice per group. Two-way ANOVA was used for statistical evaluation, followed by 
Bonferroni’s post hoc test for multiple comparisons. ***p < 0.001 vs CTR; °°°p < 0.001 vs STZ; ###p < 0.001 vs STZ + hASC. 
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allodynia, although the effect of hASC was significantly stronger than that elicited by CM-hASC. A 
significant reduction of mechanical allodynia was evident already 3 hours after treatments (Figure 1, 
panel C). Their anti-allodynic effect was maximal between 1 and 2 weeks, and was extremely long lasting 
since allodynia was maintained significantly reduced up to 12 weeks after a single hASC and CM-hASC 
injection (14 weeks after STZ, W14).  
 
Since the sensory alterations associated to diabetic neuropathy in patients are often diverse and 
associated to modified response to several stimuli, we also decided to test the action of hASC and CM-
hASC treatments on thermal hyperalgesia for the whole period (up to 14 weeks after STZ) and on cold 
allodynia during the first week after injection (3 weeks after STZ). As shown in Figure 2 - panel A, STZ-
mice are characterized by a hyperalgesic condition between 1 and 3 weeks after STZ; 4 weeks after 
diabetic-induction, STZ-mice showed a clear shift toward an hypoalgesic state, which was stabilized 6 
weeks after STZ and that remains up to 14 weeks.  
 
In the first hours after hASC and CM-hASC injection (3 and 24h) thermal hyperalgesia in STZ-diabetic 
animals was completely reduced by both treatments, but 72 hours after treatments mice return to a 
hyperalgesic state and this condition remains until the end of observation (W14); it  is clear that both 
treatments were able to counteract the transition toward the hypoalgesic state.  In addition, as reported 
in Figure 2 - panel B, administration of both hASC and CM-hASC rapidly reduces cold allodynia displayed 
by STZ-diabetic mice and their effect was still present 1 week later. These data demonstrate the ability 
of hASC and their conditioned media to relieve hypersensitivity due to different stimuli that are peculiar 
of diabetic pain. 
 
 
Figure 2| Effect of a single hASC and CM-hASC treatment on thermal hyperalgesia and cold allodynia. Mice received a single 
hASC ( 106) or CM-hASC (obtained from 2 × 106 cells) treatments, 2 weeks after STZ, and the effects on hyperalgesia (A) and cold allodynia (B) 
were monitored up to 14 or 3 weeks after STZ, respectively. Values are mean ± SEM of 6 mice per group, and were compared with Two-way 
ANOVA followed by Bonferroni’s test for multiple comparisons (thermal hyperalgesia, A) and Mann–Whitney U-test (cold allodynia, B) 
*p < 0.05, ***p < 0.001 vs CTR; °p < 0.05, °°°p < 0.001 vs STZ. 
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Figure 3| Effect of repeated or advanced hASC and CM-hASC treatment on mechanical allodynia. (A and B) Mice received two 
repeated hASC or CM-hASC administrations 2 and 6 weeks after STZ; long-lasting effects (A) and short-term effects after the second 
administration (B) are shown. (C and D) Mice received a single hASC or CM-hASC injection, 6 weeks after STZ; long-lasting (C) and short-term 
effects (D). Data represent mean ± SEM of 6 mice per group. Two-way ANOVA was used for statistical evaluation, followed by Bonferroni’s 
post hoc test for multiple comparisons. ***p < 0.001 vs CTR; °°°p < 0.001 vs STZ; #p < 0.05, ##p < 0.01, ###p < 0.001 vs STZ + hASC; £££ 
p < 0.001 vs. W6 
Moreover, 4 weeks after the first treatment (6 weeks after STZ) a group of diabetic animals was 
administered a second time with either hASC or CM-hASC. As shown in Figure 3 - panel A, the second 
CM-hASC injection increased the PWT restoring sensitivity to the level reached after the first treatment 
and prolonging its effect. The anti-allodynic effect was potentiated already few hours after the second 
CM-hASC injection (Figure 3, panel B) and its trend completely mimicked both the rapid effect evoked 
by the early treatment (compare Figure 1 - panel C to Figure 3 - panel B) and the hASC effect up to 10 
weeks after diabetes-induction (Figure 3, panel A). Repeated hASC treatment did not further ameliorate 
allodynia.  
In order to elucidate whether hASC and CM-hASC treatments were also therapeutically effective at a 
later time point, animals were treated for the first time 6 weeks after diabetes induction. Also this late 
treatment was able to provide a fast and irreversible antiallodynic effect (Figure 3, panels C and D). In 
addition, 13 weeks after STZ, the effect of hASC appeared significantly more pronounced than the one 
exerted by CM-hASC. Moreover, 6 weeks after diabetic-induction neither second nor first hASC/CM-
hASC treatment were able to modulate blood glucose level: hyperglycemia of all treated mice remained  
similar to diabetic mice (data not shown). 
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We also treated STZ-mice with lyophilized CM obtained from 2x106 hASC, to evaluate whether  the 
secretome had the same effects on mechanical allodynia once lyophilized. The possibility to store 
secretome in a lyophilized form would be useful for a potential clinical application.  Figure 4 – panel A 
shows that lyophilized CM-hASC had lost its anti-allodynic effect, in fact it exerts a very weak 
antiallodynic effect that is significant in comparison to STZ-mice only  in the first week after treatment; 
this result suggests that during the lyophilization process bioactive factors essential for pain relief are 
lost.  
Concurrently, to prove evidence that CM-hASC effect was due to the specificity of the cell source, 2 
weeks after diabetic induction STZ-mice were treated with conditioned media derived from human 
fibroblasts (CM-hF). As shown in Figure 4 - panel B, CM-hF does not counteract mechanical allodynia, 
indicating that specific factors contained in the secretome of adipose-derived mesenchymal 
stem/stromal cells are responsible of the effect observed in vivo.  
 
 
Figure 4|Effect of other CM on mechanical allodynia. Two weeks after diabetic induction, STZ-mice received lyophilized CM 
obtained from 2x106 hASC (A) or CM obtained from 2x106 human fibroblasts (B). Data represent mean ± SEM of 6 mice per group. Two-way 
ANOVA was used for statistical evaluation, followed by Bonferroni’s post hoc test for multiple comparisons. ***p < 0.001 vs CTR; °p < 0.05, 
°°°p < 0.001 vs STZ; §§§ p < 0.001 vs STZ + CM-hASC. 
Figure 5| Glucose tolerance test. 
10 weeks after diabetic induction, 
intraperitoneal (i.p.) glucose tolerance 
tests were performed following an 
overnight fast (~16 hours) and a of 2 
g/kg glucose injection. Blood glucose 
concentration was assessed at the 
indicated time points in mice. Data 
represent mean ± SEM of 4 mice per 
group. Two-way ANOVA was used for 
statistical evaluation, followed by 
Bonferroni’s post hoc test for multiple 
comparisons. ***p < 0.001 vs CTR. 
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Since we observed therapeutic effects of treatments on hypersensitivity but no change in basal blood 
glucose levels, we decided to investigate whether the treatments were able to modify the way glucose 
was metabolized and mice were subjected to the glucose tolerance test. Ten weeks after STZ diabetic, 
hASC or CM-hASC treated mice (1 single treatment)and naïve CTR, were intraperitoneally injected with 2 
g/kg D-glucose, after an overnight fast. Blood glucose levels were monitored every 30 minutes after the 
injection for the following 3 hours (Figure 5). hASC/CM-hASC treated mice, showed a glycaemic peak 
similar to that of STZ- mice, thus indicating that in both cases mice were unable to metabolize glucose.  
 
4.2 Localization of hASC 
 
We monitored the fate of the injected hASC and investigated localization of infused hASC up to 3 
weeks after the injection by using ALU sequences, dimeric primate’s specific sequences considered 
human DNA’s molecular markers. The presence of human DNA was assessed in lungs, liver, pancreas 
and sciatic nerves of both diabetic (STZ) and healthy (CTR) mice (Figure 6 - panels A and B). As 
expected, at day 1 after treatment, human DNA was present in filter organs such as lungs and liver, 
at 3 days was identified only in lungs and it was not detectable in the damaged tissues such as 
pancreas and sciatic nerves (Figure 6 - panel A and data not shown). 
However, when the antiallodynic effect was well established (week 1 and week 2 after injection), 
human DNA was noticeable only in pancreas and sciatic nerve of STZ-mice, confirming the tropism 
and recruitment of hASC to the injured tissues, and not to the CTR-undamaged ones (Figure 6, panels 
A and B). At later time, 21 days after injection, human DNA was undetectable in all the tested tissues 
(Figure 6, panel A and data not shown). 
 
 
Time after hASC treatment
1 d 3 d W1 W2 W3 W1 W2
Ti
ss
u
e
Lung + + - - - - -
Liver + - - - - - -
Pancreas - - + + - - -
Sciatic nerves - - + + - - -
STZ-mice CTR-mice
A                                                          B
Figure 6| hASC tracking by human ALU sequences detection. Representative gels showing human ALU sequences detection in 
STZ and naïve (CTR) mice tissues collected 1 week (W1) and 2 weeks (W2) after treatment  (A). Lu: lungs; Li: liver; P: pancreas;                             
N: sciatic nerves; + : positive control; −: negative control. Summary of the Alu PCR products observed in lung, liver, pancreas and 
sciatic nerve after 1 and 3 days and 1, 2 and 3 weeks from hASC administration (B).  
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4.3 Effects of hASC and CM-hASC on cytokine levels and CGRP in the main 
stations involved in pain transmission  
It is well known that in diabetic neuropathy a neuroinflammatory cascade, characterized by altered 
levels of pro- and anti- inflammatory cytokines, is present in the main sites involved in nociception 
transmission. To verify an anti-inflammatory or immunomodulatory mechanism for hASC and CM-hASC 
mediated anti-hypersensitivity action, we checked IL-1β, IL-6, TNF-α and IL-10 levels in the sciatic 
nerves, DRG and spinal cord of STZ mice. Panels A-D of Figure 7 illustrate cytokine levels 3 weeks from 
neuropathy induction and 1 week after hASC and CM-hASC injection. Proinflammatory cytokines IL-1β, 
TNF-α and IL-6 (Figure 7, panel A-C) were overexpressed in peripheral (sciatic nerve and DRG) and 
central (spinal cord) nervous system of diabetic mice. 
Both hASC and CM-hASC treatments were able to restore IL-1β, TNF-α and IL-6 basal levels, 1 week after 
treatment. In addition, IL-10 levels (Figure 7 - panel D) appeared significantly reduced in sciatic nerve, 
DRG and spinal cord of diabetic animals. Both hASC and CM-hASC significantly increased IL-10 
concentrations in DRG and spinal cord. In the sciatic nerve of hASC/CM-hASC treated animals the anti-
inflammatory cytokine was significantly elevated in comparison to STZ animals. Indeed after hASC, IL-10 
increased over basal levels, indicating a rapid switch towards an anti-inflammatory environment in all 
these areas involved in pain transmission. 
 
Fourteen weeks after STZ, Figure 8, spinal cord IL-1β, TNF-α and IL-6 levels were still significantly 
elevated and IL-10 levels were reduced in diabetic mice, indicating the persistence of 
neuroinflammation. As previously described for the antiallodynic effect (Figure 1 - panel B), cytokines 
modulation induced by hASC and CM-hASC was long lasting. In Figure 8, 12 weeks after treatments 
(W2), the levels of IL-1β (panel A), TNF-α (panel B) and IL-6 (panel C) were still significantly reduced by 
hASC and CM-hASC, while only in animals treated with hASC we observed a significant normalization of 
IL-10 (panel D). As reported in Figure 8, a second hASC and CM-hASC treatment (W2+W6) did not 
further modify pro-inflammatory cytokine levels (IL-1β, TNF-α and IL-6, panel A-C) in comparison to 
single (W2) treatment; but the second CM-hASC treatment was able to normalize IL-10 levels (panel D). 
Moreover, both treatments were still effective when administered at a later stage of the pathology 
(W6); as reported in Figure 8, panels A-D, 8 weeks after the administration of both hASC and their CM 
there is a significant modulation of cytokine levels, although the effect on IL-1β was more evident with 
hASC than with CM-hASC treatment 
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Figure 7| hASC and CM-hASC maintain a correct cytokine balance in sciatic nerves, DRG and spinal cord of STZ mice.                  
IL-1β (A), TNF-α (B), IL-6 (C) and IL-10 (D) in sciatic nerve, DRG and spinal cord of STZ mice treated 2 weeks after STZ with hASC or hASC-CM; 
cytokines were evaluated after 1 week from treatments. Protein content in nervous tissues was evaluated by ELISA and reported as pg 
cytokine/mg total protein. Data represent mean ± SEM of 6 mice per group. One-way ANOVA was used for statistical evaluation, followed 
by Bonferroni’s post hoc test for multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.001 vs CTR; °p < 0.05, °°p < 0.01, °°°p < 0.001 vs STZ. 
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Figure 8| hASC and CM-hASC maintain a correct cytokine balance in spinal cord at longer time. IL-1β (A) TNF-α (B), IL-6 (C) 
and IL-10 (D) in spinal cord, measured 14 weeks after STZ in animals treated with hASC or CM-hASC at 2 weeks (W2) or 2 and 6 weeks 
(W2+W6) or 6 weeks (W6) after STZ. Protein content in spinal cord was evaluated by ELISA and reported as pg cytokine/mg total protein. 
Data represent mean ± SEM of 6 mice per group. One-way ANOVA was used for statistical evaluation, followed by Bonferroni’s post hoc 
test for multiple comparisons. ***p < 0.001 vs CTR; °°°p < 0.001 vs STZ; ###p < 0.001 vs STZ + hASC. 
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Finally, to investigate the timing of cytokines modulation exerted by hASC and CM-hASC treatment, pro- 
and anti- cytokine levels  in sciatic nerve, DRG and spinal cord 2 weeks after STZ, 3h from treatments, 
were measured. At this time, IL-1β levels were significantly elevated and IL-10 levels decreased in all 
analyzed tissues, as shown in panels A and B of Figure 9. Three hours after injection, both treatments 
were already able to positively modulate cytokine levels, that were not any more different from CTR, 
although a complete restoration was evident only for IL-1β in sciatic nerve and for IL-10 in DRG. 
 
Figure 10| hASC and CM-hASC 
prevent alteration of CGRP levels 
in DRG. Levels of CGRP measured 3h 
and 1 week after hASC and CM-hASC 
treatment ( 2 and 3 weeks after STZ, 
respectively; panel A) in DRG. Spinal 
cord levels of CGRP detected 3h, 1 and 
12 weeks after treatments, that 
correspond to 2, 3 and 14 weeks after 
diabetic-induction. Protein content in 
nervous tissues was evaluated by ELISA 
and reported as pg cytokine/mg total 
protein. Data represent mean ± SEM of 
6 mice per group. Two-way ANOVA 
was used for statistical evaluation, 
followed by Bonferroni’s post hoc test 
for multiple comparisons. ***p < 0.001 
vs CTR; °°p < 0.01 vs STZ; +++p<0.001 vs 
STZ - 3h after treatment (W2)). 
Figure 9| Acute effect of hASC and hASC-CM on IL-1β and IL-10 in nervous tissues. IL-1β (A) and IL-10 (B) protein content in 
nervous tissues was evaluated by ELISA and reported as pg cytokine/mg total protein. Cytokines were evaluated in sciatic nerve, DRG and 
spinal cord 3 hours after hASC or CM-hASC treatments, two weeks after STZ. Data represent mean ± SEM of 6 mice per group. One-way 
ANOVA was used for statistical evaluation, followed by Bonferroni’s post hoc test for multiple comparisons. *p<0.05, **p<0.01 vs CTR; 
°p<0.05, °°p<0.01 vs STZ. 
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Figure 11| hASC and CM-hASC prevent thickness reduction and nerve fiber loss in paw skin of STZ mice. Microphotographs 
of plantar skin after PGP9.5 + immunohistochemistry and counterstaining with haematoxylin at 3 (A) and 14 weeks (B) after STZ, in CTR, 
STZ, STZ + hASC and STZ + CM-hASC groups. Animals were treated 2 weeks after STZ. Nerve fibers are stained in brown; arrow heads 
indicate PGP9.5+ fibers. Quantitative evaluation of epidermal thickness (C) and of PGP9.5 immunopositivity as percentage of 
immunopositive area in epidermal and subepidermal area (D) at 3 and 14 weeks after STZ. Data represent mean ± SEM and were 
compared by One-way ANOVA followed by a Bonferroni’s multiple comparison test. *p < 0.05, **p < 0.01, ***p < 0.001 vs CTR; °p < 0.05, 
°°°p < 0.001 vs STZ; ###p < 0.001 vs STZ + hASC.  
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In order to further confirm the effect of treatments on hypersensitivity, we measured the effect of hASC 
and CM-hASC on Calcitonin Gene Related Petide (CGRP) protein levels in DRG and spinal cord of STZ 
mice. As shown in Figure 10 - panel A, 2 weeks after STZ-injection, diabetic mice showed an increase 
(even if it is not significant) in CGRP levels in DRG. Both hASC and CM-hASC 3 hours after administration 
were able to significantly decrease CGRP levels respect to diabetic-mice. Three weeks after STZ-
injection, CGRP levels were significantly increased in STZ mice and both treatments, 1 week after 
administration, were able to prevent CGRP increase (Figure 10 - panel A). On the contrary, we did not 
find any CGRP modification in spinal cord of diabetic mice at  any time points (Figure 10 - panel B). 
 
4.4 hASC and CM-hASC normalize skin thickness and PGP9.5+nervous fibers 
Neuropathic pain is associated with epidermal thinning and reduced innervation, measured as 
expression of Protein Gene Product 9.5 (PGP 9.5) in axons of the epidermis and dermis [Van Acker et al., 
2016]. Both skin thickness and cutaneous innervation of the plantar skin were evaluated 3 and 14 weeks 
after STZ diabetes induction, corresponding to 1 and 12 weeks after hASC and CM-hASC treatment 
(Figure 11, panels A-D). Three weeks after STZ, skin thickness was not altered yet in STZ mice and 
neither treatments had effect (Figure 11, panels A and C-3W). At fourteen weeks, STZ animals showed a 
significant decrease in skin thickness (Figure 11, panels B and C-14W) and both hASC and CM-hASC 
prevented this decrease, in fact the skin thickness of treated mice was significantly higher than diabetic 
mice.  
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The high density of PGP9.5+ nervous fibers distributed both in epidermis and in subepidermal layer in 
CTR mice is progressively decreased in STZ mice between 3 and 14 weeks after diabetic induction 
(Figure 11, panels A, B and D). One week after hASC treatment, neuropathic animals showed a PGP9.5+ 
density fibers significantly higher than STZ group but still lower respect to the CTR (Figure 11, panel D-
3W). No significant effect of CM-hASC on fibers’ density was observed. Fourteen weeks after STZ (12 
weeks from treatments, panel D-14W) hASC-treated animals completely recovered nerve fibers density. 
In CM-hASC-treated animals, a significantly increase in PGP9.5+ nervous fibers was present, especially at 
subepithelial levels, although it never reached the CTR values (Figure 11, panels B and D-14W). 
 
4.5 hASC and CM-hASC modulate splenocytes cytokine levels 
The STZ multiple low-doses protocol used in our study is known to induce an autoimmune response 
against pancreatic tissue which is sustained by a Th1 pattern of activation [Van Belle et al., 2009; Rahavi 
et al., 2015]. For this reason we decided to investigate whether a T-helper polarization was present in 
splenocytes from diabetic mice and whether hASC or CM-hASC did exert any immunomodulatory 
activity. As reported in panels A and D of Figure 12, 2 weeks after STZ, ConA-stimulated splenocytes 
released higher levels of IFN-γ (panel A), while IL-10 release (panel D) was reduced; 3 hours after  hASC 
and CM-hASC administration, both treatments were able to significantly increase IL-10 levels (Figure 12, 
panel D) . Three weeks after STZ, 1 weeks after treatments, Th1/Th2 unbalance was more evident and 
hASC and CM-hASC treatments were able to re-establish both IFN-γ and IL-10 physiological levels (Figure 
12, panels E and H, respectively). When cytokine levels were measured 14 weeks after diabetes 
induction, a clear shift toward a Th1 pattern was present, characterized by higher IFN-γ and IL-2 
secretion (Figure 12, panels I and L, respectively) and lower IL-4 (panels M) and IL-10 levels (panel N). 
hASC and CM-hASC treatments were able to normalize cytokine levels, as demonstrated by the IFN-γ 
and IL-2 decrease (panels I and L) and IL-10 and IL-4 increase 8 weeks after hASC/CM-hASC injection 
(Figure 12, panels M and N, W6). When the effect was evaluated 12 weeks after administration (W2), 
both hASC and CM-hASC were able to restore IFN-γ and IL-2 (Figure 12, panels I and L). IL-4 and IL-10 
reached basal levels only in hASC-treated mice while in CM-hASC-treated animals the recovery was not 
complete (Figure 7, panels M and N), suggesting that the effects exerted by hASC is longer than the 
hASC-CM. Altogether, our data indicate that both hASC and CM-hASC treatments are able to counteract 
the Th1 polarization developed in this experimental diabetes model.  
 
In addition, to better understand wheter hASC/CM-hASC act at transcriptional or post-transcriptional 
level, IFN-γ and IL-10 mRNA (Figure 13 - panels A and B, respectively), were evaluated. These cytokines 
were selected because they were altered by the pathology at the all time observed and their mRNA, 
were evaluated at 3 (1 week after treatment) and 14 weeks (12 weeks after treatment) after STZ.  
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Figure 13| hASC and CM-hASC 
treatments modulate mRNA 
expressionof IFN-γ and IL-10 in 
splenocytes. IFN-γ (A) and IL-10 (B) mRNA 
levels, determined by Real Time PCR, were 
expressed in relation to glyceraldehydes 3-
phosphate dehydrogenase (GAPDH) and 
presented as fold-increases over the levels in 
CTR animals. mRNA levels were evaluated 3 
and 14 weeks after STZ (1 and 12 week after 
hASC and CM-hASC treatments, respectively).  
Data represent mean ± SEM of 6 mice per 
group, and have been statistically analyzed 
with Two-way ANOVA, followed by 
Bonferroni’s test for multiple comparisons. 
*p < 0.05, ***p < 0.001 vs CTR; °p < 0.05, 
°°°p < 0.001 vs STZ. 
 
 
Figure 12| hASC and CM-hASC treatments modulate cytokine release from splenocytes. IFN-γ (A, E and I), IL-2 (B, F and L), IL-4 
(C, G and M) and IL-10 (D, H, N) were evaluated by ELISA, and reported as protein concentrations in culture media. Cytokine levels were 
evaluated 2 weeks after STZ, 3 hours after hASC and CM-hASC treatments (A-D); 3 weeks after STZ , 1 week after treatments (E-H). (I-N) 
Report cytokines levels measured 14 weeks after STZ in animals treated with hASC or CM-hASC either 2 weeks (W2), 2 and 6 weeks 
(W2+W6) or 6 weeks (W6) after STZ. Data represent mean ± SEM of 6 mice per group, and have been statistically analyzed with One-way 
ANOVA, followed by Bonferroni’s test for multiple comparisons. *p < 0.05, ***p < 0.001 vs CTR; °p < 0.05, °°p < 0.01, °°°p < 0.001 vs STZ. 
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 Similarly to cytokine release, 3 and 14 weeks after STZ, diabetic mice were characterized by a significant 
increase of IFN-γ and a decrease of IL-10 expression levels.  
Three and 14 weeks after STZ, both hASC and CM-hASC treatments were able to reduce IFN-γ mRNA  to 
baseline. 3 weeks after STZ, IL-10 mRNA levels were normalized only by hASC treatment while 14 weeks 
after STZ both treatments were able to increase IL-10  mRNA beyond physiological values (panels A and 
B). These data indicate that both treatments act upstream of mRNA translation, showing a correlation 
between mRNA and protein for both cytokines (see Figure 12 panels E, I, H and N, and Figure 13 panel A 
and B). 
 
4.6 Effect of hASC and CM-hASC treatments on other diabetes associated 
alterations  
 
Considering the strong effect of hASC and CM-hASC treatments on diabetic neuropathy, we decided to 
investigate whether these treatments positively influenced also other conditions related to  diabetes.    
Figure 14| Effect of hASC and CM-hASC administrations on insulin plasma levels and pancreatic cytokines. Plasma insulin 
levels were evaluated 3 (panel A) and 14 weeks (panel B) after. IL-1β and IL-10 protein content in pancreatic tissue were 
evaluated 3 weeks (panels C and D) and 14 weeks (panels E and F) after diabetes induction. 
Plasma insulin levels and pancreas protein content, evaluated by ELISA, were reported as protein concentrations in plasma 
and pg of cytokine/mg of total protein, respectively. Data represent mean ± SEM of 6 mice per group. One way ANOVA was 
used for statistical evaluation, followed by Bonferroni’s test for multiple comparisons. *p<0.05, **p<0.01, ***p<0.001 vs 
CTR; °p<0.05 vs STZ. 
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We measured plasmatic insulin levels and pancreatic cytokines levels, since it is known that in  the STZ 
diabetes model  the destruction of β-pancreatic cells induces an altered immune-inflammatory response 
characterized by a dysregulation of cytokine expression pattern in pancreas [Cnop et., 2005; 
Amirshahrokhi and Ghazi-Khansari, 2012], 3 and 14 weeks after STZ. 
As reported in Figure 14, 3 and 14 weeks after STZ administration, plasmatic insulin levels were 
drastically reduced in STZ mice respect to the ones measured in CTR animals (panel A and B). Both hASC 
and CM-hASC treatments were able to counteract insulin decrease in the first phases of the pathology, 
that is 3 weeks after STZ. Moreover at longer time after diabetic induction, 14 weeks after STZ, single 
and double treatments (W2 and W2+W6, respectively) with hASC or CM-hASC were not able to re-
establish physiological plasmatic insulin levels even if a positive trend was present after both hASC and 
CM-hASC treatments. When administered in an avanced stage of disease (W6), hASC and CM-hASC were 
not effective in modulating insulin levels.  
Figure 14 - panels C-F report IL-1β and IL-10 protein levels in pancreas that 3 and 14 weeks after diabetic 
induction, show a marked dysregulation of cytokine balance. In particular 3 weeks after STZ we 
observed a significant decrease of IL-10 levels (panel E).  14 weeks after STZ, both IL-1β (D) and IL-10 (F) 
cytokines were significantly increased in diabetic mice, but we could not evidence any treatment effect. 
As shown in Figure 15 - panel A, 3 weeks after diabetic induction body weight significantly decreased in 
STZ mice, but a single hASC or CM-hASC administration significantly prevented body weight loss.                   
Body weight of mice treated twice with hASC or CM-hASC (W2+W6) were comparable to those that 
were treated only once; on the contrary neither hASC nor CM-hASC were able to revert the body weight 
loss if administered 6 weeks after diabetes induction (data not shown). 
Figure 15| Effect of hASC and CM-hASC administrations on body and organ weight. Body weight time course of STZ mice 
treated with hASC or CM-hASC 2 weeks after STZ (A). Data are means ± SEM of 6 animals. Two-way ANOVA was used for 
statistical evaluation, followed by Bonferroni’s test for multiple comparisons. *p < 0.05, ***p < 0.001 vs CTR; °p < 0.05, 
°°p < 0.01, °°°p < 0.001 vs STZ. Spleen (B), pancreas (C), liver (D) and kidneys (E) weight 3 weeks after diabetic induction. 
Data are means ± SD of 6 animals. One-way ANOVA was used for statistical evaluation, followed by Bonferroni’s test for 
multiple comparisons. *p < 0.05, **p < 0.01 vs CTR. 
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Moreover, 3 weeks after STZ injection, diabetic mice showed a significant decrease in the weight of 
kidneys, liver, spleen and pancreas (Figure 15, panels B-E). Both hASC and CM-hASC were able to 
significantly contrast organ weight reduction in accordance with what was observed on total body 
weight (Figure 15 – panel A). 
 
Since renal injury is a well known diabetic complication, we focused our attention also on 
glomerulopathy, which is a primary evidence of type I diabetes nephropathy. Analysing 
hematoxylin/eosin kidney sections, an evident expansion of Bowman’s space of about 114% was 
observed in diabetic mice compared to CTR (Figure 16 - panels A and B).  
Interestingly, at all time observed CM-hASC injection significantly reduced Bowman’s space area in 
respect to STZ mice; while only double or late hASC treatment was able to significantly reduce 
Bowman’s space area. In more detail, effect of CM-hASC single (W2) or double (W2+W6) administration, 
appeared more pronounced than hASC, since the early cellular treatment was able to just mildly revert 
the alteration (panel B ). In contrast, late treatments were more beneficial, since Bowman’s space area 
was restored to physiological value by both treatments (Figure 16 - panels A and B). In all groups, 
tubules morphology appeared normal without necrosis or loss of brush border and neither vascular 
fibrosis nor sclerosis was observed..  
Figure 16| Effect of hASC and 
CM-hASC on glomerular 
damage in STZ mice. A: 
Hematoxylin/eosin staining of 
kidney sections (magnification: 
200X) from CTR, STZ and STZ 
treated with hASC or CM-
hASC, 2 weeks (W2) or 2 and 6 
weeks (W2+W6), or 6 weeks 
(W6) after diabetes induction. 
B: quantification of Bowman’s 
space area for all the animal 
groups. More than 30 
glomeruli were measured for 
each group. Data were 
analyzed and compared by 
One-way ANOVA and by a 
Bonferroni’s multiple 
comparison test and are 
expressed as mean ± SEM. *p< 
0.05, ***p< 0.001 vs CTR; 
°p<0.05, °°° p< 0.001 vs STZ. 
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Neuropathic pain resulting from a damage or disease within the somatosensory system is a chronic pain 
largely resistant to treatment mainly because the underlying mechanisms are still poorly understood.  
Much of the initial research on the neuropathic pain pathogenesis focused on the properties of neurons 
following a nerve injury, leading to proposal of both peripheral and central sensitization as important 
disease mechanisms [Sacerdote et al., 2013; Costigan et al., 2009]. However, in the last years it has 
emerged that the development and maintenance of neuropathic pain is not confined to the altered 
activity of sensory neurons and the reorganization of central nociceptive circuits, but also involves 
pathological interactions between neurons, glia and inflammatory immune cells, as well as a wide 
cascade of pro- and anti-inflammatory cytokines [Austin and Moalem-Taylor, 2010; Calvo et al., 2012].  
In the present work we provide evidences about the role of bioactive factors released from hASC or 
present in their secretome in modulating inflammatory events  which occur in the peripheral and central 
nervous system following neuronal injury related to neuropathic pain development. 
Considering that one of the most common causes of neuropathic pain in patients is the presence of 
diabetes, we used a diabetic painful neuropathy model induced by chemical pancreactomy (STZ) to 
perform this study. 
Diabetic neuropathic pain is characterized by sensory alterations, including hyperalgesia, tactile and 
thermal allodynia, and current treatments are often active only on some of them [Vincent et al., 2011]. 
Our results demonstrate that hASC and their secretome can control diabetic complications such as 
neuropathic hypersensitivity, acting on several peripheral and central mechanisms involved in the 
development and maintenance of this condition, such as neural and immune elements. In particular, 
allodynia is known to be a cardinal symptom of diabetic painful neuropathy and in STZ-preclinical model 
it appeared within few days after diabetes induction, is fully developed in 1 week and persisted until 14 
weeks after STZ administrations. 
Systemic treatments with either hASC or CM-hASC are able to significantly relieve tactile and cold 
allodynia as well as heat hyperalgesia, although the effect of cells remains significantly higher than that 
of CM. Interestingly treatments seems to be effective also in modulating thermal hypoalgesia. While 
there is a general agreement on the development of allodynia in the STZ model,  other studies have 
reported, as a result of diabetic neuropathy, the presence of thermal hyperalgesia, hypoalgesia or no 
changes in thermal latency tests [Ohsawa and Kamei, 1999; Pabbidi et al., 2008a]. This discrepancy 
might be explained by the fact that there are many variables in these behavioural tests such as 
methodology, animal species, response criteria, duration of diabetic conditions, etc. [Calcutt, 2004]. In 
our experiments, STZ-mice showed thermal hyperalgesia from 1 to 3 weeks after STZ-injection, 
subsequently there was a switch from hyperalgesia to hypoalgesia that lasted until the 14th week. This 
change may depend on pathological alterations in the sensory system that result in reduced 
neurotrophic support of peripheral sensory nerves and loss of nerve fibers [Calcutt, 2004; Kakinoki et al., 
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2006]. Moreover previous studies showed that insulin has a role in activating TRPV1 receptors of 
cultured primary sensory neurons [Sathianathan et al., 2003], therefore hypoalgesia might be related to 
the reduction of insulin levels and diminished TRPV1 activity of primary sensory neurons in diabetic 
mice. Both hASC and CM-hASC treatments were able to contrast the shift from hyper- to hypo- algesia 
and this effect may be related to the ability of both treatments to contrast insulin levels decreased in 
diabetic mice up to 14 weeks after STZ and to the ability of treatments to protect nerve fibers from 
degeneration (see below). 
The concept that MSC’s secretome may be responsible for the beneficial effects of stem cell therapy is 
now a prevalent theory [Kapur and Katz, 2013; Blaber et al., 2012; Sabin and Kikyo, 2014]. However, this 
is the first report demonstrating that the conditioned medium of hASC also results in quite similar 
therapeutic effects in diabetic neuropathic condition and comparing simultaneously the effect of CM 
and of the stem cells from which it has been produced. 
One of the most striking result of our study is related to the time course of the antiallodynic effect 
exerted by both hASC and CM-hASC. In fact, their antiallodynic effect was not only rapid but also 
extremely long lasting, an effect that is hardly reached by any analgesic clinically used [The Diabetes 
Control and Complications Trial Research Group, 1993; Martin et al., 2006]. 
Furthermore, the long lasting antiallodynic effect of CM-hASC, up to 14 weeks, may lead to speculate 
that a direct engrafment of stem cells in the nervous tissue has to be excluded, favouring the hypothesis 
of a precocious reprogramming of the immune and neuronal environments that, once activated, 
changes the course of the neuropathy. In a juxtacrine or paracrine fashion hASC can crosstalk and 
modulate endogenous stem cells that may also induce nerve regeneration, as previously described in a 
different model of neuropathy [Marconi et al., 2012]. 
Similarly, the biologically active substances contained in the CM-hASC can activate/deactivate specific 
signaling pathways with a final protective outcome. It must be underlined that CM derived from human 
dermal fibroblasts are completely inactive on allodynia, confirming that the mesenchymal stem feature 
is a fundamental pre-requisite in this novel approach. Moreover lyophilized CM-hASC was not able to 
increase mechanical stimuli thresholds in diabetic mice, indicating  that  the process by which the 
secretome is obtained is crucial. The differences observed could provide a starting point to identify 
bioactive factors present in the CM through a comparison between the 3 secretomes with the final aim   
to create a mix bioactive ad hoc factors. 
The ability of hASC and their secretome to modulate the host cell response is demonstrated by the 
effect on the cytokine levels in the nervous tissues. IL-1β, IL-6, TNF-α and IL-10 in the peripheral (nerves, 
DRG) and central (spinal cord) nervous system are now recognized as a pivotal signal for maintenance of 
neuropathic pain, regardless of its origin [Sacerdote et al., 2013; Calvo et al., 2012; Yagihashi et al., 
2011]. Here we demonstrated that one week after hASC and CM-hASC treatment, neuroinflammation is 
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significantly blunted and a correct balance between IL-1β, IL-6, TNF-α and IL-10 is re-established. 
Interestingly, the levels of IL-10 after treatments in the sciatic nerves are even more elevated than those 
measured in normal animals, confirming the relevant role for this cytokine in controlling sensory 
hypersensitivity.  
In parallel with the long lasting modulation of allodynia, also the effect of hASC on IL-1β and IL-10 in 
spinal cord is fully maintained up to 12 weeks after treatment, suggesting that once the switch toward 
an anti-inflammatory program has been started, it is permanently sustained. Significant similar effect of 
both treatments on TNF-α and IL-6 levels were observed. Interestingly, at later times following 
administration, the effect of CM-hASC on IL-10 is not as evident as with stem cells. When the 
antiallodynic effect was decreased, one month after the 1st CM-hASC treatment, a 2nd treatment was 
able to restore IL-10 physiological levels and increase mechanical stimuli thresholds. In addition, it was 
noted that second hASC/CM-hASC treatment did not modify IL-1β, TNF-α and IL-6 levels compared to 
single treatment; this may depend on the fact that a single treatment with hASC or CM-hASC has already 
been able to restore cytokines basal levels. Since clinical diabetic neuropathy is a progressive disorder, 
and its manifestation may need several years to develop [Yagihashi et al., 2011], we thought it could be 
interesting to evaluate whether hASC and CM-hASC could be able to modify allodynia and 
neuroinflammation also when administered at a later stage of the disease. In our model, hyperglycemia 
and abnormal sensitivity were developed soon after STZ injection while for structural nerve 
modifications it is  necessary a longer time [Goyal et al., 2016]. Interestingly, both hASC and CM-hASC 
were fully effective in reverting allodynia and restoring all analyzed cytokines levels (IL-1β, IL-6, TNF-α 
and IL-10) in spinal cord also when injected 6 weeks after diabetes induction. 
Moreover, to try to understand the rapid effect of both treatments on painful symptoms, we checked if 
already 3 hours after administration, hASC and CM-hASC were able to modulate cytokine levels; we 
demonstrate that the cytokine levels modulation begins almost immediately after hASC or CM-hASC. 
Already 3 hours after treatment we observed a trend in the restoration of IL-1β/10 balance in nervous 
tissues (both central, spinal cord; and peripheral, DRG and sciatic nerve). In addition, since calcitonin 
gene-related peptide (CGRP) is widely distributed in nociceptive pathways in peripheral and central 
nervous system and its receptors are also expressed in pain pathways, we evaluated CGRP levels 
immediately after therapeutic treatments (3 hours) and 1 and 12 weeks after.  
Although it is well known that CGRP peptide is involved in migraine pathophysiology its role in 
neuropathic pain has not been clarified [Schou et al., 2017] and recent studies are discordant [Schou et 
al., 2017; Russell et al., 2014]. In our analysis we observed that in the early stages of the diabetic 
neuropathy, 2 weeks after STZ, diabetic mice showed a trend toward increased CGRP levels both at the 
central and peripheral nervous system level (spinal cord and DRG, respectively). Three weeks after STZ, 
CGRP peripheral levels were significantly increased. Both hASC and CM-hASC treatments at the two 
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observed time points (3 hours and 1 week after administartion) were able to significantly decrease CGRP 
levels in comparison to STZ mice, demonstrating that both hASC and CM-hASC are able to modulate 
several important mediators or neurotransmitters involved in pain sensitivity. 
The quantification of the density of intraepidermal nerve fiber to assess cutaneous innervation is 
considered a reliable mean of both diagnosing and staging of diabetic neuropathy [Van Acker et al., 
2016; Beiswenger et al., 2008; Lauria et al., 2005]. We decided to measure PGP-9.5 expression, since as 
shown in previous studies [Albrecht et al., 2006; Fundin et al., 1997; Pare et al., 2007; Hou et al., 2011] 
anti-PGP 9.5 labels all known types of peripheral innervation. Here we showed that nerve fibers damage 
began in 3 weeks after STZ and at later time point, 14 weeks after STZ, it get worse in untreated diabetic 
group, in agreement with previous findings in diabetic animals [Boric et al., 2013]. We observed that 
both treatments were able to prevent loss of nerve fibers detected by PGP9.5+, supporting a 
neuroprotective activity of our treatments in diabetes. We are however aware that further 
immunohistochemical analysis with specific fibers’ markers would be important in order to assess which 
fibers are lost and eventually recovered by treatments. Since it has been proven that in neuropathic pain 
partial denervation induces differences in epidermal thinning, we also evaluated this parameter and we 
observed that 14 weeks after STZ, when denervation of the paw skin is more evident, diabetic mice 
showed also epidermal thinning, which was completely prevented by both therapeutic treatments. 
MSCs carry out pleiotropic effects on the immune system by both secreting bioactive molecules and by 
cell-cell contact involving dendritic cells, B and T cells [Fierabracci et al., 2016; de Witte et al., 2015]. 
Inflammation and immune activation have been recognized as fundamental mechanisms in the 
pathophysiology of diabetes and its complications [Agrawal and Kant,  2014]. An autoimmune reactivity 
characterized by a T helper 1 profile is consistently present in clinical diabetes and 2 weeks after diabetic 
induction also STZ-mice were characterized by a clear shift toward Th1 profile, with high IFN-γ and low    
IL-10 levels, which becomes even more evident in the following weeks. A progressive polarization of 
peripheral immune response towards a Th1 profile is present in our STZ model and we demonstrate that 
hASC are involved in modulating the peripheral immune response.  
In fact hASC treatment, regardless the time of its injection, reduced IL-2 and IFN-γ release by peripheral 
splenocytes and increased IL-10 and IL-4 secretion, maintaining an optimal Th1/Th2 balance. This effect 
is almost completely mimicked by CM-hASC, indicating that cell-cell contact is not essential to obtain 
immune modulation, that instead appears to be mainly due to a paracrine mode of action. 
We found a parallel modification between  IFN-γ and IL-10 protein and their mRNA levels, and as with 
protein both treatments were able to restablish a correct balance.  It is possible that hASC and CM-hASC  
may induce the activation of IL-10 synthetic machinery in order to supply the strong demand and 
consumption of this cytokine required for contrasting the pro-inflammatory cascade induced by the 
lesion [Sacerdote et al., 2013].  
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Based on these results we can envisage that hASC, when i.v. injected in diabetic animals, may start to 
release bioactive factors that immediately modulate allodynia, immune responses and thereafter 
convert a pro-inflammatory/neuro-destructive environment to an anti-inflammatory/neuroprotective 
one. We showed that hASC are recruited at the site of lesioned tissue, such as pancreas and nerves of 
diabetic mice, while they are undetectable when the cells are i.v. injected in naïve animals. 
Furthermore, we suggest that hASC disappear after reprogramming the tissue cells, since cellular life 
span in the lesioned tissue (2 weeks) is shorter than the duration of their effects (12 weeks), as already 
reported [Uccelli et al., 2008]. In the case of CM-hASC, the cocktail of bioactive mediators may exert a 
similar precocious modulation of host tissue, that is maintained over-time. However, at longer time 
after the single injection, the hASC positive effect on the anti-inflammatory cytokines appears stronger, 
suggesting that either the recruitment of cells at the injured sites or the cell to cell contact with 
endogenous immune cells may be useful. The positive long lasting effect of CM-hASC have been already 
described in different models of pathological conditions, such as liver disease, urological disfunction and 
Alzheimer [Lee et al., 2015; Yiou et al., 2016; Mita et al., 2015] and here we demonstrated that a 
repeated injection of CM-hASC promotes a higher antiallodynic response and further extends its 
duration, giving promising indications for a future clinical treatment. 
At the moment, we cannot exclude that the neuroprotective effects of hASC and CM-hASC might also be 
mediated by an improvement of neural vascularity that is induced by the angiogenic factors contained in 
hASC secretome. Nonetheless, this aspect, previously suggested by others [Han et al., 2016; Davey et al., 
2014], can be combined with the effects described here of the hASC and their CM. 
The content and the relevance of CM-hASC factors is still under study. Our CM obtained from hASC 
maintained in similar culturing conditions as previously described by others [Makridakis et al., 2013; 
Kapur and Katz, 2013; Blaber et al., 2012; Konala et al., 2016], should contain a wide range of cytokines, 
chemokines, and growth factors such as BDNF, VEGF, IGF. Recently a paper by Chen et al. [2015], 
suggested that the release of TGF-β by bone marrow stromal cells may be particularly involved in the 
modulation of neuropathic pain in the CCI (chronic constriction injury) and SNI (spare nerve injury) 
models. From preliminary analysis we measured high levels of TGF-β also in our CM-hASC, and this 
cytokine may play an important role also in diabetic neuropathic pain. 
We also detected the presence of exosomes in CM-hASC (Brini, unpublished observations), and the 
secreted exosomes carry specific mRNA or miRNA, which could potentiate the reparative process and 
heal the injured tissues [Marote et al., 2016; Sabin and Kikyo, 2014]. Although it is possible that for 
different pathological conditions, diverse mediators may be responsible for the beneficial effect, we 
think that what makes the secretome unique is just the simultaneous presence of all these multiple 
factors. To confirm our hypothesis, we have also shown the CM-hASC effect on another diabetes 
alteration such as renal injury. This diabetes complication is due to the progressive inflammation and 
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immune activation promoted by the formation of advanced glycation-end products, oxidative stress, 
and activation of renin-angiotensin-aldosterone system within the kidney [Rivero et al., 2009; Forbes 
and Cooper, 2013]. Indeed, inflammation activated by the metabolic, biochemical and haemodynamic 
derangements plays a key role in the development and progression of diabetic nephropathy [Reidy et 
al., 2014]. Since in STZ-mice kidney damage is ameliorated by both treatments, we hypothesize that 
hASC and CM-hASC may control several aspects of diabetes linked to inflammation and immune 
activation. Weight loss is also a classical symptom associated to the STZ diabetes models, and a general 
positive effect of hASC and CM-hASC treatments is demonstrated by the prevention of weight loss in 
treated mice [Goyal et al., 2016; Agrawal and Kant, 2014]. Several factors may contribute to the 
prevention of weight loss that we observed in treated mice. In STZ mice, altered protein and lipid 
catabolism due either to hyperglycemia, to the inflammatory condition and oxidative stress are likely at 
the basis of weight loss [Goyal et al., 2016]. Moreover, it has been suggested that the presence of 
allodynia and painful symptoms may affect the locomotor activity and modify energy expenditure [Atif 
et al., 2007]. Interestingly, as in our work, a reduction of body weight loss has been observed also in the 
absence of modification of the hyperglycemic state in STZ mice [Old et al., 2015]. It can be suggested 
that the reduction of systemic inflammation and hypersensitivity may have a role. Moreover, recent 
studies [Zafar and Naeem-ul-hassan Naqvi, 2010] demostrated that body weight reduction in animal 
models was associated with decreased organs weight (kidney, liver, pancreas and spleen), event also 
observed by us. It can also be hypothesized that hASC and CM-hASC may contribute with hormones and 
mediators directly involved in the control of adipogenesis or body weight [Delle Monache et al., 2016]. 
This hypothesis, however, deserves to be studied in future work. 
No significant change in blood glucose levels was observed, suggesting that the efficacious relief of 
nociceptive hypersensitivity is independent from glycemia.  
It is known that the use of mesenchymal stem cells of several origin, including hASC, was able to induce 
β-cells protection in the STZ models  and to restore a correct glycemic state [Rahavi et al., 2015; Kono et 
al., 2014; Guimaraes et al., 2013; Yaochite et al., 2015; Monfrini et al., 2017] and we indeed observed 
the presence of hASC in lesioned pancreas starting from day 7 after administration. However, this 
discrepancy can rely on the different administration route, systemically or intra-pancreatic resulting in 
different numbers of cells reaching the pancreas, and, most of all, the timing of administration. In all our 
study cells and media were injected when hypeglycemia was fully developed. In fact, the data obtained 
with pancreatic cytokine study, suggest that the organ is already altered and immune responses 
modulated when we injected cells and media. Both here and in our previous study [Sacerdote et al., 
2013a] we never observed any significant variability among the in vivo effect of the different population 
of hASCs and their conditioned media. However to overcome the differences in cells’ growth, in the 
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future we might consider to set a more standardized production of both cells and CM, maybe by pooling 
several hASC populations, as also suggested by Bodle et al. [2014]. 
In conclusion, we confirm and explain the ability of i.v. hASC to exert a long lasting control of diabetic 
neuropathic hypersensitivity showing, for the first time, that the effect of the hASC is mimicked by their 
secretome, confirming the general view that stem cells act mainly throughout a paracrine action. 
The safety of autologous MSCs has been documented by a number of clinical trials [Nordberg and 
Loboa, 2015; Lalu et al., 2012; Pawitan et al., 2014] and the use of secretome could be further safer. In 
addition, considering all the studies on the effects of MSCs on diabetes, and knowing that peripheral 
neuropathy affects up to 60% of diabetic patients [Galer et al., 2000], we believe that advanced diabetic 
neuropathy could become a first clinical target for this type of medicine cellular product. Thinking about 
the future, a novel therapeutic option with hASC secretome might be suggested for treating advanced 
peripheral painful neuropathy. 
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